CATIONIC DISPLACER MOLECULES FOR HYDROPHOBIC DISPLACEMENT CHROMATOGRAPHY

Information

  • Patent Application
  • 20140284278
  • Publication Number
    20140284278
  • Date Filed
    October 03, 2012
    12 years ago
  • Date Published
    September 25, 2014
    10 years ago
Abstract
A process for separating organic compounds from a mixture by reverse-phase displacement chromatography, including providing a hydrophobic stationary phase; applying to the hydrophobic stationary phase a mixture comprising organic compounds to be separated; displacing the organic compounds from the hydrophobic stationary phase by applying thereto an aqueous composition comprising a non-surface active hydrophobic cationic displacer molecule and about 10 wt % or less of an organic solvent; and collecting a plurality of fractions eluted from the hydrophobic stationary phase containing the separated organic compounds; in which the non-surface active hydrophobic cationic displacer molecule comprises a hydrophobic cation and a counterion, CI, having the general formula A or B, as defined in the disclosure:
Description
BACKGROUND

Displacement chromatography (DC) in one of the three well-defined forms of column chromatography—elution, displacement, frontal. DC is principally a preparative method, but there are also analytical applications using “micropreparative” DC with packed “narrow-bore” or capillary columns.


Displacement chromatography may be carried out using any one of four general chromatographic methods when suitable, high-purity displacer molecules are available. DC is used in (a) ion-exchange chromatography (cation-exchange, anion-exchange), (b) hydrophobic chromatography (reversed-phase, hydrophobic-interaction, hydrophobic charge-induction, thiophilic), (c) normal-phase chromatography including hydrophilic-interaction chromatography (HILIC) and (d) immobilized metal-ion affinity chromatography (IMAC).


With optimized DC, one may obtain, simultaneously, high purity (high resolution), high recovery (high yield) and high column loading (high capacity)—the latter much higher than overloaded preparative elution chromatography. In most cases, these advantages more than compensate for the disadvantages of DC (slower flow-rates, longer run-times, need for high-purity displacers).


Displacement chromatography is carried out by choosing (a) an applicable chromatographic method, (b) a suitable chromatography column with proper dimensions, (c) proper mobile phase conditions, (d) a suitable displacer molecule and (e) suitable operation protocols with properly configured LC equipment. Initially, a suitable “weakly displacing mobile phase” (carrier) is chosen, and the column is equilibrated at a suitable flow-rate. The carrier may contain a pH-buffering compound adjusted to a useful pH value. Optimal displacement flow-rates tend to be low, typically in the range of 35-105 cm/hr, though sometimes higher. A suitable amount of the sample solution is loaded onto the column at the sample-loading flow-rate. The sample solution contains the material to be purified in the carrier along with the proper level of an ion-pairing agent if the sample or displacer molecules are charged. Typical sample loadings are 50-80% of the operative breakthrough capacity. Next, a displacer mobile phase (displacer buffer), prepared from a suitable displacer compound at the proper concentration in the carrier solution, is pumped onto the column at the displacement flow-rate until the displacer breakthrough is observed. The purified sample comes off the column before the displacer breakthrough front. Fractions from the column are collected and separately analyzed for content and purity. Finally, the displacer is removed from column using a “displacer removal solution”, and then the column is cleaned and regenerated to its original state for storage or for subsequent use.


Though different from elution chromatography, in some respects, displacement chromatography is easy to understand and easy to carry out. In DC, a sample is “displaced” from the column by the displacer, rather than “eluted” from the column by the mobile phase. When the output of the column is monitored online (e.g., via UV absorption, pH, or conductivity), a “displacement train” is obtained rather than an “elution chromatogram”. The displacement train is composed of side-by-side “displacement bands” rather than solvent-separated “elution peaks” in a chromatogram. When a displacement band is large enough to saturate the stationary phase, a trapezoidal “saturating band” is formed. When a displacement band is not large enough to saturate the stationary phase, a small, triangular “non-saturating band” is formed. The height of a saturating band is determined by the binding-isotherm at the point of operation; the area of a trapezoid-band or a triangle-band is proportional to the amount of the component.


Hydrophobic chromatography depends almost exclusively on the unique solvation properties of water that result from the highly structured, self-associated, hydrogen-bonded liquid. For conventional reversed-phase chromatography stationary phases (uncharged C18 column), binding is usually driven by entropy (+TΔS), which often must overcome unfavorable enthalpy (+ΔH). Thus, over the temperature ranges often used by chromatographers (10-70° C.), analyte-binding and displacer-binding often become stronger with increasing temperature. Another useful feature of hydrophobic chromatography is the use of additives that modify both the structure and strength of the self-hydrogen-bonding of the aqueous-based solvent. These additives include: salts (NaCl, K2HPO4, (NH4)2SO4), organic solvents (MeCN, MeOH, EtOH) and polar organic molecules (urea, oligo-ethyleneglycol) in chromatography buffers.


Hydrophobic displacement chromatography can be carried out using chiral analytes, chiral displacers and chiral chromatography matrices. Under these conditions, an achiral displacer may be used, but a racemic mixture of a chiral displacer cannot be used. Racemic chiral analytes can also be purified using an achiral chromatography column and an achiral displacer. In this case, impurities, including diastereomers, are removed from the racemic compound of interest, but there is no chiral resolution of the enantiomers. With the proper choice of chiral chromatography matrix, mobile phase and achiral displacer, enantiomers are routinely preparatively resolved (separated). Depending on the specific circumstances, a good, enantiomerically pure, chiral displacer can have performance advantages over a good achiral displacer when carrying out a displacement separation of enantiomers on a chiral stationary phase.


Development of useful, preparative hydrophobic displacement chromatography has been hampered by the unavailability of suitable, high-purity displacer molecules. We describe here new displacer molecules and methods to use them that have utility in various forms of hydrophobic displacement chromatography.


Hydrophobic displacer molecules should possess a unique combination of chemical and physical properties in order for them to function efficiently. Some soluble, hydrophobic molecules can function as displacers, but only a limited few function well. Many of the molecules described in this document fulfill the necessary requirements for well-functioning displacers.


Development of useful, reversed phase, preparative displacement chromatography has been hampered by the unavailability of suitable, high-purity displacer molecules. For example, U.S. Pat. No. 6,239,262 describes various reversed phase liquid chromatographic systems using low molecular weight surface-active compounds as displacers. U.S. Pat. No. 6,239,262 discloses an extremely wide range of possible charged moieties that may be coupled with hydrophobic moieties to form the disclosed surface active compounds used as displacers, but discloses that it is necessary to include a large proportion of organic solvent to mitigate the surface active properties of the disclosed displacers. The presence of such large proportions of organic solvents significantly alters the process, derogating from the benefits of reverse-phase hydrophobic displacement chromatography. In addition, the surface-active displacer compounds disclosed by U.S. Pat. No. 6,239,262 do not function well, resulting in relatively poor quality displacement trains in which a significant level of impurities may be present in the “purified” products.


SUMMARY

The development of useful, preparative hydrophobic displacement chromatography has been hampered by the unavailability of suitable, high-purity displacer molecules that function well and can be easily detected. We describe here a new class of cationic displacer molecules and methods to use them that have utility in various forms of hydrophobic displacement chromatography.


Many commercial, small cationic molecules simply don't bind to hydrophobic stationary phases well enough, while many large cationic molecules that do bind well enough either lack sufficient solubility or are plagued with detergency problems that lead to lower resolution, lower column capacity for the analyte and unwanted foaming. We find that many intermediate-sized cationic molecules, when properly designed, possess the unique combination of chemical and physical properties, including proper UV absorption, in order for them to function efficiently as hydrophobic displacers. It is true enough that there are some soluble, cationic hydrophobic molecules that can function as displacers, but only a limited few function well. Many of the molecules described in this document fulfill the necessary requirements for well-functioning displacers when used according to established displacement protocols.


We have discovered and developed classes of charged hydrophobic organic compounds, either salts or zwitterions, that uniquely posses that combination of chemical and physical properties necessary for good displacer behavior in hydrophobic displacement chromatography.


Accordingly, the present invention, in one embodiment, relates to a process for separating organic compounds from a mixture by reverse-phase displacement chromatography, comprising:


providing a hydrophobic stationary phase;


applying to the hydrophobic stationary phase a mixture comprising organic compounds to be separated;


displacing the organic compounds from the hydrophobic stationary phase by applying thereto an aqueous composition comprising a non-surface active hydrophobic cationic displacer molecule and about 10 wt % or less of an organic solvent; and


collecting a plurality of fractions eluted from the hydrophobic stationary phase containing the separated organic compounds;


wherein the non-surface active hydrophobic cationic displacer molecule comprises a hydrophobic cation and a counterion, CI, having the general formula A or B:




embedded image


wherein in the general formulae A and B, each CM or CM′ is an independent hydrophobic chemical moiety with a formal charge selected from: quaternary ammonium (I), quaternary phosphonium (II), sulfonium (III), sulfoxonium (IV), imidazolinium (amidinium) (V), guanidinium (VI), imidazolium (VII), 1,2,3,4-tetrahydroisoquinolinium (VIII), 1,2,3,4-tetrahydroquinolinium (IX), isoindolinium (X), indolinium (XI), benzimidazolium (XII), pyridinium (XIIIa, XIIIb, XIIIc, XIIId), quinolinium (XIV), isoquinolinium (XV), carboxylate (XVI), N-acyl-α-amino acid (XVII), sulfonate (XVIII), sulfate monoester (XIX), phosphate monoester (XX), phosphate diester (XXI), phosphonate monoester (XXII), phosphonate (XXIII), tetraaryl borate (XXIV), boronate (XXV), boronate ester (XXVI); wherein the chemical moieties (I)-(XXVI) have the following chemical structures:




embedded image


embedded image


embedded image


wherein in general formula B, CM and CM′ are independent charged chemical moieties having the same or opposite formal charge and are chemically attached to each other by a doubly connected chemical moiety, R*, which replaces one R1, R2 (if present), R3 (if present) or R4 (if present) chemical moiety on CM and replaces one R1, R2 (if present), R3 (if present) or R4 (if present) chemical moiety on CM′;


wherein each of R1, R2, R3 and R4 is a linear or branched chemical moiety independently defined by the formula,





—CxX2x-2r-AR1—CuX2u-2s-AR2,


R* is a direct chemical bond or is a doubly connected, linear or branched chemical moiety defined by the formula,





—CxX2x-2r-AR1—CuX2u-2s—,


and R5 is a linear or branched chemical moiety defined by the formula,





—CxX2x-2r-AR2;


wherein each AR1 independently is a doubly connected methylene moiety (—CX1X2—, from methane), a doubly connected phenylene moiety (—C6G4-, from benzene), a doubly connected naphthylene moiety (—C10G6-, from naphthalene) or a doubly connected biphenylene moiety (—C12G8-, from biphenyl);


wherein AR2 independently is hydrogen (—H), fluorine (—F), a phenyl group (—C6G5), a naphthyl group (—C10G7) or a biphenyl group (—C12G9);


wherein each X, X1 and X2 is individually and independently —H, —F, —Cl or —OH;


wherein any methylene moiety (—CX1X2—) within any —CxX2x-2r— or within any —CuX2u-2s— or within any —(CX1X2)p— may be individually and independently replaced with an independent ether-oxygen atom, —O—, an independent thioether-sulfur atom, —S—, or an independent ketone-carbonyl group, —C(O)—, in such a manner that each ether-oxygen atom, each thioether-sulfur atom or each ketone-carbonyl group is bonded on each side to an aliphatic carbon atom or an aromatic carbon atom;


wherein not more than two ether-oxygen atoms, not more than two thioether-sulfur atoms and not more than two ketone-carbonyl groups may be replaced into any —CxX2x-2r— or into any —CuX2u-2s—;


wherein mx is the total number of methylene groups in each —CxX2x-2r— that are replaced with ether-oxygen atoms, thioether-sulfur atoms and ketone-carbonyl groups, and mu is the total number of methylene groups in each —CuX2u-2s— that are replaced with ether-oxygen atoms, thioether-sulfur atoms and ketone-carbonyl groups;


wherein G is individually and independently any combination of —H, —F, —Cl, —CH3, —OH, —OCH3, —N(CH3)2, —CF3, —CO2Me, —CO2NH2; —CO2NHMe, —CO2NMe2;


wherein G* is individually and independently any combination of —F, —CI, —R2, —OH, —OR2, —NR2R3, —CF3, —CO2Me, —CO2NH2; —CO2NHMe, —CO2NMe2;


wherein a pair of R2, R3, and R4 may comprise a single chemical moiety such that R2/R3, R2/R4, R3/R4, R2′/R3′, R2′/R4′ or R3′/R4′ is individually and independently —(CX1X2)p— with p=3, 4, 5 or 6;


wherein the integer values of each of x, r, u, s, mx, mu are independently selected for each R1, R2, R3, R4, R5 and R*, integer values r and s are the total number of contained, isolated cis/trans olefinic (alkene) groups plus the total number of contained simple monocyclic structures and fall in the ranges 0≦r≦2 and 0≦s≦2, the numeric quantity x+u−mx−mu falls in the range 0≦x+u−mx−mu≦11;


wherein at least one aromatic chemical moiety, heterocyclic aromatic chemical moiety, imidazoline chemical moiety, amidine chemical moiety or guanidine chemical moiety is contained within CM or CM′ of A or B;


wherein a group-hydrophobic-index for each R-chemical-moiety (n) is numerically equal to the sum of the number of aliphatic carbon atoms plus the number of olefinic carbon atoms plus the number of thioether-sulfur atoms plus the number of chlorine atoms plus one-fifth the number of fluorine atoms plus one-half the number of ether-oxygen atoms plus one-half the number of ketone-carbon atoms plus one-half the number of aromatic carbon atoms beyond the number six minus the number of hydroxyl-oxygen atoms beyond the number one;


wherein an overall-hydrophobic-index (N) for each [CM] or [CM-R*-CM′] is numerically equal to the sum of the number of aliphatic carbon atoms plus the number of olefinic carbon atoms plus the number of thioether-sulfur atoms plus the number of chlorine atoms plus one-fifth the number of fluorine atoms plus one-half the number of ether-oxygen atoms plus one-half the number of ketone-carbon atoms plus one-half the number of aromatic carbon atoms beyond the number six minus the number of hydroxyl-oxygen atoms beyond the number one;


wherein the group-hydrophobic-indices (1n and 1′n) for R1 and R1′ fall in the range 4.0<1n,1′n<12.0, the group-hydrophobic-indices (2n, 2′n, 3n, 3′n, 5n, 5′n and *n) for R2, R2′, R3, R3′, R5, R5′, R*, when present, fall in the range 0.0≦2n,2′n,3n,3′n 5n,5′n,*n<12.0 and the group-hydrophobic-indices (4n and 4′n) for R4 and R4′, when present, fall in the range 0.0≦4n,4′n≦5.0;


wherein the overall-hydrophobic-index (N) divided by the value of g falls in the range 10.0≦N/g<24.0;


wherein in A, when the charged moiety, CM, has a formal positive charge or a formal negative charge, g=1, and in B, when CM and CM′ have formal positive charges or when CM and CM′ have formal negative charges, g=2, and in B when CM has a formal positive charge and CM′ has a formal negative charge, g=1;


wherein the numeric value of the group-hydrophobic-index calculated for a cyclic chemical moiety is divided equally between the two respective R-chemical-moieties;


wherein R1 is identified as that R-chemical-moiety when only one such chemical moiety is attached to CM or CM′; wherein R1 is identified as that R-chemical-moiety having the largest value of the group-hydrophobic-index when there are more than one such chemical moieties attached to CM or CM′; wherein R4 is identified as that R-chemical-moiety having the smallest value of the group-hydrophobic-index when there are more than three such chemical moieties attached to CM or CM′; and


wherein CI is a non-interfering, oppositely-charged counter-ion or mixture of such counter-ions, and the value of d is zero, a positive whole number or a positive fraction such that electroneutrality of the overall hydrophobic compound is maintained.


In one embodiment, the aqueous composition comprising a non-surface active hydrophobic displacer molecule is free of added salt other than a pH buffer.


In one embodiment, CM has a general formula I or II:




embedded image


wherein in the general formula I or II, R1 is a C8-C11 hydrocarbyl moiety, R2 and R3 are independently a C1-C4 hydrocarbyl moiety or benzyl, and R4 is selected from benzyl, halo-substituted benzyl, 4-alkylbenzyl, 4-trifluoromethyl benzyl, 4-phenylbenzyl, 4-alkoxybenzyl, 4-acetamidobenzyl, H2NC(O)CH2—, PhHNC(O)CH2—, dialkyl-NC(O)CH2—, wherein alkyl is C1-C4, provided that no more than one benzyl group is present in the CM.


In one embodiment, CM has a general formula I or II:




embedded image


wherein in the general formula I or II, R1 and R2 are independently C4-C8 alkyl or cyclohexyl, R3 is C1-C4 alkyl, and R4 is phenyl, 2-, 3- or 4-halophenyl, benzyl, 2-, 3- or 4-halobenzyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or 3,5-dihalobenzyl, 2,4,6- or 3,4,5-trihalobenzyl, C6H5CH2CH2— or 2-, 3- or 4-trifluoromethylbenzyl.


In one embodiment, CM has a general formula VIII, IX, X or XI, R1 is C5-C11 alkyl and R2 is C1-C8 alkyl.


In one embodiment, CM has a general formula I or II:




embedded image


wherein in the general formula I or II, R1 is C6-C11 alkyl, R2 and R3 independently are C1-C4 alkyl, and R4 is PhC(O)CH2—, 4-FC6H4C(O)CH2—, 4-CH3C6H4C(O)CH2—, 4-CF3C6H4C(O)CH2—, 4-ClC6H4C(O)CH2—, 4-BrC6H4C(O)CH2—, dl-PhC(O)CH(Ph)-, Ph(CH2)2—, Ph(CH2)3—, Ph(CH2)4—, dl-PhCH2CH(OH)CH2—, t-PhCH═CHCH2—, 1-(CH2)naphthylene, 9-(CH2)anthracene, 2-, 3- or 4-FC6H4CH2— or benzyl.


In one embodiment, CM has a general formula I or II:




embedded image


wherein in the general formula I or II, R1 is C6-C11 alkyl, R2 and R3 together are —(CH2)4—, and R4 is PhC(O)CH2—, 4-FC6H4C(O)CH2—, 4-CH3C6H4C(O)CH2—, 4-CF3C6H4C(O)CH2—, 4-ClC6H4C(O)CH2—, 4-BrC6H4C(O)CH2—, dl-PhC(O)CH(Ph)-, Ph(CH2)2—, Ph(CH2)3—, Ph(CH2)4—, dl-PhCH2CH(OH)CH2—, t-PhCH═CHCH2—, 2-, 3- or 4-FC6H4CH2—, benzyl, 3-ClC6H4CH2—, 2,6-F2C6H3CH2—, 3,5-F2C6H3CH2—, 4-CH3C6H4CH2—, 4-CH3CH2C6H4CH2—, 4-CH3OC6H4CH2—, (CH3)2NC(O)CH2— or (CH3CH2)2NC(O)CH2—.


In one embodiment, CM has a general formula I or II:




embedded image


wherein in the general formula I or II, R1 is C4-C6 alkyl, benzyl or 2-, 3- or 4-FC6H4CH2—, R2 and R3 independently are C1-C8 alkyl, CH3(OCH2CH2)2—, CH3CH2OCH2CH2OCH2CH2— or CH3CH2OCH2CH2—, and R4 is Ph(CH2)4—, 4-PhC6H4CH2—, 4-FC6H4CH2—, 4-CF3C6H4CH2—, PhC(O)CH2—, 4-FC6H4C(O)CH2—, 4-PhC6H4C(O)CH2—, 4-PhC6H4CH2—, naphthylene-1-CH2—, anthracene-9-CH2— or Ph(CH2)n—, where n=5-8.


In one embodiment, CM has a general formula [(R1R2R3NCH2)2C6H3G]2+, wherein R1 is C4-C11 alkyl, R2 and R3 independently are C1-C6 alkyl or R2 and R3 taken together are —(CH2)4—, and G is H or F.


In one embodiment, CM has a general formula [R1R2R3NCH2C6H4—C6H4CH2NR1R2R3]2+, wherein R1 is C4-C11 alkyl, R2 and R3 independently are C1-C6 alkyl or R2 and R3 taken together are —(CH2)4—.


In one embodiment, CM has a general formula III or IV:




embedded image


wherein in the general formula III or IV, R1 is C8-C11 alkyl or 4,4′-CH3(CH2)4C6H4—C6H4CH2—, R2 is C1-C6 alkyl or 4-FC6H4CH2—, and R3 is C1-C6 alkyl.


In one embodiment, CM has a general formula XIV or XV:


wherein in the general formula XIV or XV, R1 is C8-C11 alkyl, and each G and R5 are as defined above.


In one embodiment, CM has a general formula XIIIa, XIIIb, XIIIc, XIIId or XIIIe:




embedded image


wherein in the general formula XIIIa, XIIIb, XIIIc, XIIId or XIIIe, R1 is C8-C11 alkyl or C8-C11 4-phenyl, R2 is H, C1-C6 alkyl or alkoxy, 2-pyridyl, C1-C6 alkyl substituted 2-pyridyl, or pyrrolidinyl, and each G is as defined above.


In one embodiment, CM has a general formula VII:




embedded image


wherein in the general formula VII, R1 is C5-C11 alkyl, R2 and R5 are independently H or C1-C6 alkyl or phenyl.


In one embodiment, CM has a general formula XII:




embedded image


wherein in the general formula XII, R1 is C5-C11 alkyl, R2 and R5 are independently H or C1-C6 alkyl or phenyl, and G is as defined above.


In one embodiment, CM has a general formula XXIV or XXV:




embedded image


wherein in the general formula XXIV, R1 is phenyl, 4-EtC6H4—, 4-nPrC6H4—, 4-nBuC6H4—, 4-MeOC6H4—, 4-FC6H4—, 4-MeC6H4—, 4-MeOC6H4—, 4-EtC6H4—, 4-ClC6H4—, or C6F5—; and each of R2, R3 and R4 independently are phenyl, 4-FC6H4—, 4-MeC6H4—, 4-MeOC6H4—, 4-EtC6H4—, 4-ClC6H4— or C6F5—; and


wherein in the general formula XXV, R1 is 4-(4-nBuC6H4)C6H4— or 4-(4-nBuC6H4)—3-ClC6H3


In one embodiment, CM has a general formula selected from 4-R1C6H4SO3H, 5-R1-2-HO—C6H3SO3H, 4-R1—C6H4—C6H3X-4′-SO3H, and 4-R1—C6H4—C6H3X-3′-SO3H, wherein R1 is CH3(CH2)n, wherein n=4-10 and X is H or OH.


In one embodiment, CM has a general formula XVIII or XXIII:




embedded image


wherein in the general formula XVIII and in the general formula XXIII, R1 is C6H5(CH2)n—, wherein n=5-11.


In one embodiment, CM has a general formula selected from 5-R1-2-HO—C6H3CO2H and R1C(O)NHCH(C6H5)CO2H, wherein R1 is CH3(CH12)n—, wherein n=4-10.


In one embodiment, CM has a general formula 4-R1C6H4PO3H2 wherein R1 is CH3(CH2)n—, wherein n=4-10.


In one embodiment, CI is a non-interfering anion or mixture of non-interfering anions selected from: Cl, Br, I, OH, F, OCH3, d,l-HOCH2CH(OH)CO2, HOCH2CO2, HCO2, CH3CO2, CHF2CO2, CHCl2CO2, CHBr2CO2, C2H5CO2, C2F5CO2, nC3H7CO2, nC3F7CO2, CF3CO2, CCl3CO2, CBr3CO2, NO3, ClO4, BF4, PF6, HSO4, HCO3, H2PO4, CH3OCO2, CH3OSO3, CH3SO3, C2H5SO3, NCS, CF3SO3, H2PO3, CH3PO3H, HPO32−, CH3PO32−, CO32−, SO42−, HPO42−, PO43−.


In one embodiment, CI is a non-interfering inorganic cation or mixture of such non-interfering cations selected from the groups: alkali metal ions (Li+, Na+, K+, Rb+, Cs+), alkaline earth metal ions (Mg2+, Ca2+, Sr2+, Ba2+), divalent transition metal ions (Mn2+, Zn2+) and NH4+; wherein CI is a non-interfering organic cation or mixture of such non-interfering cations selected from the groups: protonated primary amines (1+), protonated secondary amines (1+), protonated tertiary amines (1+), protonated diamines (2+), quaternary ammonium ions (1+), sulfonium ions (1+), sulfoxonium ions (1+), phosphonium ions (1+), bis-quaternary ammonium ions (2+) that may contain C1-C6 alkyl groups and/or C2-C4 hydroxyalky groups.





BRIEF DESCRIPTION OF THE DRAWINGS


FIGS. 1
b, 2, 3, 4, 5, 6b(a)B and 7 are fraction analyses of the displacement data plotting fraction number (x-axis) against concentration (mg/mL) of each component in each fraction for the displacement chromatography process in accordance with exemplary embodiments of the present invention.



FIG. 6
b(a)A is a displacement trace for the purification of a crude synthetic peptide plotting time (x-axis) against relative absorbance units (y-axis) for the displacement chromatography process in accordance with an exemplary embodiment of the present invention.





DETAILED DESCRIPTION

As used herein, “non-surface-active”, with respect to a cationic non-surface-active displacer compound employed in accordance with the present invention, means that the compound so described has a critical micelle concentration (“CMC”) greater than the concentration of the compound employed in a displacement chromatography process in accordance with the present invention. In one embodiment, the concentration of the non-surface-active displacer compound is less than about 80% of the CMC for that compound in water in the absence of organic solvent, salt or other agent that would affect the CMC. In one embodiment, the concentration of the non-surface-active displacer compound is less than about 60% of the CMC for that compound in water in the absence of organic solvent, salt or other agent that would affect the CMC. In one embodiment, the concentration of the non-surface-active displacer compound is less than about 50% of the CMC for that compound in water in the absence of organic solvent, salt or other agent that would affect the CMC.


In one embodiment, the aqueous composition comprising a non-surface-active cationic hydrophobic displacer molecule employed in accordance with the present invention does not exhibit adverse surface-active characteristics due to one or a combination of two or more of (1) the cationic non-surface active displacer compound is present at a concentration lower than its CMC; (2) the overall-hydrophobic-index (N) for each [CM] or [CM-R*-CM′] divided by the value of g falls in the range 10≦N/g<24; (3) the group-hydrophobic-index (1n) for each R1 falls in the range 4<1n<12, the group-hydrophobic-index (2n, 3n, 5n and *n) for each R2, R3, R5 and R*, when present, falls in the range 0≦2n, 3n, 5n,*n<12, and the group-hydrophobic-index (4n) for each R4, when present, falls in the range 0≦4n≦5; (4) the composition contains greater than about 5 volume % or more of an organic solvent.


As used herein, “low organic solvent content” generally refers to an organic solvent content in, e.g., an aqueous “carrier” composition comprising a cationic non-surface-active displacer compound in accordance with the present invention, of less than about 25% by volume. In one embodiment, the organic solvent content of the aqueous “carrier” composition contains less than about 20% by volume of any organic solvent. In one embodiment, the organic solvent content of the aqueous “carrier” composition contains less than about 15% by volume of any organic solvent. In one embodiment, the organic solvent content of the aqueous “carrier” composition contains less than about 10% by volume of any organic solvent. In one embodiment, the organic solvent content of the aqueous “carrier” composition contains less than about 5% by volume of any organic solvent. In one embodiment, the aqueous “carrier” composition contains no organic solvent.


In one embodiment, the organic solvent is one or a mixture of two or more of methanol (CH3OH or MeOH), ethanol (C2H5OH or EtOH) or acetonitrile (CH3CN or MeCN). In one embodiment, the aqueous “carrier” composition contains a mixture of suitable organic solvents. In one embodiment, the aqueous “carrier” composition contains no organic solvent.


Hydrophobic displacement chromatography can be carried out using chiral analytes, chiral displacers and chiral chromatography matrices. Under these conditions, an achiral displacer may be used, but a racemic mixture of a chiral displacer cannot be used. Racemic chiral analytes can also be purified using an achiral chromatography column and an achiral displacer. In this case, impurities, including diastereomers, are removed from the racemic compound of interest, but there is no chiral resolution of the enantiomers.


Some of the cationic displacers described here have a quaternary nitrogen with four different groups attached and hence are inherently chiral; see for example racemic displacer compounds 43-45, 50-53, 58-59, 64-66 in Tables V-IX below. Furthermore, some of the cationic displacers contain a single chiral group attached to an achiral nitrogen atom; see for example racemic displacer compounds 203 and 206 as well as the enantiomerically pure displacer compound 67 that is derived from l-phenylalanine. With the proper choice of chiral chromatography matrix, mobile phase and achiral displacer, enantiomers are routinely preparatively resolved (separated). Depending on the specific circumstances, a good, enantiomerically pure, chiral displacer can have performance advantages over a good achiral displacer when carrying out a displacement separation of enantiomers on a chiral stationary phase.


Useful pH Ranges—Various classes of cationic hydrophobic displacers having the general formula A or B, have different useful pH ranges depending on the chemical nature of the charged moieties. Cationic hydrophobic displacers that contain deprotonatable cationic groups should be operated at a pH of 1-2 units or more below the actual pKa values. Cationic hydrophobic displacers that contain protonatable anionic groups should be operated at a pH of 1-2 units or more above the actual pKa values.

    • Onium Groups—Generally, quaternary ammonium, quaternary phosphonium, tertiary sulfonium, tertiary sulfoxonium and related cationic groups such as pyridinium, imidazolium, guanidinium have a wide useful pH range, 1-11 or greater, because they don't have deprotonatable N—H, S—H or P—H moieties under normal conditions.
    • Amine and Guanidine Groups—Tertiary aliphatic amines (pKa˜9.5) and related substituted quanidines (pKa˜13.5) with deprotonatable N—H moieties are useful cationic groups when operated at a pH of 1-2 units or more below the actual pKa values.


Displacer Binding-Strength

The displacer should bind to the column more strongly than all of the components of the sample or at least more strongly than all of the major components of interest. A good rule-of-thumb is that no more than 1-4% of the sample mass should bind more strongly than the displacer.


An optimal displacer should not bind too strongly nor too weakly to the stationary phase. The proper binding strength depends on the analyte of interest and the associated binding-isotherms. Usually, a range of displacers with a range of binding strengths is needed for a variety of different columns and analytes to be purified. If a displacer binds too strongly, poor performance is obtained such as lower resolution, lower analyte binding capacity, difficulty in displacer removal and longer cycle-times. If a displacer binds too weakly, a poor displacement train may result with too much “tailing” of the displaced analytes underneath the displacer, or there may be only partial displacement or no displacement at all.


A convenient, rule-of-thumb method that helps in choosing displacers with the proper binding strength is to carry out simple gradient elution chromatography of potential displacers and analytes using similar columns and mobile phases that are to be used in the displacement experiment. As a first screen, the displacer should elute 5-15 minutes later than the analytes of interest in a 60 minute gradient. Ideally one would measure the isotherms of the single analytes and mixtures of analytes but this is time-consuming and often impractical. Because it operates early on the binding-isotherm, this rule-of-thumb method is not perfect, but provides a convenient starting point for further DC optimization.


Displacer Binding-Strength

The displacer should bind to the column more strongly than all of the components of the sample or at least more strongly than all of the major components of interest. A good rule-of-thumb is that no more than 1-4% of the sample mass should bind more strongly than the displacer.


An optimal displacer should not bind too strongly nor too weakly to the stationary phase. The proper binding strength depends on the analyte of interest and the associated binding-isotherms. Usually, a range of displacers with a range of binding strengths is needed for a variety of different columns and analytes to be purified. If a displacer binds too strongly, poor performance is obtained such as lower resolution, lower analyte binding capacity, difficulty in displacer removal and longer cycle-times. If a displacer binds too weakly, a poor displacement train may result with too much “tailing” of the displaced analytes underneath the displacer, or there may be only partial displacement or no displacement at all.


A convenient, rule-of-thumb method that helps in choosing displacers with the proper binding strength is to carry out simple gradient elution chromatography of potential displacers and analytes using similar columns and mobile phases that are to be used in the displacement experiment. As a first screen, the displacer should elute 5-15 minutes later than the analytes of interest in a 60 minute gradient. Ideally one would measure the isotherms of the single analytes and mixtures of analytes but this is time-consuming and often impractical. Because it operates early on the binding-isotherm, this rule-of-thumb method is not perfect, but provides a convenient starting point for further DC optimization.


Usable Binding-Isotherms

Apart from proper binding strength, useful hydrophobic displacers need to have binding-isotherms with certain other useful characteristics.


(1) Monomodal, convex upward isotherms (Langmuir-type isotherm behavior) for displacer and analyte molecules facilitate the orderly formation of isotactic displacement trains and simplify the method optimization process. This is a useful property of many cationic displacer molecules in contrast to binding-isotherms of many other uncharged hydrophobic displacer molecules (non-zwitterions) such as aromatic alcohols (e.g., substituted phenols, naphthols, hydroxybiphenyls), fatty alcohols (e.g., 1-dodecanol, 1,2-dodecanediol) and uncharged fatty carboxylic acids (e.g., myristic acid) behave normally at lower concentrations and then become bimodal and rise again at higher concentrations (BET-type isotherm behavior). This binding behavior often arises from deposition of multiple layers of the hydrophobic displacer, each layer having different binding characteristics. This binding behavior greatly complicates the displacement process and its useful implementation.


(2) Chromatographic results in DC are also complicated when displacer molecules undergo self-association in solution. As concentrations increase, problems with displacer self-association become worse. Again, the charged groups in cationic hydrophobic displacers inhibit self-association problems in aqueous solution.


(3) Further complications also arise when product and/or impurity isotherms cross the displacer isotherm in the higher, non-linear binding region. This behavior leads to reversal of displacement order, broadening of overlap regions between displacement bands and problems with co-displacement. In this case, minor variations in displacer concentration can lead to large changes in the displacement train thereby making method optimization very difficult.


We have found that properly designed cationic displacer molecules supplemented with the proper counter-ions and small amounts of useful organic solvents provide a family of effective hydrophobic displacers with Langmuir-type binding behavior and useful ranges of binding strengths.


Ion-Pairing Anions for Cationic Displacers

With all of their many advantages, cationic hydrophobic displacer molecules have one extra requirement: choosing a good ion-pairing anion, CI. The ion-pairing anion significantly affects the binding-isotherm of the displacer and the functioning and utility of the displacer. The concentration of the ion-pairing agent is independently adjusted by adding appropriate amounts of K+, NH4+, protonated amine salts of an ion-pairing anion or Cl/HCO2 salts of an ion-pairing cation. The properties of an ion-pairing anion for a cationic hydrophobic displacer strongly affects its displacement properties. A few anions may be involved in ion-pairing in solution, and nearly all anions are involved in ion-pairing in the adsorbed state on the hydrophobic chromatography matrix. The same ion-pairing agent(s) for displacer and analyte should be used for good chromatographic resolution. Useful ion-pairing counter-ions are usually singly charged. Owing to their higher solvation energies, divalent ions (SO42−) and trivalent ions (PO43−) are generally less useful but may be used in some specialized cases. Exceptions to this general rule are multiple, singly-charged moieties spaced apart in a single organic ion such as O3S(CH2)4SO3.


Anions with greater hydrophobic character tend to increase binding-strength and also decrease solubility. Furthermore, when using hydrophobic displacer salts, resolution of DC may decrease if the anion itself is either too hydrophobic or too hydrophilic. Typically, intermediate hydrophobic/hydrophilic character of the anion gives best results, but this varies depending on the molecule being purified. The optimal counter-ion for each purification should be determined experimentally. For example, a hydrophobic quaternary ammonium displacer with CH3CO2 counter-ion gives good solubility and mediocre resolution, with CF3CO2 gives mediocre, but acceptable, solubility and good resolution, and with CCl3CO2 gives poor solubility and mediocre resolution. Volatile ion-pairing agents are conveniently removed under reduced pressure, while nonvolatile ones are readily removed by other means such as diafiltration, precipitation or crystallization. Table I gives a partial list of useful monovalent ion-pairing anions. When using anionic ion-pairing agents, the operating pH should be 1-2 pH units or more above the pKa of the respective acid. A notable exception to this guideline is trifluoroacetic acid that acts as both ion-pairing agent and pH buffer at the same time.









TABLE I





Monovalent Anions in Approximate Order of Ion-pairing Strength
















Weak
Fluoride < Hydroxide < Gluconate < Glycerate <



Glycolate < Lactate


Moderate
Formate < Acetate < Bicarbonate < Propionate < Butyrate <



Methanesulfonate < Ethanesulfonate < Difluoroacetate <



Chloride


Medium Strong
Bromide < Trifluoroacetate < Dichloroacetate < Nitrate


Strong
Triflate < Iodide < Dibromoacetate < Thiocyanate <



Trichloroacetate < Perchlorate < Hexafluoroisobutrate <



Pentafluoropropionate < Tetrafluoroborate <



Hexafluorophosphate < Tribromoacetate









Mixed anions often lead to loss of chromatographic resolution and are generally to be avoided. However, there is one set of conditions when mixed anions may be used; that is, when both (a) the anion of interest has significantly stronger ion-pairing properties than the other anions that are present and (b) the anion of interest is present in stoichiometric excess in the sample loading mixture and in the displacer buffer.


The most commonly used ion-pairing anions are formate, acetate, chloride, bromide and trifluoroacetate. Owing to lower ion-pairing strength, formate and acetate require careful optimization in order to obtain good resolution. Bromide and trifluoroacetate seem to give the best results for peptides and small proteins. Generally, good chromatographic results can be obtained with chloride and bromide as ion-pairing anions, but two special precautions should be exercised. (1) Under acidic conditions, the chromatography solutions cannot be degassed by helium purging or by vacuum degassing owing to loss of gaseous HCl or HBr thereby changing the pH and changing the concentration of the anion. This problem is overcome by using degassed distilled water for preparing chromatography solutions and storing the solutions in closed containers to prevent reabsorption of air. (2) Chloride and bromide are potentially corrosive to stainless steel HPLC equipment, but equipment made from PEEK, Teflon, ceramic, glass and titanium is safe. The main problem is halide-catalyzed corrosion of stainless steel caused by air (oxygen) at low pH. If HPLC solutions are properly deoxygenated, halide-promoted corrosion of stainless steel is greatly reduced.


Solubility

In “hydrophobic chromatography” or, more properly, “solvophobic chromatography”, where the principal solvent component is water, potential hydrophobic displacer molecules often have limited solubility. Hydrophobic molecules usually do not dissolve in water to any appreciable extent unless there are “hydrophillic groups” attached to the hydrophobic molecule, such as charged ionic-groups, hydrophillic counter-ions, polar groups or groups that function as hydrogen-bond donors or acceptors. Aromatic molecules interact with water in a unique fashion owing to the unique manner in which the pi-electrons act as weak hydrogen-bond acceptors. Furthermore, aromatic molecules can engage in face-to-face pi-stacking in aqueous solution. These small but important effects are reflected in the higher solubility in water of benzene (9 mM) and naphthalene (200 μM) compared with cyclohexane (˜10 μM) and trans-decalin (<1 μM) and in the higher solubility of phenol (960 mM) and β-naphthol (7 mM) compared with the unhydroxylated arenes. The molecular structure of a useful displacer molecule should facilitate a reasonable solubility (10-50 mM) in water or in water with low organic content yet at the same time be sufficiently hydrophobic that it binds strongly to the stationary phase. Generally, charged displacer molecules have better solubility properties than neutral ones owing to the increased solvation energies of charged species, especially counter-ions. It requires a unique balance of physical and chemical properties for neutral zwitterionic molecules to behave as good displacers. Cationic hydrophobic displacers display unique solubility properties.


It is important to note, generally speaking, that increasing the levels of the organic solvent in order to compensate for poor displacer solubility rarely leads to useful results. Best chromatographic results are obtained with 0-25% organic solvent, or more preferably, 2-15% organic solvent. Higher organic content (25-75%) of the mobile phase may be used in some cases but usually capacity and resolution often suffer badly.


Reduced Product-Displacer Association

One potential problem with hydrophobic displacement chromatography is the possible association of a hydrophobic displacer with a hydrophobic analyte in solution. This can lead to significant loss of resolution and contamination. Displacer-analyte association in the adsorbed state on the stationary phase also can occur but is less problematic with proper amounts of suitable ion-pairing agents present. A good method to deal with this problem is to use charged analytes and charged hydrophobic displacers with the same charge.


Displacer Self-Association and Micelle Formation

In some cases when the chemical structure and physical properties are conducive, cationic hydrophobic molecules can self-associate, forming micelles and micelle-like, self-associated structures in solution. This situation can lead to loss of resolution in DC as well as unwanted foaming of displacer solutions. The displacer in solution finds itself in various forms that are interrelated by various chemical equilibria. Furthermore, micelles can act as carriers for hydrophobic analyte molecules causing them to exist in solution in various forms. This unwanted phenomenon is concentration dependent and is effectively inhibited by the addition of small amounts of a suitable organic solvent such as methanol, ethanol or acetonitrile. Properly designed, cationic displacer molecules disenhance micelle formation and give better displacement results. Thus, keeping the group-hydrophobic-indices below 12.0 for R-groups, R1-R3, reduces the problem of unwanted detergency.


High Purity—Impurities in Displacers

A displacer should have adequate purity. The object of preparative chromatography is to remove the impurities from a component of interest. Contamination of the desired compound by the displacer itself is rarely a problem, but contamination by “early displacing” impurities in the displacer solution may be problematic in some cases depending on the amounts of the impurities and their binding properties. Thus, a good displacer should contain little or no early displacing impurities.


Suitable UV Absorbance

In order to track the location and amounts of displacer throughout the DC experiment, to watch displacer breakthrough curves and to follow displacer removal during column regeneration procedures, it is useful to have a displacer with moderate ultraviolet absorption. High absorption is not needed nor is it preferred owing to the high concentrations of displacer and analyte. Generally, colorless displacers are preferred with a UV spectrum that has strategically located windows of low absorbance so that the analytes can be followed at some frequencies and the displacer monitored at other frequencies.


Ease of Manufacturing and Cost

Convenient and cost-effective methods of chemical synthesis, production and manufacturing are important in order to produce useful displacers and reasonable costs. Furthermore, practical methods of purification, especially non-chromatographic purification, are needed in order to achieve the purity requirements in a cost-effective manner.


Chemical Stability, Low Toxicity and Long Shelf-Life

Among all its other desired chemical and physical properties, a useful displacer molecule should be chemically stable. It should be inert toward analyte molecules and chemically stable (non-reactive) toward water, common organic solvents, mild bases, mild acids and oxygen (air). It should be photo-stable and thermally stable under typical use and storage conditions and have a reasonable shelf-life. It greatly preferred that displacer molecules be visually colorless, yet have the requisite levels of UV absorbance. Useful displacer molecules also need to have low toxicity, not only to protect workers but to protect biological and drug samples that may come into contact with the displacer.


Suitable Chromatographic Columns:

While the most common type of reversed-phase column is octadecyl coated silica, many hydrophobic stationary phases find utility in DC (see Table III). Ultimately, the best choice of stationary phase is experimentally determined for each system under study.









TABLE II





Materials for Hydrophobic Stationary Phases















Coated Porous Silica (covanently bonded silanes)










Octadecyl (C18)
Docecyl (C12)



Octyl (C8)
Hexyl (C6)



Butyl (C4)
Pentafluorophenylpropyl (C6F5—C3)



Phenylpropyl (Ph—C3)
Phenylhexyl (Ph—C6)



p-Biphenyl (Ph—Ph)
β-Naphthylethyl (Nap-C2)







Uncoated Porous Polystyrene/Divinylbenzene


Porous Fluorocarbon Polymer


Porous Polyoctadecylmethacrylate Polymer


Carbon-like Phases:









Porous Graphitized Carbon



Cleaned Charcoal



Carbon over Porous Zirconia



C18 Bonded to Carbon over Porous Zircona







Organic Polymer Coatings over Inorganic Oxides


Mixed-Mode Hydrophobic Phases









C18 with negative surface charge



C18 with positive surface charge



C18 with buried negative charge



C18 with buried positive charge










Better results in displacement chromatography are obtained with longer, well-packed columns that give better recovery and yield. Table IV provides a guide for initial choices of column dimension and initial flow-rates.









TABLE III







Chromatography Column Dimensions












Particle
Column
Column
Column
Initial
Sample


Size
Length
Dia.
Volume
Flow
Injection


(μm)
(mm)
(mm)
(mL)
Rateb
Method

















2
100
2.1
0.3464
43.3
μL/min
3
mL loop


3
150
2.1
0.5195
43.3
μL/min
5
mL loop


3
150
3.0
1.060
88.4
μL/min
10
mL loop


3
150
4.6
2.493
208
μL/min
20
mL loop/


Pump






Inject.


5
250
4.6
4.155
208
μL/min
40
mL loop/


Pump






Inject.













5
250
10.0
19.63
982
μL/min
Inject. Pump


5
250
20.0
78.54
3.93
mL/min
Inject. Pump


10

500a

10.0
39.27
982
μL/min
Inject. Pump


10

500a

20.0
157.1
3.93
mL/min
Inject. Pump


10

500a

30.0
353.4
8.84
mL/min
Inject. Pump


10

500a

50.0
981.7
24.5
mL/min
Inject. Pump





a) 500 mm or 2 × 250 mm


b) Initial flow-rate = 75 cm/hr (12.5 mm/min); needs to be optimized






Proper column length is important for good results. It should be long enough to fully sharpen the displacement train and give good resolution. Yet columns that are too long needlessly increase separation time and often lead to poorly packed beds and reduced resolution. In many cases, two well-packed columns can be attached end-to-end with good chromatographic results. Considerable experimentation with small molecules (MW<3 KDa) indicates that optimal column length falls in the range 15-45 cm for 5 μm particles and 20-60 cm for 10 μm particles. Porous particles with pore sizes of 80-100 Å are suitable for traditional drugs and small peptides, 120-150 Å are suitable for medium and large oligopeptides and oligonucleotides and 300-500 Å are suitable for most proteins and DNA. Non-porous particles can be used, but loading capacity will significantly decrease.


In cylindrical columns, it is important that a planar flow-front be established so that it is perpendicular to the axis of flow. Scaling up to purify larger amounts of sample is simple and straightforward in displacement chromatography once an optimized protocol has been developed on a smaller column. After the shortest acceptable column-length is found, scale-up is simply accomplished by increasing column diameter while maintaining a constant linear flow-rate. With proper modifications, displacement chromatography can be used with radial-flow columns and with axial-flow monolith columns. The principles of displacement chromatography can be applied in analytical and preparative thin-layer chromatography.


Running Successful Displacement Chromatography Experiments

Though displacement chromatography of organic compounds, traditional drugs and peptides has been carried out for many years, mediocre-to-poor results are often obtained. Good displacers, good columns and good operational protocols lead to excellent reproducibility and remarkably good chromatographic performance.


Displacer and Concentration

Initial evaluation is carried out using a good general purpose cationic displacer with proper binding strength. Cationic displacers can be used to purify cationic, neutral non-ionic and neutral zwitterionic analytes. The displacer should bind to the column more strongly than the material to be purified, but the displacer should not bind too strongly. Typical displacer concentrations are in the range 10-50 mM. Initially, displacer concentration is set at 10-15 mM. As needed, pH buffer and ion-pairing anion are added to the displacer solution. The displacer solution and carrier solution should have identical compositions (including pH), except for the presence of displacer and the level of the ion-pairing anion. Displacers 14, 198 and 318 (below) are examples of good general-purpose cationic displacers. During method optimization, it may be helpful to increase displacer concentration up to 20-30 mM or higher.


Choosing an Ion-Pairing Agent


Not using an ion-pairing agent, using an ineffective ion-pairing agent, using mixed ion-pairing agents and using insufficient levels of a good ion-pairing agent are some of the major causes of poor chromatographic performance in displacement chromatography experiments. This is not generally appreciated or understood by those who carry out hydrophobic displacement chromatography. This is amply demonstrated in Example 8 below. Table I contains lists of useful, monovalent, ion-pairing anions that are useful for hydrophobic chromatography. They are needed when the analyte or displacer is charged. For charged analytes and displacers, binding-isotherms strongly depend on the chemical properties of the counter-ion and its concentration. Those ion-pairing agents with moderate to moderately strong binding properties are usually the best to use. When starting experimentation with ion-pairing agents, try bromide or trifluoroacetate (free acid or NH4+ salt) as ion-pairing anions. When the analyte requires an ion-pairing anion, it usually dictates the choice of ion-pairing anion for the cationic displacer in the DC experiment. The ion-pairing anion for the analyte and the displacer should be the same.


Concentration of Ion-Pairing Agent

As noted earlier, using insufficient levels of a good ion-pairing agent is one of the major causes of poor chromatographic performance in displacement chromatography experiments. The formula for calculating the suitable concentration of the ion-pairing agent in the sample solution (CIPS, mM)) is given by,






C
IPS
=E
s
×C
s(mM)×Gs


where Es is the excess factor for the sample, Cs is the concentration of the sample (mM) and Gs is the absolute value of the net charge of the sample at the operative pH. The optimal value of Es is a parameter that needs to be determined experimentally. The formula for calculating the suitable concentration of the ion-pairing agent in the displacer solution (CIPD, mM) is given by,






C
IPD
=E
d
×C
d(mM)×Gd


where Ed is the excess factor for the displacer, Cd is the concentration of the displacer (mM) and Gd is the absolute value of the net charge of the displacer at the operative pH. The optimal value of Ed is a parameter that needs to be determined experimentally. It is essential that at least a stoichiometric amount of the ion-pairing agent be present in the solutions (Es≧1.0 and Ed≧1.0). In practice, it is our experience that Es should be in the range 1.1-10.0, more preferably in the range 1.2-6.0, more preferably yet in the range 1.5-4.5. Furthermore, it is our experience that Ed should be in the range 1.1-10.0, more preferably in the range 1.2-4.0. Serious deterioration in chromatographic performance results when the ion-pairing concentrations are unoptimized or too low, that is Es<1.0 and/or Ed<1.0.


Choosing a Good RP Column

For initial reversed-phase work, several good quality octadecyl on silica or phenylhexyl on silica columns should be evaluated (5 μm spherical particles with dimensions 4.6×250 mm). Scaleup to larger preparative columns can come later and is relatively straightforward. A critical issue is to choose a suitable pore size. Matrices with pores that are too large or too small often lead to reduced capacity and sometimes reduced resolution. See Tables II and III above.


Flow-Rates

Because displacement chromatography is a “quasi-equilibrium technique”, relatively slow flow-rates are often needed. The optimal flow-rate is the fastest flow-rate possible without losing resolution. Sample loading flow-rate and displacement flow-rate should be about the same, both in the range of 35-105 cm/hr. Start at 75 cm/hr for traditional drugs, oligopeptides and oligonucleotides or 40 cm/hr for proteins and DNA. Regeneration flow-rates should be 2-8 times the displacement flow-rate. When purifying drugs, peptides or oligonucleotides at elevated temperatures on reversed-phase columns, faster flow-rates might be used.


Temperature

Because reversed-phase chromatography and other forms of hydrophobic chromatography are largely driven by +TΔS with +ΔH, higher temperature often leads to stronger binding, faster binding kinetics and distinctly different resolution. As a consequence, the temperature of the column and, to some extent, displacement buffers should be carefully regulated (+/−0.5° C.) in order to prevent band broadening. Initial work is often carried out at 25° C., and then elevated temperatures (45, 65° C.) are tried if the sample will tolerate it, and the boiling point of the organic solvent is suitable.


Choosing an Organic Solvent

Although most water-miscible organic solvents will function, acetonitrile, methanol and ethanol are most commonly used. Some DC purifications are carried out with little or no organic solvent at all. This allows practical RPC and HIC purification of undenatured proteins with low salt and low organic solvent. Operating without organic solvent may also be helpful when there are safety issues associated with volatile, flammable solvents. When experimenting, first try acetonitrile for peptides, low molecular-weight organic drugs and small proteins or methanol for large proteins oligonucleotides and DNA. If solubility of the sample in water is acceptable, start with 3% v/v MeCN, 4% v/v EtOH or 5% v/v MeOH in the carrier buffer, the displacer buffer and sample loading solution; the organic content of these three solutions should be the same. Organic solvent content is an important parameter that needs to be optimized for each sample, column and displacer. For general purpose operation, organic solvent should be less than about 15 volume %, more preferably less than about 10 volume %, more preferably yet about 5 volume %. When Octadecyl columns are used, 2-3% acetonitrile, 3-4% ethanol or 4-5% methanol is usually needed for optimal functioning of the matrix. Phenylhexyl and Octyl columns can usually tolerate the absence of organic solvent.


Choice of pH and pH Buffer

pH buffers are needed when there are ionizable protons in


the sample, displacer, ion-pairing agent or on the stationary phase. Some samples are only stable within certain pH ranges. For some samples, chromatographic resolution is strongly pH-dependent. Generally, cationic samples are purified using cationic displacers and cationic buffers. The anions associated with the cationic buffers should be the same as the ion-pairing anion. In some cases, a different anion can be used as long as it has significantly weaker ion-pairing properties. Likewise, an anionic pH-buffer may be used if it has much weaker ion-pairing properties than the principle ion-pairing anion; thus, formic acid and acetic acid can be used as pH buffers when trifluoroacetate is the ion-pairing anion. For obvious reasons, neutral and cationic amines with low pKa values are useful pH-buffers: N,N,N′,N′-tetramethylethylene-diamine (5.9, TMEDA), N-ethylpiperazine (5.0, NEP), N,N-dimethypiperazine (4.2, DMP), diazobicyclooctane (3.0, DABCO).









TABLE IV







Buffering Systems for 10 mM [D+] [O2CF3] Displacer










pH
Buffer
IP Agenta
Adjust pH





2.0
12 mM CF3CO2H
CF3CO2
NH4OH


2.0
18 mM H3PO4 +
CF3CO2
NH4OH



10 mM CF3CO2H




3.0
20 mM DABCO +
CF3CO2
HCO2H



10 mM CF3CO2H




3.5
20 mM HCO2H +
CF3CO2
NH4OH



10 mM CF3CO2H




4.2
20 mM DMP +
CF3CO2
HCO2H



10 mM CF3CO2H




4.6
20 mM CH3CO2H +
CF3CO2
NH4OH



10 mM CF3CO2H




5.9
20 mM TMEDA +
CF3CO2
HCO2H



10 mM CF3CO2H









Co-Displacement

When working with samples that contain hundreds components and impurities, co-displacement is an almost unavoidable phenomenon because there are likely to be several minor components that co-displace with the major component of interest no matter where on the binding isotherms the DC experiments take place. Fortunately, co-displacement in displacement chromatography is a far less serious problem than co-elution in preparative elution chromatography. Co-displacement occurs under two, conditions: (1) when binding-isotherms are so similar that there is poor resolution and (2) when there is crossing of binding-isotherms near the operating region of the binding-isotherm. Fortunately, there are simple ways to deal with this issue: carry out a second DC experiment under different conditions by operating at a different point on the binding-isotherms by,

    • a. changing the concentration of the displacer,
    • b. changing to a different displacer with different binding properties.


Alternatively, the isotherms themselves can be changed by,

    • c. changing the chromatography matrix (stationary phase),
    • d. changing the concentration of the organic solvent,
    • e. changing to a different organic solvent,
    • f. changing to a different ion-pairing agent,
    • g. changing the temperature.


A second “orthogonal” IP-RP DC step typically gives excellent purity (˜99.5%) with excellent yield (90-95%).


Method of Sample Loading

A sample is loaded onto the column through a sample injection valve using one of two methods. The sample should be loaded under frontal chromatography conditions at the same point on the binding-isotherm at which the DC experiment takes place. The carrier is not passed through the column after the sample is loaded. Method 1: A sample loading pump is used; Method 2: An injection loop is used. Usually, only partial loop injection is used. The sample in the loop should be driven out of the loop onto the column first by the carrier and then the displacer solution. Not more that 85-95% of the loop volume should be loaded onto the column so that sample diluted by carrier is not loaded.


Column Loading

DC experiments are carried out at relatively high loading, typically in the range 60-80% of maximum loading capacity. The operative column loading capacity is not a fixed number; rather, it depends upon where on the binding-isotherm the DC experiment operates.


Not all of the column capacity is available for use (see “Exception” below). In practice, only 90-98% of the column capacity can is usable. Once the sample has been loaded onto the column, the displacer buffer is then pumped onto the column. There are three fronts that develop each traveling at different velocities down the column: (1) the liquid front (T1, displacer buffer minus displacer), (2) the sample front (T2) and (3) the displacer saturation front itself (T3). The first front travels faster than the second and third fronts and limits the useable column capacity because the first front should exit the column before the displacement train (T2) begins to exit. The actual velocities of the fronts depend directly on the displacement flow-rate. The ratio, α, of the front velocities, Vel1/Vel2, is given by the formula:





α=Km/(R×Cd)


where Km is the displacer binding capacity of the matrix (mg displacer per mL packed matrix) at displacer concentration of Cd, where Cd is the displacer concentration in the displacer buffer (mg displacer per mL displacer buffer), R is the ratio of the volume of the liquid in the column to the total volume of the column (mL liquid per mLm bed volume). The maximum % usable column capacity is given by,





(100×(α−1))/α.


In examples 1 b and 6b(a) below, the respective α-values are 22.24 and 21.49, and the respective maximum column capacities are 95.5% and 95.3%. Note that as Cd increases, Km will also increase, but not as much if operating high on the nonlinear part of the isotherm. Thus, α will decrease and maximum % usable column capacity will decrease.


Exception—If significant levels of unwanted, early-displacing impurities are present in the sample, one can increase the usable capacity of the column, even beyond 100% by overloading the column and spilling out these impurities during sample loading before the displacer flow is started. Thus, the column loading could be 105% of maximum based on the whole sample, but the column loading would be only 80% based on the amount of main product plus late-displacing impurities.


Concentration and Volume of Sample Solution

The concentration of the load sample is an important operating parameter. The optimal sample loading concentration (mg/mL) is the same as the output concentration of the purified product from the displacement experiment—the plateau region of the displacement train. Binding-isotherms, the column binding capacities and the output concentrations are initially unknown. Simply carry out the first displacement experiment with the sample solution loaded onto the column using initial estimates as shown below:


(1) Pick an initial column loading percentage at which the one wishes to work, say 75%.





Sample loading time=displacer breakthrough time (T3−T1)×0.75=(586 min−270 min)×0.75=237 min (for Example 6b(a))


(2) Pick an initial concentration for the sample by one of two methods:


(a) Initial sample conc. (mg/mL)=0.25×disp. conc. (mM)×formula wt. (mg/μmole)

    • =0.12×10 mM×1.7466 mg/μmole=2.10 mg/mL (for Example 6b(a))


(b) Pick an estimated column binding capacity for the sample, say 50 mg sample/mL matrix. Assume displacement flow-rate and sample loading flow-rate are the same:

    • Initial sample conc. (mg/mL)=(col. binding capacity (mg/mLm)×col. volume (mLm)/((T2−T1)×sample flow-rate (mL/min))=(50 mg/mLm×4.155 mLm)/((586 min−270 min)×0.208 mL/min)=3.16 mg/mL (for Example 6b(a))


If the first DC experiment with loaded sample leads to overloaded conditions (>100% loading), rerun the experiment at one-half the sample concentration. From the results of the first successful DC experiment while using a sample, actual loading concentration and actual column loading capacity are readily calculated, and those values are then used in adjusting sample concentration and loading for the second DC experiment.


Sample Preparation

The loading sample solution is prepared at the concentration and amount described above. Enough excess solution is needed for overfilling the loop or filling the dead volume of a sample loading pump and delivery lines. The pH, amount of pH buffer and amount of organic solvent are the same as the carrier and displacer buffer. Dissolving the sample in the carrier changes its pH, so the pH of the sample solution will have to be re-adjusted after dissolution. However, the amount of ion-pairing agent may be different. The ion-pairing agent used in the sample solution must be the same one used in the displacer buffer. In this regard, the ion-pairing requirements of the sample dictate which ion-pairing agent is used in the sample solution and in the displacer solution. Based on the formal chemical charge at the operating pH and the concentration of the main analyte, the concentration of the concentration is the ion-pairing agent or ion-pairing salt is calculated. See “Concentration of Ion-Pairing Agent” above.


The composition and history of the sample should be known. If the sample contains an anion, its chemical nature and amount (concentration) should also be known. (a) Obviously, if no anion is present, then no adjustment is made in sample preparation. (b) If the anion in the sample is the same as the ion-pairing anion used in the DC, then the amount of added ion-pairing anion to the sample solution is reduced accordingly. (c) If the anion in the sample has significantly weaker ion-pairing properties than the ion-pairing anion used in the DC, then its presence is ignored. (d) If the anion in the sample has stronger ion-pairing properties than the ion-pairing agent used in the DC, then the anion should be exchanged or removed before proceeding.


Collecting Fractions

Displacement chromatography gives excellent chromatographic resolution, especially with optimized protocols using a good C18-reversed-phase column. However, the resolution is difficult to see because all of the bands come off the column together as back-to-back bands in the displacement train. Many of the small impurity triangle-bands are less than 30 seconds wide (<100 μL). Thus, an experiment with a displacer breakthrough time of 250 minutes and 80% sample loading, the displacement train would be about 200 minutes wide, and more that 400 fractions would have to be taken so that chromatographic resolution is not lost during the fraction-collection process. Analyzing 400 fractions is truly enlightening and interesting but also a daunting task. This is when online real-time fraction analysis would be useful. In practice, we throw away resolution and collect only 100-130 larger fractions. Even this number of fractions represents a lot of work.


In the circumstance in which a preparative DC experiment is conducted and only the purified main component is of interest, the fraction collecting process is greatly simplified. Based on the shape of the displacement train observed at various frequencies (UV), the beginning and ending of main band of interest is judged and then about 10 fractions are analyzed in both regions in order to determine which fractions to pool. Analyzing 20 fractions instead of 100-130 fractions is an easier task.


Displacer Removal and Column Regeneration

The displacer is removed using 5-10 column volumes of 95/5 (v/v) ethanol-water or 80/10/10 (v/v/v) acetonitrile-npropanol-water without any pH buffer or ion-pairing agent. The object is to efficiently remove >99.9% or more of the displacer from the column in the shortest amount of time. The flow-rate is increased (100-400 cm/hr) in order to speed up the column regeneration process if the matrix will tolerate the increased back-pressure. Observing the displacer removal near the absorption maximum of the displacer (see displacer instructions) allows the regeneration process to be carefully monitored and optimized by UV detection.


Effects of Added Salt

Salts in aqueous solvents lead to solvents that are less hospitable to dissolved hydrophobic analytes and hydrophobic displacers resulting in stronger binding to hydrophobic chromatographic matrices. This is the principle behind hydrophobic-interaction chromatography (HIC). So long as solubility of the analyte is sufficient in the salt solution, the addition of salt is a good way to modulate analyte binding and selectivity to a hydrophobic matrix.


In some cases, analyte binding to a hydrophobic matrix is so weak that added salt is needed in order to obtain sufficient analyte binding. Commonly used salt solutions are 0.5-2.5M (NH4)2SO4, K2SO4, Na2SO4, NaCl, KCl. With the help of many different salts at various concentrations, HIC in displacement mode offers many options for useful chromatographic separations of proteins.


Instrument Protocols

See example protocol for Example 1 (dual pump operation). Because residual displacer from previous experiments is a potential problem, the protocol has line purging operations, a quick column regeneration and equilibration operations in order to make sure that the HPLC system and column are completely clean and properly equilibrated just before sample loading. These steps are simply precautionary and not always necessary. The protocol includes the (a) a pre-equilibration sequence, (b) an equilibration sequence, (c) a sample loading sequence (d) a displacement sequence and (e) a regeneration sequence in a single protocol. In order to overcome problems with dead-volume in the system, all loading buffers, displacer buffers and sample solutions are purged through the system to waste just prior to pumping onto the column. This way, the column sees a sharp front of undiluted solutions immediately upon valve switching. The sample solutions should be degassed so that gas bubbles do not form in them. When injection loops are used, they need to be overfilled by about 10%. The overfill can be collected for further use. Full loop injections should not be used, only partial loop injections. Experience dictates that only 85-95% of the loop volume can be used depending on the inner diameter of the loop tubing because the sample solution mixes with the driver solution and dilutes it. The sample in the loop is driven onto the column by the loading buffer, but toward the end of the sample loading process, the driving solution is changed to the displacer buffer. This allows the displacer buffer to be purged through the system just prior to the displacer buffer itself being pumped directly onto the column. During the initial part of the regeneration process, slower flow-rates are used Thus, problems with high backpressure rarely occur. Once most of the displacer has been removed, higher flow-rates can be used.


Method Optimization

As with all forms of preparative chromatography, optimization of the chromatographic methods and procedures is important, but it requires some effort. The benefits of displacement chromatography come with a price-time. The time-consuming factors are minimized during method optimization.

    • Determine near optimal conditions for the displacement purification without regard for the time of the separation.
    • Increase the displacer concentration and the concentration of the sample loading solution until resolution decreases.
    • Increase the displacement flow-rate and the sample loading flow-rate until resolution decreases.
    • Shorten the pre-equilibration sequence and the displacer removal/column regeneration sequences.


Existing protocols provide a useful starting point for method optimization, but they will need modification for the specific sample under study. A sample protocol (Example 1) is shown below that has been optimized for purity without regard to time. It is important to carry out method optimization adapted for the specific physical properties and chromatographic properties of the sample of interest. Upon optimization, longer methods (600-800 min) often can be reduced to 200-300 minutes and in some cases reduced to 100-150 minutes.


Hydrophobic chromatography used in displacement mode has (a) high matrix productivity (gram of product per liter matrix over the lifetime of the matrix), (b) high volume productivity (gram of product per liter of column volume), (c) high solvent productivity (gram of product per liter of solvent used) yet (d) may have mediocre time productivity (gram of product per liter of unit time). Proper method optimization mitigates the time factor.


Properly Configured Instrumentation:

A typical instrumental configuration for a small preparative HPLC system is given below.

    • Main Pump: stainless steel, titanium, ceramic, PEEK; accurate 0.01-10 mL/min flow-rate; 3000-4500 psi pressure.
    • Optional Column Bypass Valve: two-position, six-port switching valve (stainless steel, PEEK); column inline or bypass column. This is a convenience option.
    • Required Sample Injection Valve: two-position, six-port injection valve (stainless steel, PEEK) for injection loop or sample injection pump.
    • Injection Loop: 20-40 mL injection loop (stainless steel, PEEK). Loop should be overloaded (˜10%). Only partial loop injection is used, typically no more than 85-95% of loop volume. Use one, either an injection loop or a sample pump.
    • Sample Pump: this is similar to main pump for sample injection. Sample should be compatible with flow path of pump head. Use one, either an injection loop or a sample pump. With a two-pump operation, the flow-rates of the two pumps should be calibrated so that their flows can be matched.
    • No Gradient Mixer: bypass or remove the gradient mixer in displacement chromatography.
    • UV Detector: Multiple wavelength or photo-diode-array detector, 200-400 nm frequency range, with short-path, low-volume quartz flow-cell (0.2-2.0 mm flowpath, <10 μL flow-volume).
    • Optional Conductivity Detector: conductivity detector with flow cell, 0.1-200 mS, <100 μL flow-volume after UV detector; bypass conductivity flow-cell when collecting fractions for analysis at displacement flow-rate <500 μL/min.
    • Fraction Collector: 10 μL to 10 mL per fraction by time or by number of drops.
    • Column Cooler/Heater: 0-100° C.+/−0.5° C. If the column is operated at a temperature substantially different from ambient temperature, arrangements for heating or cooling the buffer solutions need to be made.


Example 1a
Example Protocol. Displacement Chromatography Purification of Crude Synthetic Angiotensin I
Equipment Configuration:

Single Main Pump with 4 solvent lines, Sample Injection Valve with 40 mL Loop, Column Bypass Valve


Sample Injection Valve: 6-port valve controlled by single-channel toggle logic (S3=0, bypass loop, S3=1 loop inline)


Column Bypass Valve: 6-port valve controlled by single-channel toggle logic (S6=0, column inline, S6=1 bypass column)


UV photodiode array detector after column (flow-cell: 0.5 mm pathlength, 10 μL volume) followed by conductivity detector (flow-cell: 170 μL volume). Conductivity cell bypassed when collecting fraction for analysis.


Loading Buffer=A-Buffer (S1=1, flow on, S1=0 flow off); Displacer Buffer=B-Buffer (S2=1, flow on, S2=0 flow off);


Displacer Removal Buffer=C-Buffer (S4=1, flow on, S4=0 flow off); Column Storage Buffer=D-Buffer (S5=1, flow on, S5=0 flow off)


Before sequence begins, cleaned column briefly purged with A-buffer to remove column storage buffer. About 44 mL of degassed sample solution in a syringe is loaded into the sample injection loop; air is prevented from entering loop.


See Example 7b for description of column, details about initial sample and contents of Loading Buffer/Displacer Buffer/Sample Solution.


Displacer Removal Buffer (C-Buffer)=10% (v/v) 1-propanol, 10% (v/v) DI water in acetonitrile.


Column Storage Buffer (D-Buffer)=50/50 (v/v) acetonitrile/water with formic acid (15 mM) and ammonium formate (15 mM).

















Pump1
Flow-
Switch





Time
Rate
(S1-S6)





(min.)
mL/min
123456
Operations-Functions
Comments
Volumes




















0.00
0.208
100000
start Buffer A
Stabilize/Purge system
(2 min.)


1.98
0.208
100000
continue




2.00
1.039
100001
set column-bypass; flow-rate = 1.039
purge A-line
(0.25 CV Buffer D)


3.00
1.039
000011
start storage Buffer D
purge D-line
(0.25 CV Buffer A)


4.00
1.039
000101
start regeneration Buffer C
purge C-line
(0.25 CV Buffer C)


5.00
1.039
000100
set column-inline; C-buffer
Start pre-equilibration
(2.0 CV Buffer C)


13.00
1.039
100000
start load buffer A
equilibrate Buffer A
(3.0 CV Buffer A)


24.98
1.039
100000
continue Buffer A




25.00
0.208
100000
flow-rate = 0.208
equilibrate Buffer A
(1.0 CV Buffer A)


45.00*
0.208
101000
set loop-inline; pump Buffer A into loop
Start Sample load-Loop
(27.04 mL Buffer A into loop)


175.00
0.208
011000
purge Buffer B into back of loop
35.38/40 mL load (88.5%)
(8.34 mL Buffer B into loop)


215.10*
0.208
010000
set loop-bypass; Buffer B thru column
Start Displacement
(18.1 CV buffer B)


593.00*
0.208
010000
continue




593.02
0.780
100000
start Buffer A
Start regeneration
(0.5 CV Buffer A)


595.72
0.780
000010
start storage Buffer D

(0.5 CV Buffer D)


598.40
0.780
000100
start regeneration Buffer C

(1.8 CV Buffer C)


608.00
0.780
000100
continue




608.02
1.039
000100
set flow-rate = 1.039

(7.5 CV Buffer C)


638.00
1.039
000010
start storage Buffer D

(8.5 CV Buffer D)


671.96
1.039
000010
continue storage Buffer D




671.98
0.000
000010
stop flow




672.00
0.000
000000
close all valves
Stop









Example 1b
Displacement Chromatography Purification of Crude Angiotensin I Using Displacer 14—Higher Loading at Lower Concentration (See FIG. 1b—Analysis)
Operating Conditions:

Starting Peptide: Desalted crude synthetic Angiotensin I, 82.7% purity, FW˜1.296 mg/μmole,

    • charge=+4


Column: Waters Xbridge BEH130, 5 μm, 135 Å, 4.6×250 mm SS, —C18 on silica


Flow-Rates: Loading=208 μL/min; Displacement=208 μL/min


Ion-Pairing Agent: Trifluoroacetate (CF3CO2)


Temperature: 23° C.


pH: 2.0


Displacer Buffer: 10.0 mM Displacer 14+12 mM CF3CO2H in DI water w/ 3% (v/v) MeCN, pH=2.0

    • w/ NH4OH


Loading Buffer: 12 mM TFA in water w/ 3% (v/v) MeCN, pH=2.0 w/ NH4OH


Sample Solution: 4.38 mg/mL peptide in water with 3% (v/v) MeCN and 27 mM CF3CO2; pH=2.0

    • w/ NH4OH


Load Amount: 155.0 mg, 35.4 mL from 40 mL loop;


Loading Time: 170.1 min. (2.84 hr)


Fraction Size: 416 μL


Results:















Fraction
Fractions diluted (20 μL sample + 40 μL loading


Analysis:
buffer) and analyzed (25 μL injection) by analytical



elution HPLC at 215 nm; calculations based on area %.


Total Run
8.4 hr


Time:



Output
3.29 mg/mL


Concentration:



Column
71.2% of maximum capacity


Loading:



Column
~52.4 mg peptide/mL matrix @ 3.29 mg peptide/mL


Capacity:
solution ~167 μmole displacer/mL matrix @



10.0 μmole displacer/mL solution











Purity %:
99.1%
99.0%
98.8%
98.6%


Yield %:
  80%
  85%
  90%
  95%









Comments: Sample Conc./Output Conc.=1.3





    • Amount CF3CO2 in sample=2.0 times stoichiometric.





Excellent results are obtained. Good loading (37.3 g/L), good purity and good yield (>99% purity @ 80% yield; >98.5% purity @ 95% yield) are all obtained at the same time in this example where a small “analytical-type” column is used. This illustrates the power of optimized reversed-phase displacement chromatography.


Example 2
Displacement Chromatography Purification of Crude Angiotensin I Using Displacer 14—Lower Loading at Higher Concentration (See FIG. 2—Analysis)
Operating Conditions:

Starting Peptide: Desalted crude synthetic Angiotensin I, 82.7% purity, FW˜1.296 mg/μmole,

    • charge=+4


Column: Waters Xbridge BEH130, 5 μm, 135 Å, 4.6×250 mm SS, —C18 on silica


Flow-Rates: Loading=208 μL/min; Displacement=208 μL/min


Ion-Pairing Agent: Trifluoroacetate (CF3CO2)


Temperature: 23° C.


pH: 2.0


Displacer Buffer: 10.0 mM Displacer 14+12 mM CF3CO2H in DI water w/ 3% (v/v) MeCN, pH=2.0

    • w/ NH4OH


Loading Buffer: 12 mM TFA in water w/ 3% (v/v) MeCN, pH=2.0 w/ NH4OH


Sample Solution: 24.0 mg/mL peptide in water with 3% (v/v) MeCN and 140 mM CF3CO2; pH=2.0

    • w/ NH4OH


Load Amount: 109.3 mg, 4.56 mL from 5 mL loop


Loading Time: 21.9 min. (0.37 hr)


Fraction Size: 458 μL


Results:















Fraction
Fractions diluted (20 μL sample + 40 μL loading


Analysis:
buffer) and analyzed (25 μL injection) by analytical



elution HPLC at 215 nm; calculations based on area %.


Total Run
5.9 hr


Time:



Output
3.30 mg/mL


Concentration:



Column
50.1% of maximum capacity


Loading:



Column
~52.5 mg peptide/mL matrix @ 3.30 mg


Capacity:
peptide/mL solution ~167 μmole displacer/mL matrix @



10.0 μmole displacer/mL solution











Purity %:
99.1%
99.0%
98.9%
98.8%


Yield %:
  80%
  85%
  90%
  95%









Comments: Sample Conc./Output Conc.=7.3





    • Amount CF3CO2 in sample=1.9 times stoichiometric.





Good results are obtained with moderate loading (26.3 g/L), good purity and good yield (>99% purity @ 85% yield; >98.5% purity @ 95% yield) using a small “analytical-type” column. Total run-time is shortened (5.9 hr) because sample loading time is shortened (2.84 hr to 0.37 hr). Similar results at ˜70% sample loading give inferior purities (data not shown) so loading percentage is reduced to about 50% at which point purity levels are improved. These data show that lower percent column loading can effectively compensate for reduced resolution caused by loading the sample at concentrations that are too high (7.3×). Thus, there is a tradeoff if high purity and high yield are to be maintained: (a) higher sample loading and longer time or lower sample loading and shorter time. For some samples that contain easy to remove impurities, high sample loading and shorter time can still lead to high purity and high yield.


Example 3
Displacement Chromatography Purification of Crude Angiotensin I Using Displacer 413—Different Displacer with “Lower Binding-Isotherm” (See FIG. 3—Analysis)
Operating Conditions:

Starting Peptide: Desalted crude synthetic Angiotensin I, 82.7% purity, FW˜1.296 mg/μmole, charge=+4


Column: Waters Xbridge BEH130, 5 μm, 135 Å, 4.6×250 mm SS, —C18 on silica


Flow-Rates: Loading=208 μL/min; Displacement=208 μL/min


Ion-Pairing Agent: Trifluoroacetate (CF3CO2)


Temperature: 23° C.


pH: 2.0


Displacer Buffer: 10.0 mM Displacer 413+12 mM CF3CO2H in DI water w/ 3% (v/v) MeCN, pH=2.0

    • w/ NH4OH


Loading Buffer: 12 mM TFA in water w/ 3% (v/v) MeCN, pH=2.0 w/ NH4OH


Sample Solution: 7.27 mg/mL peptide in water with 3% (v/v) MeCN and 43 mM CF3CO2; pH=2.0

    • w/ NH4OH


Load Amount: 160.7 mg, 22.1 mL from 30 mL loop


Loading Time: 106.3 min. (1.77 hr)


Fraction Size: 312 μL


Results:















Fraction
Fractions diluted (10 μL sample + 40 μL loading


Analysis:
buffer) and analyzed (25 μL injection) by analytical



elution HPLC at 215 nm; calculations based on area %.


Total Run
5.6 hr


Time:



Output
5.38 mg/mL


Concentration:



Column
66.7% of maximum capacity


Loading:



Column
~58.0 mg peptide/mL matrix @ 5.38 mg


Capacity:
peptide/mL solution ~115 μmole displacer/mL matix @



10.0 μmole displacer/mL solution











Purity %:
99.1%
99.0%
98.9%
98.8%


Yield %:
  80%
  85%
  90%
  95%









Comments: Sample Conc./Output Conc.=1.3





    • Amount CF3CO2 in sample=1.9 times stoichiometric.





Excellent results are obtained with good loading (38.7 g/L), excellent purity and excellent yield (>99% purity @ 85% yield; >98.5% purity @ 95% yield) using a small “analytical-type” column. Run-time is shortened (5.6 hr) because both sample loading time and displacement time are shortened owing to the higher sample loading and higher operating concentrations which are, in turn, caused by the “lower binding-isotherm” of Displacer 413. In this example, the same column and same peptide is used, but the displacer is changed (compare Example 1 b). These results show that equally good purities and yields are obtained when working higher on the binding-isotherms of the product and impurities. Because less Displacer 413 is needed to saturate the column at 10 mM (115 vs 167 μmole displacer/mL matrix), the peptide comes off the column at higher concentration (5.38 vs 3.19 mg/mL), and the experiment operates higher on the peptide binding-isotherm (58.0 vs 52.5 mg peptide/mL matrix).


Example 4
Displacement Chromatography Purification of Crude Angiotensin I Using Displacer 14—Different Reversed-Phase Column (See FIG. 4—Analysis)
Operating Conditions:

Starting Peptide: Desalted crude synthetic Angiotensin I, 82.7% purity, FW˜1.296 mg/μmole, charge=+4


Column: Varian/Polymer Labs PLRP-S, 5 μm, 100 Å, 4.6×250 mm SS, uncoated porous

    • polystyrene/divinylbenzene


Flow-Rates: Loading=208 μL/min; Displacement=208 μL/min


Ion-Pairing Agent: Trifluoroacetate (CF3CO2)


Temperature: 23° C.


pH: 2.0


Displacer Buffer: 10.0 mM Displacer 14+12 mM CF3CO2H in DI water w/ 3% (v/v)


MeCN, pH=2.0 w/ NH4OH


Loading Buffer: 12 mM TFA in water w/ 3% (v/v) MeCN, pH=2.0 w/ NH4OH


Sample Solution: 3.50 mg/mL peptide in water with 3% (v/v) MeCN and 22 mM CF3CO2; pH=2.0 w/ NH4OH


Load Amount: 116.0 mg, 33.2 mL from 40 mL loop


Loading Time: 159.4 min. (2.66 hr)


Fraction Size: 458 μL


Results:















Fraction
Fractions diluted (30 μL sample + 20 μL loading


Analysis:
buffer) and analyzed (25 μL injection) by analytical



elution HPLC at 215 nm; calculations based on area %.


Total Run
9.7 hr


Time:



Output
1.86 mg/mL


Concentration:



Column
73.2% of maximum capacity


Loading:



Column
~38.1 mg peptide/mL matrix @ 1.86 mg peptide/mL


Capacity:
solution ~212 μmole displacer/mL matrix @



10.0 μmole displacer/mL solution











Purity %:
98.2%
98.0%
97.8%
97.5%


Yield %:
  60%
  75%
  80%
  90%









Comments: Sample Conc./Output Conc.=2.0





    • Amount CF3CO2 in sample=2.0 times stoichiometric.





Good results are obtained with low-to-moderate loading (27.9 g/L), moderate purity and reasonable yield (>97.5% purity @ 90% yield) using a small “analytical-type” column. This example is designed to show a side-by-side comparison of two columns using the same peptide and same displacer (compare Example 1b). Generally speaking, the results for the polystyrene column are good, but not as good as those for the C18-on-silica column. Total run time is somewhat longer, column binding capacity is lower and final purity is somewhat lower (97.5% vs 98.5-99.0%). By adjusting the type of displacer, its concentration and the ion-pairing agent (data not shown), total run-times are shortened, and binding capacities are increased approaching those for the C18-on-silica columns. However, product purities largely remain about the same as this run on the polystyrene column. These results generally correspond to data from preparative elution chromatography that suggest that polystyrene columns give reduced chromatographic resolution compared to C18-on-silica columns.


Example 5
Displacement Chromatography Purification of Crude α-Melanotropin Using Displacer 318—Different Peptide and Different Displacer (See FIG. 5—Analysis)
Operating Conditions:

Starting Peptide: Desalted crude synthetic α-Melanotropin, 80.8% purity, FW˜1.665 mg/μmole, charge=+3


Column: Waters Xbridge BEH130, 5 μm, 135 Å, 4.6×250 mm SS, —C18 on silica


Flow-Rates: Loading=208 μL/min; Displacement=208 μL/min


Ion-Pairing Agent: Trifluoroacetate (CF3CO2)


Temperature: 23° C.


pH: 2.0


Displacer Buffer: 10.0 mM Displacer 318+12 mM CF3CO2H in DI water w/ 3% (v/v) MeCN, pH=2.0 w/ NH4OH


Loading Buffer: 12 mM TFA in water w/ 3% (v/v) MeCN, pH=2.0 w/ NH4OH


Sample Solution: 9.04 mg/mL peptide in water with 3% (v/v) MeCN and 33 mM


CF3CO2; pH=2.0 w/ NH4OH


Load Amount: 216.2 mg, 23.9 mL from 30 mL loop


Loading Time: 115.0 min.


Fraction Size: 312 μL


Results:















Fraction
Fractions diluted (10 μL sample + 50 μL loading


Analysis:
buffer) and analyzed (25 μL injection) by analytical



elution HPLC at 215 nm; calculations based on area %.


Total Run
6.2 hr


Time:



Output
6.52 mg/mL


Concentration:



Column
66.7% of maximum capacity


Loading:



Column
~79.3 mg peptide/mL matrix @ 6.52 mg


Capacity:
peptide/mL solution ~129 μmole displacer/mL matrix



@ 10.0 μmole displacer/mL solution











Purity %:
99.1%
99.0%
98.9%
98.8%


Yield %:
  80%
  85%
  90%
  95%









Comments: Sample Conc./Output Conc.=1.4





    • Amount CF3CO2 in sample=2.0 times stoichiometric amount.





Excellent results are obtained with good loading (52.0 g/L), good purity and good yield (>99% purity @ 85% yield; >98.5% purity @ 95% yield) using small “analytical-type” column. This example is designed to show a side-by-side comparison (see Example 1 b) on the same column (C18-on-silica) using a different peptide and a different displacer. α-Melanotropin has a higher intrinsic binding capacity, and less Displacer 318 is needed to saturate the column (129 vs 167 μmole displacer/mL). Both of these factors together lead to a higher binding capacity for the peptide (79.3 vs 52.4 g peptide/L matrix), yet the displacement train sharpens nicely giving both high purity and high yield.


Example 6a
Example Protocol and Displacement Train. Displacement Chromatography Purification of Crude Synthetic α-Endorphin
Equipment Configuration:

Main Pump(1) with 4 solvent lines, Sample Loading Pump(2) with 2 solvent lines, Pump Selector Valve


Pump Selector Valve: 6-port valve controlled by single-channel toggle logic (S3=0, Pump1 to column-Pump2 to waste, S3=1 Pump1 to waste-Pump2 to column)


UV photodiode array detector after column (flow-cell: 0.5 mm pathlength, 9 □L volume) followed by conductivity detector (flow-cell: 170 □L volume).


Loading Buffer=A-Line on Pump1 (S1=1, flow on, S1=0 flow off); Displacer Buffer=B-Line on Pump 1 (S2=1, flow on, S2=0 flow off); Displacer Removal Buffer=C-Line on Pump1 (S4=1, flow on, S4=0 flow off); Column Storage Buffer=D-Line on


Pump1 (S5=1, flow on, S5=0 flow off); Loading Buffer=A-Line on Pump2 (S6=1, flow on, S6=0, flow off); Sample Solution=B-Line on Pump2 (S7=1, flow on, S7=0 flow off).


Before sequence begins, cleaned column briefly purged with A-buffer to remove column storage buffer.


See Example 12b for description of column, details about initial sample and contents of Loading Buffer/Displacer Buffer/Sample Solution.


Displacer Removal Buffer (C-Buffer)=10% (v/v) 1-propanol, 10% (v/v) DI water in acetonitrile.


Column Storage Buffer (D-Buffer)=50/50 (v/v) acetonitrile/water with formic acid (15 mM) and ammonium formate (15 mM).




















Flow-
Control
Flow-






Time
Rate-1
Switches
Rate-2
Pump 1
Pump 2


(min.)
(mL/min)
1234567
(mL/min)
Operations - Functions
Operations - Functions
Comments
Volumes






















0.00
4.909
1010010
1.061
purge Buffer A to waste
Buffer A to column
Purge System (A-line)
1,.5 min.


1.50
4.909
0010110
1.061
purge Buffer D to waste

purge D-line
(0.37 CV Buffer D









to waste)


3.00
4.909
0011010
1.016
purge Buffer C to waste

purge C-line
(0.50 CV Buffer A









to wasste)


5.00
4.909
0001010
1.016
Buffer C to column
purge Buffer A to waste
Start pre-equilibration
(2.0 CV Buffer C









to column)


5.50
4.909
0001010
1.016

continue


5.52
4.909
0001010
0.000

flow-rate = 0.000


13.00
4.909
1000010
0.000
Buffer A to column

equilibrate Buffer A
(3.0 CV Buffer A)


24.98
4.909
1000010
0.000
continue


25.00
0.961
1000010
0.000
flow-rate = 0.961

equilibrate Buffer A
(1.03 CV Buffer A)


42.98
0.961
1000010
0.000

continue


43.00
0.961
1000001
1.016

purge Sample to waste
purge Sample to waste


46.00
0.961
1010001
1.016
purge Buffer A to waste
load Sample to column
Start Sample load-Pump2


46.10
0.010
1010001
1.016
set flow-rate to 0.010

slow purge Pump1


243.98
0.010
1010001
1.016


246.80
0.961
0110001
1.016
purge Buffer B to waste
purge B-line

(4.0 mL Buffer B)


251.00
0.961
0100001
1.016
B-buffer to column
purge Sample to waste
Start Displacement-Pump1
(17.96 CV Buffer B)


251.50
0.961
0100010
1.016

purge Buffer A to waste
wash Pump2
6.1 mL Buffer A to









waste)


257.00
0.961
0100010
1.016

continue


257.02
0.961
0100010
0.000

stopflow-Pump2


257.04
0.961
0100000
0.000

close valves-Pump2
stop Pump2


618.00
0.961
0100000
0.000
continue


618.02
3.682
1000000
0.000
Buffer A to column

Start Reqeneration-Pump1
(0.5 CV Buffer A









slow flow)


620.72
3.681
0000100
0.000
Buffer D to column


(0.5 CV Buffer D









slow flow)


623.40
3.682
0001000
0.000
Buffer C to column


(1.8 CV Buffer C









slow flow)


633.00
3.682
0001000
0.000
continue


633.02
4.909
0001000
0.000
flow-rate = 4.909


(7.5 CV Buffer C









fast flow)


663.00
4.909
0000100
0.000
start storage buffer D


(8.5 CV Buffer D









fast flow)


696.96
4.909
0000100
0.000
continue storage D-buffer


696.98
0.000
0000100
0.000
stop flow


697.00
0.000
0000000
0.000
close all valves

Stop Pump1









Example 6b
Displacement Chromatography Purification of Crude Synthetic α-Endorphin Using Displacer 198—Larger Particles, Larger Columns and Lower Initial Purity (See FIG. 6b(a)A—Displacement Trace; FIG. 6b(a)B—Analysis)
Operating Conditions:

Starting Peptide: Desalted crude synthetic α-Endorphin, 64.3% purity, FW˜1.746 mg/μmole, charge=+2 all on —C18 on silica


Column: 6b(a): Waters Xbridge BEH130, 5 μm, 135 Å, 10.0×250 mm SS, —C18 on silica

    • 6b(b): Waters Xbridge BEH130, 10 μm, 135 Å, 10.0×250 mm SS, —C18 on silica
    • 6b(c): Waters Xbridge BEH130, 10 μm, 135 Å, 10.0×500 (2×250) mm SS, —C18 on silica


Flow-Rates: Loading=1016 μL/min; Displacement=961 μL/min for all three experiments.


Ion-Pairing Agent: Trifluoroacetate (CF3CO2)


Temperature: 23° C.


pH: 2.0


Displacer Buffer: 10.0 mM Displacer 198+12 mM CF3CO2H in DI water w/ 3% (v/v) MeCN, pH=2.0


Loading Buffer: 12 mM TFA in water w/ 3% (v/v) MeCN, pH=2.0 w/ NH4OH


Sample Solution:

    • (a) 5.59 mg/mL peptide in water with 3% (v/v) MeCN and 26 mM CF3CO2; pH=2.0
    • (b) 5.59 mg/mL peptide in water with 3% (v/v) MeCN and 26 mM CF3CO2; pH=2.0
    • (c) 11.18 mg/mL peptide in water with 3% (v/v) MeCN and 52 mM CF3CO2; pH=2.0


Load Amount:

    • (a) 1164 mg, 208.3 mL from loading pump; Loading Time=205.0 min.
    • (b) 1164 mg, 208.3 mL from loading pump; Loading Time=205.0 min. (3.42 hr)
    • (c) 2329 mg, 208.3 mL from loading pump; Loading Time=205.0 min. (3.42 hr)


Fraction Sizes: (a) 1.49 mL (b) 1.49 mL (c) 2.98 mL


Results-6b(a) (see FIGS. 6b(a)A and 6b(a)B)















Fraction
Fractions diluted (10 μL sample + 40 μL loading


Analysis:
buffer) and analyzed (25 μL injection) by analytical



elution HPLC at 215 nm; calculations based on area %.


Total Run
8.9 hr


Time:



Output
5.47 mg/mL


Concentration:



Column
70.5% of maximum capacity


Loading:



Column
~84.1 mg peptide/mL matrix @ 5.47 mg


Capacity:
peptide/mL solution ~161 μmole displacer/mL matrix



@ 10.0 μmole displacer/mL solution











Purity %:
98.8%
98.7%
98.5%
98.2%


Yield %:
  80%
  85%
  90%
  95%










Results-6b(b) (no Figure):















Fraction
Fractions diluted (10 μL sample + 40 μL loading


Analysis:
buffer) and analyzed (25 μL injection) by analytical



elution HPLC at 215 nm; calculations based on area %.


Total Run
9.1 hr


Time:



Output
5.27 mg/mL


Concentration:



Column
71.3% of maximum capacity


Loading:



Column
~83.2 mg peptide/mL matrix @ 5.27


Capacity:
mg peptide/mL solution ~165 μmole displacer/mL



matrix @ 10.0 μmole displacer/mL solution











Purity %:
98.2%
98.1%
97.9%
97.5%


Yield %:
  80%
  85%
  90%
  95%










Results-6b(c) (no Figure):















Fraction
Fractions diluted (10 μL sample + 40 μL loading


Analysis:
buffer) and analyzed (25 μL injection) by analytical



elution HPLC at 215 nm; calculations based on area %.


Total Run
14.5 hr


Time:



Output
5.41 mg/mL


Concentration:



Column
70.7% of maximum capacity


Loading:



Column
~83.7 mg peptide/mL matrix @ 5.41 mg peptide/mL


Capacity:
solution ~162 μmole displacer/mL matrix



@ 10.0 μmole displacer/mL solution











Purity %:
98.8%
98.7%
98.5%
98.2%


Yield %:
  80%
  85%
  90%
  95%










Comments: Sample Conc./Output Conc.: 1.0 (6b(a)); 1.1 (6b(b)); 2.1 (6b(c)).
    • Amount CF3CO2 in sample=4.0 times stoichiometric amount (6b(a), 6b(c) & 6b(c)).


Excellent results are obtained from all three runs with good loading (59.2-59.3 g/L), high purities and good yields (>98.5% purity @ 90% yield) using “semiprep-type” columns with both 5 μm and 10 μm particle sizes. Percent loadings (70.5-71.3%) and output concentrations (5.27-5.47 mg/mL) are uniform and reproducible. These examples illustrate power and utility of optimized preparative displacement chromatography. (1) There is little difference in preparative resolution between 4.6 mm and 10.0 mm ID columns of the same length packed with the same reversed-phase matrix. (2) At 25 cm column length, both 5 μm and 10 μm matrices give good results with the 10 μm material giving slightly inferior resolution as demonstrated by slightly reduced purity (˜0.6%). (3) At 50 cm column length, the 10 μm matrix regains full resolution; simple calculations suggest that a 30-40 cm bed length is sufficiently long. (4) Two well-packed columns properly attached end-to-end function effectively in displacement chromatography experiments. (5) The best pooled purity (98.8%) for a peptide (α-Endorphin) with 60+% initial purity is not much worse than the best pooled purity (99.1%) for a peptide (Angiotensin I, α-Melanotropin) with 80 μm initial purity. (6) In many cases, 1.5-2.0 times the stoichiometric amount of ion-pairing agent is used in the sample loading solution with good results; however, with α-Endorphin, significantly better resolution is obtained with 3.5-4.0 times the stoichiometric amount of CF3CO2.


Example 7
Displacement Chromatography Purification of Prepurified α-Endorphin Using Displacer 198—Different Binding-Isotherms Lead to Improved Purity (See FIG. 7—Analysis)
Operating Conditions:

Starting Peptide: Prepurified α-Endorphin, 98.4% purity, FW˜1.746 mg/μmole, charge=+2


Column: Waters Xbridge BEH130, 5 μm, 135 Å, 4.6×250 mm SS, —C6Ph on silica


Flow-Rates: Loading=208 μL/min; Displacement=208 μL/min


Ion-Pairing Agent: Trifluoroacetate (CF3CO2);


Temperature: 23° C.


pH: 2.0


Displacer Buffer: 10.0 mM Displacer 198+12 mM CF3CO2H in DI water w/ 3% (v/v) MeCN, pH=2.0 w/ NH4OH


Loading Buffer: 12 mM TFA in water w/ 3% (v/v) MeCN, pH=2.0 w/ NH4OH


Sample Solution: 5.26 mg/mL peptide in water with 3% (v/v) MeCN and 21 mM CF3CO2; pH=2.0 w/ NH4OH


Load Amount: 158.9 mg, 30.2 mL from 40 mL loop


Loading Time: 145.2.0 min.


Fraction Size: 437 μL


Results:















Fraction
Fractions diluted (15 μL sample + 35 μL loading


Analysis:
buffer) and analyzed (25 μL injection) by analytical



elution HPLC at 215 nm; calculations based on area %.


Total Run
7.3 hr


Time:



Output
3.85 mg/mL


Concentration:



Column
71.1% of maximum capacity


Loading:



Column
~53.8 mg peptide/mL matrix @ 3.85 mg


Capacity:
peptide/mL solution ~147 μmole displacer/mL matrix



@ 10.0 μmole displacer/mL solution











Purity %:
99.6%
99.6%
99.6%
99.5%


Yield %:
  80%
  85%
  90%
  95%









Comments: Sample Conc./Output Conc.=1.3





    • Amount CF3CO2 in sample=3.6 times stoichiometric amount.





Excellent results are obtained with good loading (38.3 g/L), excellent purity and excellent yield (>99.5% purity @ 95% yield) using a small “analytical-type” column. This example is designed to show how purifying a prepurified sample under suitable conditions can efficiently lead to high purity peptides. (1) The sum of the impurities drops significantly from 1.6% to 0.4-0.5% with minimal loss (5-10%) in product. (2) The reduction in impurities is primarily caused by changes in binding-isotherms of product and impurities, not by improved resolution of the column. In the starting material, the 1.6% impurity is composed of 12 minor impurities 8 of which are effectively removed during this purification. The levels of the remaining 4 co-displacing components are somewhat reduced during the purification. (3) Because co-displacement of the 4 remaining impurity is the principal factor limiting final purity, the purity profile is nearly invariant from 60% recovery to 95% recovery. (4) The success of this purification results from the choice of a phenylhexyl column with different binding-isotherms. An attempt to carry out a similar displacement chromatography purification of the same sample on an octaadecyl (C18) column failed to yield significant improvement (data not shown). This is likely the case because the octadecyl column is used to purify the sample from crude material in the first step. (5) These results show that two back-to-back displacement purifications can routinely lead to high-yield production of high-purity peptides.


Example 8
Displacement Chromatography Purification of Crude Angiotensin I Using Displacer 14—Using Different Ion-Pairing Anions, Concentrations and Mixtures

All operating conditions for the seven experiments in Example 7 are the same except that the counter-ion for the displacer and the added amounts of ion-pairing anion (acid). In all cases, the operating pH is the same (pH=2.0). In order to reduce the amount of analytical work, comparative purity data is given for a pool of the center 15 fractions. Because the level of co-displacement is nearly invariant across the major displacement band for a given displacement experiment, analytical data from this method of pooling gives representative and comparable results.


Results:


















Center-cut


Displacer Buffer
Load Buffer
Sample SoIn.
Purity







Aa 10 mM [D][CF3CO2] +
12 mM CF3CO2H
27 mM CF3CO2H
99.1%


12 mM CF3CO2H





B 10 mM [D][Br] +
12 mM HBr
27 mM HBr
99.0%


12 mM HBr





C 10 mM [D][Cl] +
12 mM HCl
27 mM HCl
98.6%


12 mM HCl





D 10 mM [D][Br] +
12 mM CF3CO2H
27 mM CF3CO2H
98.1%


12 mM CF3CO2H





E 10 mM [D][Cl] +
12 mM CF3CO2H
27 mM CF3CO2H
99.0%


12 mM CF3CO2H





F 10 mM [D][Cl] +
24 mM CF3CO2H
27 mM CF3CO2H
99.1%


24 mM CF3CO2H





G 10 mM [D][Cl] +
6 mM CF3CO2H
27 mM CF3CO2H
96.7%


6 mM CF3CO2H





Note:


a) Example 1






Comments:

Generally good results are obtained under most conditions except experiment “G”. There are clear results from this study regarding types, mixtures and levels of ion-pairing anions.

    • 1. Trifluoroacetate-only (A) and bromide-only (B) experiments yield similar results (0.9-1.0% impurity) while those for the chloride-only (C) experiment gives higher impurity levels (1.4% inpurity). Thus, trifluoroacetate and bromide are better ion-pairing agents than chloride.
    • 2. Mixed trifluoroacetate-chloride (E, F) experiments give about the same impurity levels as trifluoroacetate-only experiments as long as enough trifluoroacetate is present (0.9-1.0% impurity). In contrast, the mixed trifluoroacetate-bromide (D) experiment gives worse results; the impurity level increases from 0.9% to 1.9%. While trifluoroacetate-only (A) and bromide-only (B) experiments give good results, the mixture of anions does not. Apparently, a mixture of two ion-pairing anions of similar (but no the same) ion-pairing strength interfere with each other resulting in band broadening and higher impurity levels. The presence two ion-pairing anions of significantly different ion-pairing strength results in the stronger one dominating (as long there is enough of it present) and lower impurity levels result.
    • 3. The worst results (G) are obtained when two ion-pairing agents are present (Cl, CF3CO2) and the stronger one is present in substiochiometric amounts. This results in “double-banding” where the displacer and many components of the mixture come off the column as two bands, the first one as the chloride salt and the second as the trifluoroacetate salt. This leads to significant band broadening and overlap of each double-banded component thereby increasing the overall impurity level from 0.9% to 3.3%. Adding insufficient amounts of trifluoroacetate (stronger ion-pairing anion) gives worse results than having no trifluoroacetate at all (3.3% impurity vs 1.4% impurity). Adding higher levels of trifluoroacetate in excess of the stoichiometric amount causes the impurity levels to decrease again (3.3% to 0.9%).
    • 4. Note that the above results apply only to the levels of trifluoroacetate (ion-pairing anion) in the displacer buffer. There was sufficient trifluoroacetate in the sample loading solution. When there is a deficiency of trifluoroacetate in the sample solution, impurity levels become even higher (data not shown).


Example 9
HPLC Analyses

Methods 9a, 9b—Reversed-Phase for Cations:


Analyses were carried out using Waters Corp. (Milford, Mass.) gradient HPLC equipped with a Waters 996 PDA detector in tandem with a Dionex/ESA Biosciences (Chelmsford, Mass.) Corona Plus CAD detector and a Waters Xbridge BEH130, 5 μm, 135 Å, 4.6×250 mm SS, —C18 on silica, reversed-phase chromatography column (Chelmsford, Mass.).


Sample Injection: 25 μL of ˜1 mM sample solution in A buffer


UV detection: 208-220 nm depending on compounds to be analyzed


Flow-Rate: 1.0 mL/min.


A buffer: 5% CH3CN (v/v) in HPLC-grade dist. water with 0.1% (v/v) trifluoroacetic acid


B buffer: 5% H2O (v/v) in HPLC-grade CH3CN with 0.1% (v/v) trifluoroacetic acid. Survey Gradient Method:


















100% A
  0-2 min



100% A to 100% B
 2-62 min



100% B
62-70 min










Analytical Gradient Method


















 10% B
  0-2 min



 10% B to 50% B
 2-57 min



 50% B to 100% B
57-62 min



100% B
62-67 min










Method 9c—Reversed-Phase for Long-Chain Alkyl Halides:


Sample Injection: 25 μL of ˜1 mM sample solution in A buffer


UV detection: 200-220 nm depending on compounds to be analyzed


Flow-Rate: 1.0 mL/min.


A buffer: 5% CH3CN (v/v) in HPLC-grade distilled water with 0.1% (v/v) trifluoroacetic acid.


B buffer: 5% H2O (v/v) in HPLC-grade CH3CN with 0.1% (v/v) trifluoroacetic acid. Gradient Method:


















 50% A/50% B
  0-2 min



 50% A/50% B to 100% B
 2-62 min



100% B
62-70 min










Example 10
Preparation of N-Decylpyrrolidine (fw=211.39)

426.7 g Freshly distilled pyrrolidine (6.0 mole, fw=71.12, ˜500 mL) is added to 500 mL stirring acetonitrile in a 2 L 4-neck round-bottom flask that is equipped with a heating mantle, mechanical stirrer, 500 mL addition funnel, reflux condensor and teflon-coated thermocouple. The reaction is carried out under a nitrogen atmosphere with a slow N2 purge. 442.4 g Freshly distilled 1-bromodecane (2.0 mole, fw=221.19, ˜415 mL) is added to the stirring mixture in a dropwise fashion at such a rate that the reaction exotherm maintains the reaction temperature in the range 45-55° C. Under these conditions, the bromodecane addition requires about 2 hours. After the entire bromodecane is added and the reaction temperature drops below 45° C., the stirring reaction mixture is heated to 80° C. for 1 hr and then allowed cool. The reaction mixture is periodically monitored by HPLC (Method 10g) in order to ensure that the bromodecane is entirely consumed. During the reaction, a less dense upper layer of the product begins to form that increases in volume as the reaction mixture cools to ambient temperature. Upon cooling as the reaction temperature reaches about 50° C., 100 mL distilled water is added portionwise to the stirring mixture in order to facilitate phase separation and prevent crystallization of pyrrolidine hydrobromide. When the reaction temperature is below 30° C., it is transferred to a 2 L separatory funnel and allowed to stand for about 3 hours in order to allow for full phase separation. The upper phase is retained in the funnel, 1.0 L 10% w/w NaOH in distilled water is added, the mixture is thoroughly mixed and then allowed to settle overnight. The phases are separated, the upper product phase is retained, 1.0 L 1% w/w NaOH in distilled water is added, the mixture is through mixed and then allowed again to settle overnight. The phases are separated, and the upper product phase is placed in a beaker along with 80 g anhydrous magnesium sulfate powder. The viscous mixture is manually mixed for about 15 minutes and then filtered through fine-porosity sintered-glass filter. Once, the product is filtered, the magnesium sulfate is washed with a small amount of n-pentane and then filtered. The pentane solution is combined with the filtered product and placed on a rotary evaporator. Most of the volatile components (pentane, residual acetonitrile, pyrrolidine, water) are removed under reduced pressure. Using the rotary evaporator, the viscous product is stirred and heated (70° C., glycol-water bath) under vacuum (˜10 torr) overnight (18 hr) while the volatiles are trapped at liquid N2 temperature. Finally, the mixture is again stirred and heated overnight on a vacuum-line (0.5 torr, 100° C.) to remove the last traces of volatiles. This procedure yields 399 g (94%) of a pale yellow viscous liquid with a purity of 99.0-99.6% (GC, HPLC). This material is sufficiently pure for most applications. If needed, this material is distilled (118-122° C., 3 torr) giving a 90% distillation yield of a colorless liquid (99.8% purity).


This is a clean reaction that produces pure product if the starting secondary amine and primary alkyl halide are themselves pure. Primary alkyl chlorides function quite well in this reaction, and the reaction time needs to be slightly extended for complete reaction. This reaction is also successfully carried out using various secondary amines: 50% aqueous dimethylamine, N-methylethylamine, diethylamine, di-n-propylamine, di-n-butylamine, pyrrolidine, piperidine, N-methylbenzylamine, N-ethylbenzylamine, N-methylaniline while using various nC5-nC12 alkyl halides. For the above reaction, a ratio of 1:3 is chosen to minimize the production of the didecyl pyrrolidinium bromide byproduct. The excess secondary amine can be regenerated and recycled by addition of inorganic base (NaOH pellets, 50% aqueous NaOH, LiOH, anhydrous Na2CO3, Na3PO4) to the spent reaction mixture in order to regenerate the free amine followed by distillation to recover the amine or amine/solvent mixture.


Example 11
Preparation of N-(4-Fluorobenzyl)-N-decylpyrrolidinium Chloride (fw=355.97)

380.5 g Purified N-decylpyrrolidine (1.8 mole, fw=211.39) is added to 720 mL stirring acetonitrile in a 2 L, 4-neck round-bottom flask that is equipped with a heating mantle, mechanical stirrer, 500 mL addition funnel, reflux condensor and teflon-coated thermocouple. The reaction is carried out under a nitrogen atmosphere with a slow N2 purge. The stirring mixture is heated to 50° C., and 289.1 g freshly distilled 4-fluorobenzyl chloride (2.0 mole, fw=144.58) is added in a dropwise fashion over a period of about 60 minutes. The reaction mixture is then heated to about 80° C. for 8-12 hours and periodically monitored by HPLC (Method 10a) in order to ensure that the starting amine is entirely consumed. The reaction mixture is cooled to room temperature, filtered through sintered-glass and placed on a rotary evaporator to remove the solvent (acetonitrile). 1.0 L Methyl t-butyl ether (MTBE) is added portionwise with mechanical stirring to the sticky orange-yellow reaction residue. Once this mixture is fully suspended in the solvent, it is transferred to a clean 4 L Erlenmeyer flask, and an additional amount of MTBE (1.9 L) is slowly added with stirring. The mixture is allowed to stand at ambient temperature overnight, filtered through a large sintered-glass filter, twice washed with MTBE and then dried by passing dry N2 through the product. Note: this crystalline substance is very hygroscopic and rapidly absorbs moisture from the air turning white crystals into a puddle of colorless liquid within a few minutes. Thus, ordinary filtrations are difficult and should be carried out in a dry-box or under a blanket of dry N2 or dry air. The product is finally dried in a vacuum oven (55° C., 20 torr, 3 hr; 95° C., 20 torr, 15 hr), cooled and stored in a sealed container in a desiccator over P2O5. This procedure yields about 576 g (90%) of a white crystalline product (platelets) with >99% purity. A sharp melting point in a glass capillary is measured at 137-138° C. when measured between 90-140° C. at the heating rate of 1.0° C./minute. This compound appears to exist in multiple polymorphic crystalline forms with different melting points. This crystallized material from acetonitrile/MTBE forms crystals that will melt at or below 120° C., recrystallize and remelt at about 137° C. Slow heating seems to promote thermal interconversion of polymorphs. If allowed to age long enough at 90° C. (several days), the material is converted to the higher melting form. Note that the apparent melting points are significantly lowered by the presence of small amounts of moisture.


Recrystallization is accomplished using hot DME/MTBE. 100 g of the above product is dissolved in 450 g hot (˜75° C.) peroxide-free 1,2-dimethoxyethane (DME) and quickly filtered through a sintered glass filter into a clean 1 L filter-flask. 55 g hot DME is used to wash the filter. The arm of the filter flask is plugged, and the mixture in the flask is heated to about 75° C. and then allowed to cool to about 50° C. About 270 g MTBE is then added to the stirring mixture, and the mixture is briefly heated again to 50° C. The flask is then covered, and the warm solution is allowed to cool to room temperature undisturbed. Within three hours at ambient temperature copious amounts of large, white platelets crystallize from solution. Finally, the mixture is allowed to stand at 4° C. overnight (15-18 hr) in order to complete the crystallization. Taking proper precautions to protect from atmospheric moisture (see above), the cold mixture is filtered through a sintered-glass filter, twice washed with MTBE (ambient temperature) and dried on the filter as above. The product is again dried in a vacuum oven overnight, cooled and stored in a sealed container in a desiccator over P2O5. This procedure yields about 76 g (76%) of the white, crystalline salt (99.7-99.9% purity by HPLC). The filtrate solution contains substantial amounts of pure product. The solvent is completely removed, and the white residue is recrystallized again using the same method or combined with the next batch of product for recrystallization. Overall yield of recrystallization is 87-95%.


Example 12
Preparation of N-(4-Fluorobenzyl)-N-decylpyrrolidinium Hydroxide (fw=337.53)

178 g Recrystallized N-(4-fluorobenzyl)-N-decylpyrrolidinium chloride (500 mmole, fw=355.97) is dissolved in 445 mL degassed, deionized water under a CO2-free, N2 atmosphere in a polypropylene flask. 61.4 g Silver (I) oxide (265 mmole, fw=231.74) is added to the solution, and it is vigorously stirred with a mechanical polypropylene propeller at room temperature for 48 hours. The mixture is filtered through a polypropylene filter/felt in a polypropylene Buechner filter into a polypropylene receiving flask under a blanket of nitrogen gas. The water-clear solution is placed on a rotary evaporator, and the water is partially removed under vacuum over a period of 36-48 hours while the product (viscous liquid) is maintained at about 50° C. using an external heating bath. Acid-Base titration (hydroxide) and HPLC analysis (cation) show the final solution to contain about 41% of the quat hydroxide; atomic absorption shows residual Cl to be less than 2 ppm. The solution is stored at ambient temperature in a sealed, clean, polypropylene container. Yield is nearly quantitative.


Modifications: This method is generally applicable to most quaternary ammonium chloride/bromide salts described here. Compounds that have base-sensitive groups (alcohols, amides, esters etc), of course, are often unstable as hydroxide salts. Stable quaternary ammonium salts are also converted to hydroxide salts using other methods such as ion-exchange, electrolysis or electrodialysis.


Example 13
Preparation of N-(4-Fluorobenzyl)-N-decylpyrrolidinium Trifluoroacetate (fw=433.53)

Method A.


35.6 g Purified and recrystallized N-(4-fluorobenzyl)-N-decylpyrrolidinium chloride (100 mmole, fw=355.97) is placed in a 100 mL separatory funnel followed by 35.6 g degassed, deionized water. The flask is shaken until a clear, viscous solution is formed (˜1.5 M solution). 17.1 g Trifluoroacetic acid (150 mmole, fw=114.02) is added to the mixture which is vigorously mixed. Immediately two phases form which fully separate after 60 minutes. The quat trifluoroacetate is contained in the lower layer, and the water, HCl and excess CF3CO2H is in the upper layer. The layers are separated, the product in the lower layer is placed on a rotary evaporator in order to remove the residual water, HCl and CF3CO2H under vacuum (bath temperature=50° C., vacuum=20 torr). This procedure yields 40.8 g (94%) of a pure, clear, viscous oil (ionic liquid). This material is suitable for use a displacer. HPLC purity of the quat cation is essentially identical to the starting material. Residual chloride content is about 1 mole % (chloride titration) and excess trifluoroacetate as free trifluoroacetic acid is 2-5 mole % (acid titration). A second extraction with equal weight of 30% (w/w) trifluoroacetic in water following the same procedure yields the same product with the same amount of residual trifluoroacetic acid but with chloride content reduced to <0.1 mole %. While the solubility of the trifluoroacetate (TFA) salt (˜120 mM) in pure water is lower than the solubility of the chloride salt (2.0 M), the TFA salt is nonetheless adequately soluble for displacer use (10-50 mM).


Method B.


This is a modification of Method A based on the partitioning behavior in a two-phase diethyl ether-water extraction. The quat chloride salt strongly partitions into the water layer while the quat trifluoroacetate salt strongly partitions into the ether layer. 53.4 g Purified and recrystallized N-(4-fluorobenzyl)-N-decylpyrrolidinium chloride (150 mmole, fw=355.97) is placed in a 250 mL separatory funnel followed by 53.4 g degassed, deionized water. The flask is shaken until a clear, viscous solution is formed (˜1.5 M solution). 25.6 g Trifluoroacetic (225 mmole, fw=114.02) is added to the mixture which is vigorously mixed. Immediately two phases form with the product in the lower layer. 110 mL peroxide-free diether ether is added to the separatory funnel and the mixture is vigorously mixed again. After 2 hours, the phases fully separate with the product in the upper ether phase. The lower phase is discarded and the upper is retained. 55 mL 1% trifluoroacetic acid in distilled water is added, the mixture is vigorously mixed and phases are again allowed to separate. Again, the upper phase is retained, dried over anhydrous magnesium sulfate, filtered and placed on a rotary evaporator in order to remove the ether along with residual HCl, trifluoroacetic acid and water. This procedure yields 59.2 g (91%) of a pure, clear, viscous oil (ionic liquid). This material is suitable for use as a displacer. HPLC purity of the quat cation is essentially identical to the starting material. Residual chloride content is <0.1 mole % (chloride titration) and excess trifluoroacetate as free trifluoroacetic acid is 1-3 mole % (acid titration).


Method C.


35.6 g Purified and recrystallized N-(4-fluorobenzyl)-N-decylpyrrolidinium chloride (100 mmole, fw=355.97) is dissolved in 75 mL distilled water in a 250 mL Erlenmeyer flask. 23.1 g Silver (I) trifluoroacetate (105 mmole, fw=220.88) and 100 mL peroxide-free diethyl ether are added to the solution, and it is vigorously stirred magnetically for 48 hours at room temperature. The mixture is filtered in order to remove silver salts, the two liquid phases are separated, the upper product phase is dried and then filtered again. The ether solution is placed on a rotary evaporator in order to remove the ether along with residual water. This procedure yields 41.2 g (95%) of a pure, clear, viscous oil (ionic liquid). This material is suitable for use a displacer. HPLC purity of the quat cation is essential identically to that of the starting material. Residual chloride content is <0.01 mole %.


Method D.


84.6 g N-(4-Fluorobenzyl)-N-decylpyrrolidinium hydroxide solution (100 mmole, 39.9%, fw=337.53) is placed in a calibrated 1000 mL volumetric flask and about 800 mL CO2-free distilled water is added and mixed. Without delay, trifluoroacetic acid (˜11.4 g, fw=114.2) is carefully added dropwise with stirring and pH-monitoring. When 95% of the acid has been added, small droplets of the acid are added one-at-a-time until the unbuffered endpoint (pH=5-8) is attained. Additional CO2-free distilled water is added until the volume is exactly 1000 mL). This 100 mM stock solution is suitable for use a displacer.


A wide range of salts are readily prepared using this method including, formate, acetate, bromide, nitrate, iodide, methanesulfonate, trifluoromethanesulfonate (triflate), trichloroacetate and perchlorate.


Method E.


84.6 g N-(4-Fluorobenzyl)-N-decylpyrrolidinium hydroxide solution (100 mmole, 39.9%, fw=337.53) and 100 mL peroxide-free diethyl ether are placed in a 250 mL Erlenmeyer flask. Without delay, the mixture is vigorously stirred magnetically, and trifluoroacetic acid (˜11.4 g, fw=114.2) is carefully added dropwise at an addition rate so that there is a minimal temperature rise. The room-temperature mixture is separated into two liquid phases, the upper product phase is dried and filtered, the ether solution is placed on a rotary evaporator in order to remove the ether along with residual trifluoroacetic acid and water. This procedure yields 42.0 g (97%) of a pure, clear, viscous oil (ionic liquid). This material is suitable for use a displacer. HPLC purity of the quat cation is essential identical to the starting material. Residual chloride content is <0.01 mole %.


Method F.


38.1 g Purified N-decylpyrrolidine (0.18 mole, fw=211.39) is added to 75 mL stirring acetonitrile in a 250 mL 4-neck round-bottom flask that is equipped with a heating mantle, magnetic stirrer, 50 mL addition funnel and reflux condensor. The reaction is carried out under a nitrogen atmosphere. The stirring mixture is warmed to about 50° C., and 44.4 g freshly distilled 4-fluorobenzyl trifluoroacetate4 (0.20 mole, fw=222.14) is added in a dropwise fashion over a period of about 60 minutes. The reaction mixture is then heated under refluxing conditions for about 24 hours and periodically monitored by HPLC in order to ensure that the starting amine is entirely consumed. The reaction mixture is cooled to room temperature, filtered through sintered-glass and placed on a rotary evaporator to remove the solvent (acetonitrile). 100 mL n-pentane is added portionwise with mechanical stirring to the yellow reaction residue. Once this mixture is fully mixed with the solvent, the upper layer is completely removed and discarded. To the oily product layer is added an equal volume of peroxide-free diethyl ether and thoroughly mixed. 100 mL n-Pentane is added, the mixture is thoroughly mixed and allowed to settle and the upper layer is separated and discarded. This trituration process with diethyl ether and pentane is repeated two more times in order to remove as much color and organic impurities as possible. Finally, the mixture is heated over night on a vacuum-line (0.5 torr, 80° C.) to remove the last traces of volatiles. This procedure yields about 55 g (71%) of a pale yellow, oily product with purity of 98.5-99.0% (HPLC). This oily product is easily purified using chromatography, but difficult to purify by other methods; for this reason, this method of preparation is less preferred.


Example 14
Preparation of N,N-Diheptyl-1,2,3,4-tetrahydroisoquinolinium Bromide (fw=410.49)

48.0 g Freshly distilled 1,2,3,4-tetrahydroisoquinoline (360 mmole, fw=133.19) and 49.1 g diisopropylethylamine (380 mmole, fw=129.25) are added to 120 mL acetonitrile in a 500 mL, 3-neck, round-bottom flask that is equipped with a magnetic stirring bar, heating mantle, 250 mL addition funnel, reflux condenser and teflon-coated thermocouple. The reaction is carried out under a nitrogen atmosphere with a slow N2 purge. The stirring mixture is heated to 50° C., and 143.3 g freshly distilled 1-bromoheptane (0.80 mole, fw=179.11) is added in a dropwise fashion over a period of about 60 minutes. The reaction mixture is then heated to about 80° C. for 10-12 hours and periodically monitored by HPLC in order to ensure that the starting amine is entirely consumed. The reaction mixture is cooled to room temperature, and 50% aqueous sodium hydroxide is added dropwise with strong agitation. The pH of the aqueous layer is monitored with pH paper. When the mixture becomes sufficiently basic (˜29 g NaOH), the lower aqueous phase is removed, and the organic solution is filtered and placed in a rotary evaporator in order to partially remove the volatile components (acetonitrile, water, diisopropylethylamine) under vacuum. When the product begins to crystallize from solution, about 300 mL diethyl ether is added portionwise with stirring. The mixture is allowed to stand at 4° C. overnight. The cold mixture is filtered through sintered glass, the solid is washed with diethyl ether and dried on the filter by passing dry nitrogen through it. It is finally dried in a vacuum oven (50° C., 20 torr) overnight. This crude product is recrystallized by dissolving it in a minimum amount of hot (70° C.) acetonitrile, quickly filtering the hot solution through sintered-glass and the allowing it to cool. Crystallization occurs on standing at room temperature and is completed by the addition of diethyl ether with cooling. The product is worked up as before. This procedure yields about 102 g (69%) of a white, crystalline product with >99% purity (HPLC).


Example 15
Preparation of 3,5-Bis(N,N-dimethyldecylammoniummethyl)-1-fluorobenzene Dibromide (fw=652.68)

77.9 g Freshly distilled N,N-dimethyldecylamine (420 mmole, fw=185.36) is added to 1 L stirring acetonitrile in a 2 L, 4-neck round-bottom flask that is equipped with a heating mantle, mechanical stirrer, 500 mL addition funnel, reflux condenser and teflon-coated thermocouple. The reaction is carried out under a nitrogen atmosphere with a slow N2 purge. The stirring mixture is heated to 50° C., and 56.4 g freshly recrystallized 3,5-bis(bromomethyl)-1-fluorobenzene5 (200 mmole, fw=281.96) in 200 mL acetonitrile is added in a dropwise fashion over a period of about 60 minutes; the reaction is mildly exothermic. The reaction mixture is then heated to about 80° C. for 3-5 hours and then rapidly filtered while hot through a sintered-glass filter into a 2 L clean filter-flask. On cooling to room temperature, copious amounts of white crystals form in solution. The product is allowed to crystallize from solution by standing at room temperature for about 3 hours, and then the mixture is allowed to stand at 4° C. overnight. The cold mixture is filtered through a sintered-glass filter, washed with cold acetonitrile, then n-pentane and finally dried by passing dry N2 through the product. The product is finally dried in a vacuum oven (50° C., 20 torr) overnight, cooled and stored in a sealed container. This procedure yields about 125 g (96%) of a white, crystalline product. It is recrystallized from hot acetonitrile (9-10 g solvent per gram of product) yielding 120 g of the purified product (99.5-99.8% pure, HPLC).









TABLE V







Cationic Displacer Compounds



















HPLC








Method 9a














[R1R2R3R4N] +[X]





Form.
Ret.



















Nu.
R1
R2
R3
R4
X
Amine
CAS Num.
Alkylating Agent
CAS Num.
Formula
Weight
Time





 1

nDecyl

Methyl
Methyl
Benzyl
Cl
NR1R2R3
1120-24-7
R4X
100-44-7
C19H34NCl
311.938
41.2


 2

nDecyl

Methyl
Methyl
Benzyl
Br
NR1R2R3
1120-24-7
R4X
100-39-0
C19H34NBr
356.390
41.2


 3

nDecyl

Methyl
Methyl
Benzyl
Br
NR2R3R4
103-83-3
R1X
112-29-8
C19H34NBr
356.390
41.2


 4

nDecyl

Methyl
Methyl
Benzyl
OH




C19H35NO
293.493
41.2


 5

nDecyl

Methyl
Methyl
Benzyl
CF3CO2




C21H34NO2F3
389.502
41.2


 6

nDecyl

Methyl
Ethyl
Benzyl
Br
NR2R3R4
4788-37-8
R1X
112-29-8
C20H36NBr
370.417
42.2


 7

nDecyl

Methyl

nPropyl

Benzyl
Br
NR2R3R4
2532-72-1
R1X
112-29-8
C21H38NBr
384.443
44.2


 8

nDecyl

Methyl

nButyl

Benzyl
Br
NR2R3R4
31844-65-2
R1X
112-29-8
C22H40NBr
398.470
46.5


 9

nDecyl

Methyl
Methyl
2-FC6H4CH2
Cl
NR1R2R3
1120-24-7
R4X
345-35-7
C19H33NClF
329.929
41.3


 10

nDecyl

Methyl
Methyl
3-FC6H4CH2
Cl
NR1R2R3
1120-24-7
R4X
456-42-8
C19H33NClF
329.929
41.3


 11

nDecyl

Methyl
Methyl
4-FC6H4CH2
Cl
NR1R2R3
1120-24-7
R4X
352-11-4
C19H33NClF
329.929
41.4


 12

nDecyl

Methyl
Methyl
4-FC6H4CH2
Br
NR1R2R3
1120-24-7
R4X
23915-07-3
C19H33NBrF
374.380
41.4


 13

nDecyl

Methyl
Methyl
4-FC6H4CH2
OH




C19H34NOF
311.484
41.4


 14

nDecyl

Methyl
Methyl
4-FC6H4CH2
CF3CO2




C21H33NO2F4
407.492
41.4


 15

nDecyl

Methyl
Methyl
2-ClC6H4CH2
Cl
NR1R2R3
1120-24-7
R4X
611-19-8
C19H33NCl2
346.383
42.8


 16

nDecyl

Methyl
Methyl
3-ClC6H4CH2
Cl
NR1R2R3
1120-24-7
R4X
620-20-2
C19H33NCl2
346.383
42.9


 17

nDecyl

Methyl
Methyl
3-ClC6H4CH2
Br
NR1R2R3
1120-24-7
R4X
766-80-3
C19H33NBrCl
390.834
42.9


 18

nDecyl

Methyl
Methyl
4-ClC6H4CH2
Cl
NR1R2R3
1120-24-7
R4X
104-83-6
C19H33NCl2
346.383
43.2


 19

nDecyl

Methyl
Methyl
3-BrC6H4CH2
Cl
NR1R2R3
1120-24-7
R4X
93277-4
C19H33NBrCl
390.834
43.6


 20

nDecyl

Methyl
Methyl
3-BrC6H4CH2
Br
NR1R2R3
1120-24-7
R4X
823-78-9
C19H33NBr2
435.286
43.6


 21

nDecyl

Methyl
Methyl
4-BrC6H4CH2
Br
NR1R2R3
1120-24-7
R4X
823-78-9
C19H33NBr2
435.286
44.0


 22

nDecyl

Methyl
Methyl
2,4-F2C6H3CH2
Cl
NR1R2R3
1120-24-7
R4X
452-07-3
C19H32NClF2
347.919
41.7


 23

nDecyl

Methyl
Methyl
2,6-F2C6H3CH2
Cl
NR1R2R3
1120-24-7
R4X
67-73-4
C19H32NClF2
347.919
41.4


 24

nDecyl

Methyl
Methyl
3,5-F2C6H3CH2
Cl
NR1R2R3
1120-24-7
R4X
220141-71-9
C19H32NClF2
347.919
42.0


 25

nDecyl

Methyl
Methyl
2,4,6-F3C6H2CH2
Br
NR1R2R3
1120-24-7
R4X
151411-98-2
C19H31NBrF3
410.361
41.8


 26

nDecyl

Methyl
Methyl
3,4,5-F3C6H2CH2
Cl
NR1R2R3
1120-24-7
R4X
732306-27-3
C19H31NClF3
365.910
42.8


 27

nDecyl

Methyl
Methyl
4-MeC6H4CH2
Cl
NR1R2R3
1120-24-7
R4X
104-82-5
C20H36NCl
325.965
43.7


 28

nDecyl

Methyl
Methyl
4-CF3C6H4CH2
Cl
NR1R2R3
1120-24-7
R4X
939-99-1
C20H33NClF3
379.937
44.1


 29

nDecyl

Methyl
Methyl
4-EtC6H4CH2
Cl
NR1R2R3
1120-24-7
R4X
1467-05-6
C21H38NCl
339.992
45.9


 30

nDecyl

Methyl
Methyl
4-tuC6H4CH2
Cl
NR1R2R3
1120-24-7
R4X
19692-45-6
C23H42NCl
368.039
48.7


 31

nDecyl

Methyl
Methyl
4-PhC6H4CH2
Cl
NR1R2R3
1120-24-7
R4X
1667-11-4
C25H38NCl
388.036
47.7


 32

nDecyl

Methyl
Methyl
4-MeOC6H4CH2
Cl
NR1R2R3
1120-24-7
R4X
824-94-2
C20H36NOCl
341.965
42.1


 33

nDecyl

Methyl
Methyl
4-AcNHC6H4CH2
Cl
NR1R2R3
1120-24-7
R4X
54777-65-0
C21H37N12OCl
368.990
36.6


 34

nDecyl

Methyl
Methyl
4-MeO2CC6H4CH2
Br
NR1R2R3
1120-24-7
R4X
2417-72-3
C21H36NO2Br
414.426
40.2


 35

nDecyl

Methyl
Methyl
H2NC(O)CH2
Cl
NR1R2R3
1120-24-7
R4X
79-07-2
C14H31N2OCl
278.866
32.1


 36

nDecyl

Methyl
Methyl
PhHNC(O)CH2
Cl
NR1R2R3
1120-24-7
R4X
587-65-5
C20H35N2OCl
354.963
41.5


 37

nDecyl

Methyl
Methyl
Me2NC(O)CH2
Cl
NR1R2R3
1120-24-7
R4X
2675-89-0
C16H35N2OCl
306.915
35.5


 38

nDecyl

Methyl
Methyl
Et2NC(O)CH2
Cl
NR1R2R3
1120-24-7
R4X
2315-36-8
C18H39N2OCl
334.968
39.8


 39

nNonyl

Methyl
Methyl
Benzyl
Cl
NR1R2R3
17373-27-2
R4X
100-44-7
C18H32NCl
297.912
38.0


 40

nNonyl

Methyl
Methyl
Benzyl
Br
NR1R2R3
17373-27-2
R4X
100-39-0
C18H32NBr
342.363
38.0


 41

nNonyl

Methyl
Methyl
Benzyl
OH




C18H33NO
279.466
38.0


 42

nNonyl

Methyl
Methyl
Benzyl
CF3CO2




C20H32NO2F3
375.475
38.0


 42b

nNonyl

Methyl
Methyl
4-FC6H4CH2
Cl
NR1R2R3
17373-27-2
R4X
352-11-4
C18H31NClF
315.904
38.3


 42c

nNonyl

Methyl
Methyl
4-FC6H4CH2
CF3CO2




C20H31NO2F4
393.456
38.3


 43

nNonyl

Methyl
Ethyl
Benzyl
Br
NR2R3R4
4788-37-8
R1X
693-58-3
C19H34NBr
356.390
39.7


 44

nNonyl

Methyl

nPropyl

Benzyl
Br
NR2R3R4
2532-72-1
R1X
693-58-3
C20H36NBr
370.417
41.7


 45

nNonyl

Methyl

nButyl

Benzyl
Br
NR2R3R4
31844-65-2
R1X
693-58-3
C21H38NBr
384.443
44.0


 46

nOctyl

Methyl
Methyl
4-CH3C6H4CH2
Cl
NR1R2R3
7378-99-6
R4X
104-82-5
C18H32NCl
297.912
37.7


 47

nOctyl

Methyl
Methyl
4-tuC6H4CH2
Cl
NR1R2R3
7378-99-6
R4X
19692-45-6
C21H38NCl
339.986
43.6


 47b

nOctyl

Methyl
Methyl
4-FC6H4CH2
Cl
NR1R2R3
7378-99-6
R4X
352-11-4
C17H29NClF
301.877
34.9


 48

nOctyl

Methyl
Methyl
Benzyl
Cl
NR1R2R3
7378-99-6
R4X
100-44-7
C17H30NCl
283.885
34.7


 49

nOctyl

Methyl
Methyl
Benzyl
CF3CO2




C19H30NO2F3
361.448
34.7


 49b

nOctyl

Methyl
Methyl
4-FC6H4CH2
Cl
NR1R2R3
7378-99-6
R4X
352-11-4
C17H29NClF
301.867
35.2


 49c

nOctyl

Methyl
Methyl
4-FC6H4CH2
CF3CO2




C19H29NO2F4
379.430
35.2


 50

nOctyl

Methyl
Ethyl
Benzyl
Br
NR2R3R4
4788-37-8
R1X
111-83-1
C18H32NBr
342.363
35.7


 51

nOctyl

Methyl

nPropyl

Benzyl
Br
NR2R3R4
2532-72-1
R1X
111-83-1
C19H34NBr
356.390
37.7


 52

nOctyl

Methyl

nButyl

Benzyl
Br
NR2R3R4
31844-65-2
R1X
111-83-1
C20H36NBr
370.417
40.0


 53

nOctyl

Methyl

nPentyl

Benzyl
Br
NR2R3R4
77223-58-6
R1X
111-83-1
C21H38NBr
384.443
42.5


 53b

nHeptyl

Methyl
Methyl
Benzyl
Cl
NR1R2R3
5277-11-2
R4X
100-44-7
C16H28NCl
269.850
31.8


 53c

nHeptyl

Methyl
Methyl
Benzyl
CF3CO2




C18H28NO2F3
347.413
31.8


 53d

nHeptyl

Methyl
Methyl
4-FC6H4CH2
Cl
NR1R2R3
5277-11-2
R4X
352-11-4
C16H27NClF
287.840
32.0


 53e

nHeptyl

Methyl
Methyl
4-FC6H4CH2
CF3CO2




C18H27NO2F4
365.404
32.0


 54

nUndecyl

Methyl
Methyl
Benzyl
Cl
NR1R2R3
17373-28-3
R4X
100-44-7
C20H36NCl
325.965
44.3


 55

nUndecyl

Methyl
Methyl
Benzyl
Br
NR1R2R3
17373-28-3
R4X
100-39-0
C20H36NBr
370.417
44.3


 56

nUndecyl

Methyl
Methyl
Benzyl
OH




C20H37NO
307.520
44.3


 57

nUndecyl

Methyl
Methyl
Benzyl
CF3CO2




C22H36NO2F3
403.529
44.3


 58

nUndecyl

Methyl
Ethyl
Benzyl
Br
NR2R3R4
4788-37-8
R1X
693-67-4
C21H38NBr
384.443
45.3


 59

nUndecyl

Methyl

nPropyl

Benzyl
Br
NR2R3R4
2532-72-1
R1X
693-67-4
C22H40NBr
398.470
47.3


 60

nUndecyl

Methyl
Methyl
4-FC6H4CH2
Cl
NR1R2R3
17373-28-3
R4X
352-11-4
C20H35NClF
343.956
44.5


 61

nUndecyl

Methyl
Methyl
4-FC6H4CH2
Br
NR1R2R3
17373-28-3
R4X
459-46-1
C20H35NBrF
388.407
44.5


 62

nUndecyl

Methyl
Methyl
4-FC6H4CH2
OH




C20H36NOF
325.510
44.5


 63

nUndecyl

Methyl
Methyl
4-FC6H4CH2
CF3CO2




C22H35NO2F4
421.519
44.5


 64

nDecyl

Methyl
Benzyl
NH2C(O)CH2
Cl
NR1R2R3
112778-25-3
R4X
79-07-2
C20H35N2OCl
354.963
36.5


 65

nDecyl

Methyl
Benzyl
PhNHC(O)CH2
Cl
NR1R2R3
112778-25-3
R4X
587-65-5
C26H39N2OCl
431.061
41.6


 66

nDecyl

Methyl
Benzyl
Me2NC(O)CH2
Cl
NR1R2R3
112778-25-3
R4X
2675-89-0
C22H39N2OCl
383.017
39.9


 67

nDecyl

Methyl
Methyl
l-Me2NC(O)CH(Bz)—
Br
NR2R3R4
91904-44-8r
R1X
112-29-8
C23H41N2OBr
441.488
41.5


 67b

nDecyl

Methyl
Methyl
d-Me2NC(O)CH(Bz)—
Br
NR2R3R4
91904-44-8r
R1X
112-29-8
C23H40N2OBr
440.487
41.5


 68

nDecyl

Methyl
Benzyl
Et2NC(O)CH2
Cl
NR1R2R3
112778-25-3
R4X
2315-36-8
C24H43N2OCl
411.071
44.2


 69
Phenyl
Methyl

nPentyl


nButyl

Br
NR1R3R4
138374-52-4
R2X
74-83-9
C16H28NBr
314.309
29.7


 70
Phenyl
Methyl

nPentyl


nPentyl

Br
NR1R3R4
6249-76-9
R2X
74-83-9
C17H30NBr
328.336
32.5


 71
Phenyl
Methyl

nPentyl


nHexyl

Br
NR1R3R4
138374-53-5
R2X
74-83-9
C18H32NBr
342.363
35.1


 72
Phenyl
Methyl

nHexyl


nHexyl

Br
HNR1R2
100-61-8
2xR4X + base
111-25-1
C19H34NBr
356.390
37.7


 73
Phenyl
Methyl

nHexyl


nHexyl

Br
NR1R3R4
4430-09-5
R2X
74-83-9
C19H34NBr
356.390
37.7


 74
Phenyl
Methyl

nHeptyl


nHexyl

Br
NR1R3R4
288572-97-4
R2X
74-83-9
C20H36NBr
370.417
40.2


 75
Phenyl
Methyl

nHeptyl


nHeptyl

Br
NR1R3R4
100-61-8
R2X
74-83-9
C21H38NBr
384.443
42.7


 76
Phenyl
Methyl

nHeptyl


nHeptyl

Br
NR1R3R4
16341-05-2
R2X
74-83-9
C21H38NBr
384.443
42.7


 77
Phenyl
Methyl

nHeptyl


nHeptyl

CF3CO2




C23H38NO2F3
417.555
42.7


 78
4-FC6H4
Methyl

nHeptyl


nHeptyl

Br
HNR1R2
405-66-3
2xR4X + base
629-04-9
C21H37N1BrF
402.434
42.9


 79
4-FC6H4
Methyl

nHeptyl


nHeptyl

CF3CO2




C23H37NO2F4
435.546
42.9


 80
Phenyl
Methyl

nHeptyl


nOctyl

Br
NR1R2R4
13063-61-1
R3X
629-04-9
C22H40NBr
398.470
45.1


 81
Phenyl
Methyl

nOctyl


nOctyl

Br
NR1R3R4
3007-75-8
R2X
74-83-9
C23H42NBr
412.497
47.5


















 82
R1 + R2 = INw

nButyl


nPentyl

Br
NR1R2R3
5878-10-8
R4X
110-53-2
C17H28NBr
326.320
29.7


 83
R1 + R2 = INw

nPentyl


nPentyl

Br
NR1R2R3
496-15-1
R4X
110-53-2
C18H30NBr
340.347
32.9


 84
R1 + R2 = INw

nHexyl


nPentyl

Br
NR1R2R3
593281-15-3
R4X
110-53-2
C19H32NBr
354.374
35.9


 85
R1 + R2 = INw

nHexyl


nHexyl

Br
HNR1R2
496-15-1
2xR4X + base
111-25-1
C20H34NBr
368.401
38.7


 86
R1 + R2 = INw

nHexyl


nHeptyl

Br
NR1R2R3
593281-15-3
R4X
629-04-9
C21H36NBr
382.428
41.4


 87
R1 + R2 = INw

nHeptyl


nHeptyl

Br
NR1R2R3
496-15-1
2xR4X + base
629-04-9
C22H38NBr
396.448
43.9


 88
R1 + R2 = INw

nHeptyl


nHeptyl

CF3CO2




C24H38NO2F3
429.566
43.9


 89
R1 + R2 = INw

nHeptyl


nOctyl

Br
NR1R2R3
157363-64-9
R4X
111-83-1
C23H40NBr
410.481
46.3


 90
R1 + R2 = INw

nOctyl


nOctyl

Br
HNR1R2
496-15-1
2xR4X + base
111-83-1
C24H42NBr
424.508
48.6


 91
R1 + R2 = INw
Methyl

nNonyl

Br
NR1R2R3
824-21-5
R4X
693-58-3
C18H30NBr
340.347
36.5


 92
R1 + R2 = INw
Methyl

nDecyl

Br
NR1R2R3
824-21-5
R4X
112-29-8
C19H32NBr
354.368
39.9


 93
R1 + R2 = INw
Methyl

nUndecyl

Br
NR1R2R3
824-21-5
R4X
693-67-4
C20H34NBr
368.395
43.0


 94
R1 + R2 = THQw

nPentyl


nButyl

Br
NR1R2R3
63074-60-2
R4X
109-65-9
C18H30NBr
340.347
31.0


 95
R1 + R2 = THQw

nPentyl


nPentyl

Br
NR1R2R3
635-46-1
2xR4X + base
110-53-2
C19H32NBr
354.374
34.1


 96
R1 + R2 = THQw

nPentyl


nHexyl

Br
NR1R2R3
63074-60-2
R4X
111-25-1
C20H34NBr
368.401
37.1


 97
R1 + R2 = THQw

nHexyl


nHexyl

Br
HNR1R2
635-46-1
2xR4X + base
111-25-1
C21H36NBr
382.428
39.7


 98
R1 + R2 = THQw

nHexyl


nHeptyl

Br
NR1R2R3
593281-16-4
R4X
629-04-9
C22H38NBr
396.454
42.6


 99
R1 + R2 = THQw

nHeptyl


nHeptyl

Br
NR1R2R3
635-46-1
2xR4X + base
629-04-9
C23H40NBr
410.481
44.6


100
R1 + R2 = THQw

nHeptyl


nHeptyl

CF3CO2




C25H40NO2F3
443.593
44.6


101
R1 + R2 = THQw

nOctyl


nHeptyl

Br
NR1R2R3
912546-48-6
R4X
629-04-9
C24H42NBr
424.508
47.0


102
R1 + R2 = THQw

nOctyl


nOctyl

Br
HNR1R2
635-46-1
2xR4X + base
111-83-1
C25H44NBr
438.535
49.2


103
R1 + R2 = THQw
Methyl

nNonyl

Br
NR1R2R3
491-34-9
R4X
693-58-3
C19H32NBr
354.368
37.6


104
R1 + R2 = THQw
Methyl

nDecyl

Br
NR1R2R3
491-34-9
R4X
112-29-8
C20H34NBr
368.395
40.8


105
R1 + R2 = THQw
Methyl

nUndecyl

Br
NR1R2R3
491-34-9
R4X
693-67-4
C21H36NBr
382.421
43.9



















106
Benzyl
Methyl

nPentyl


nButyl

Br
NR1R2R3
77223-58-6
R4X
109-65-9
C17H30NBr
328.336
32.0


107
Benzyl
Methyl

nPentyl


nPentyl

Br
NR1R2R3
77223-58-6
R4X
110-53-2
C18H32NBr
342.363
34.8


108
Benzyl
Methyl

nPentyl


nHexyl

Br
NR1R2R3
77223-58-6
R4X
111-25-1
C19H34NBr
356.390
37.4


109
Benzyl
Methyl

nPentyl


nHeptyl

Br
NR1R2R3
77223-58-6
R4X
629-04-9
C20H36NBr
370.417
40.3


110
Benzyl
Methyl

nHexyl


nHexyl

Br
HNR1R2
100-6108
2xR4X + base
111-25-1
C20H36NBr
370.417
40.0


111
Benzyl
Methyl

nHexyl


nHexyl

Cl
NR2R3R4
37615-53-5
R1X
100-44-7
C20H36NCl
325.965
40.0


112
Benzyl
Methyl

nHexyl


nHexyl

CF3CO2




C22H36NO2F3
403.529
40.0


113
Benzyl
Methyl
Cyclohexyl
Cyclohexyl
Br
NR2R3R4
7560-83-0
R1X
100-39-0
C20H32NBr
366.385
30.7


114
PhC(O)CH2
Methyl

nHexyl


nHexyl

Cl
NR2R3R4
37615-53-5
R1X
532-27-4
C21H36NOCl
353.976
41.5


115
2-FC6H4CH2
Methyl

nHexyl


nHexyl

Cl
NR2R3R4
37615-53-5
R1X
345-35-7
C20H35NClF
343.956
40.1


116
3-FC6H4CH2
Methyl

nHexyl


nHexyl

Cl
NR2R3R4
37615-53-5
R1X
456-42-8
C20H35NClF
343.956
40.1


117
4-FC6H4CH2
Methyl

nHexyl


nHexyl

Cl
NR2R3R4
37615-53-5
R1X
352-11-4
C20H35NClF
343.956
40.2


118
4-FC6H4CH2
Methyl

nHexyl


nHexyl

Br
NR2R3R4
37615-53-5
R1X
23915-07-3
C20H35NBrF
388.407
40.2


119
4-FC6H4CH2
Methyl

nHexyl


nHexyl

OH




C20H36NOF
325.510
40.2


120
4-FC6H4CH2
Methyl

nHexyl


nHexyl

CF3CO2




C22H35NO2F4
421.519
40.2


121
2-ClC6H4CH2
Methyl

nHexyl


nHexyl

Cl
NR2R3R4
37615-53-5
R1X
611-19-8
C20H35NCl2
360.410
41.7


122
3-ClC6H4CH2
Methyl

nHexyl


nHexyl

Cl
NR2R3R4
37615-53-5
R1X
620-20-2
C20H35NCl2
360.410
41.8


123
3-ClC6H4CH2
Methyl

nHexyl


nHexyl

Br
NR2R3R4
37615-53-5
R1X
766-80-3
C20H35NBrCl
404.861
41.8


124
4-ClC6H4CH2
Methyl

nHexyl


nHexyl

Cl
NR2R3R4
37615-53-5
R1X
104-83-6
C20H35NCl2
360.410
42.1


125
4-F-2-ClC6H3CH2
Methyl

nHexyl


nHexyl

Cl
NR2R3R4
37615-53-5
R1X
93286-22-7
C20H34NCl2F
378.401
42.3


126
6-F-2-ClC6H3CH2
Methyl

nHexyl


nHexyl

Cl
NR2R3R4
37615-53-5
R1X
55117-15-2
C20H34NCl2F
378.401
41.8


127
2-F-3-ClC6H3CH2
Methyl

nHexyl


nHexyl

Br
NR2R3R4
37615-53-5
R1X
85070-47-9
C20H34NBrClF
422.846
42.3


128
4-F-3-ClC6H3CH2
Methyl

nHexyl


nHexyl

Br
NR2R3R4
37615-53-5
R1X
192702-01-5
C20H34NBrClF
422.846
42.7


129
2,3-F2C6H3CH2
Methyl

nHexyl


nHexyl

Br
NR2R3R4
37615-53-5
R1X
113211-94-2
C20H34NBrF2
406.398
41.0


130
2,4-F2C6H3CH2
Methyl

nHexyl


nHexyl

Cl
NR2R3R4
37615-53-5
R4X
452-07-3
C20H34NClF2
361.941
41.1


131
2,5-F2C6H3CH2
Methyl

nHexyl


nHexyl

Cl
NR2R3R4
37615-53-5
R1X
495-07-8
C20H34NClF2
361.941
40.8


132
2,6-F2C6H3CH2
Methyl

nHexyl


nHexyl

Cl
NR2R3R4
37615-53-5
R1X
697-73-4
C20H34NClF2
361.941
40.9


133
3,4-F2C6H3CH2
Methyl

nHexyl


nHexyl

Cl
NR2R3R4
37615-53-5
R1X
698-80-6
C20H34NClF2
361.941
41.2


134
3,5-F2C6H3CH2
Methyl

nHexyl


nHexyl

Cl
NR2R3R4
37615-53-5
R1X
220141-71-9
C20H34NClF2
361.941
41.4


135
2,4,6-F3C6H2CH2
Methyl

nHexyl


nHexyl

Br
NR2R3R4
37615-53-5
R1X
151411-98-2
C20H33NBrF3
424.388
41.3


136
3,4,5-F3C6H2CH2
Methyl

nHexyl


nHexyl

Cl
NR1R2R3
37615-53-5
R1X
732306-27-3
C20H33NClF3
379.937
42.2


137
3-BrC6H4CH2
Methyl

nHexyl


nHexyl

Cl
NR2R3R4
37615-53-5
R1X
932-77-4
C20H35NBrCl
404.861
42.2


138
3-BrC6H4CH2
Methyl

nHexyl


nHexyl

Br
NR2R3R4
37615-53-5
R1X
823-78-9
C20H35NBr2
449.313
42.7


139
4-BrC6H4CH2
Methyl

nHexyl


nHexyl

Br
NR2R3R4
37615-53-5
R1X
589-15-1
C20H35NBr2
449.313
43.1


140
Ph(CH2)2
Methyl

nHexyl


nHexyl

Br
HNR1R2
589-08-2
2xR4X + base
111-25-1
C21H38NBr
384.443
41.6


141
4-CF3C6H4CH2
Methyl

nHexyl


nHexyl

Br
NR2R3R4
37615-53-5
R1X
939-99-1
C21H35NBrF3
438.415
43.4


142
Benzyl
Ethyl

nHexyl


nHexyl

Cl
NR2R3R4
1097732-09-6
R1X
100-44-7
C21H38NCl
339.992
41.3


143
Benzyl
Ethyl

nHexyl


nHexyl

CF3CO2




C23H38NO2F3
417.555
41.3


144
4-FC6H4CH2
Ethyl

nHexyl


nHexyl

Cl
NR2R3R4
1097732-09-6
R1X
352-11-4
C21H37NClF
357.983
41.5


145
4-FC6H4CH2
Ethyl

nHexyl


nHexyl

CF3CO2




C23H37NO2F4
435.546
41.5


146
Benzyl
Methyl

nHeptyl


nPentyl

Br
NR1R2R3
8140453-7
R4X
110-53-2
C20H36NBr
370.417
40.1


147
Benzyl
Methyl

nHeptyl


nHexyl

Br
NR1R2R3
8140453-7
R4X
111-25-1
C21H38NBr
384.443
42.5


147b
4-FC6H4CH2
Methyl

nHeptyl


nHexyl

Cl
NR1R2R3
8140453-7
R4X
352-11-4
C21H37NClF
357.985
42.7


148
Benzyl
Methyl

nHeptyl


nHeptyl

Br
NR1R2R3
8140453-7
R4X
629-04-9
C22H40NBr
398.470
45.0


149
Benzyl
Methyl

nHeptyl


nHeptyl

CF3CO2




C24H40NO2F3
431.582
45.0


150
4-FC6H4CH2
Methyl

nHeptyl


nHeptyl

Br
HNR1R2
405-66-3
2xR4X + base
629-04-9
C22H39NBrF
416.461
45.2


151
4-FC6H4CH2
Methyl

nHeptyl


nHeptyl

CF3CO2




C24H39NO2F4
449.573
45.2


152
Benzyl
Ethyl

nHeptyl


nHeptyl

Cl
NR2R3R4
1097732-10-9
R1X
100-44-7
C23H42NCl
368.046
46.2


153
Benzyl
Ethyl

nHeptyl


nHeptyl

CF3CO2




C25H42NO2F3
445.609
46.2


154
4-FC6H4CH2
Ethyl

nHeptyl


nHeptyl

Cl
NR2R3R4
1097732-10-9
R1X
352-11-4
C23H41NClF
386.036
46.4


155
4-FC6H4CH2
Ethyl

nHeptyl


nHeptyl

CF3CO2




C25H41NO2F4
463.600
46.4


156
Benzyl
Methyl

nHeptyl


nOctyl

Br
NR1R2R3
71404-53-7
R4X
111-83-1
C23H42NBr
412.497
47.4


157
Benzyl
Methyl

nOctyl


nOctyl

Br
HNR1R2
103-67-3
2xR4X + base
111-83-1
C24H44NBr
426.524
49.8


158
Benzyl
Methyl

nOctyl


nOctyl

Cl
NR2R3R4
4455-26-9
R1X
100-44-7
C24H44NCl
382.073
50.0


159
4-FC6H4CH2
Methyl

nOctyl


nOctyl

Cl
NR2R3R4
4455-26-9
R1X
352-11-4
C24H43NClF
400.063
50.2


















160
R1 + R2 = iINw

nPentyl


nButyl

Br
NR1R2R3
1197914-56-9
R4X
109-65-9
C17H28NBr
326.320
30.3


161
R1 + R2 = iINw

nPentyl


nPentyl

Br
HNR1R2
496-12-8
2xR4X + base
110-53-2
C18H30NBr
340.347
33.5


161b
R1 + R2 = iINw
Ph(CH2)3
Ph(CH2)3
Br
HNR1R2
496-12-8
2xR4X + base
637-59-2
C26H30NBr
436.427
39.6


161c
R1 + R2 = iINw
Ph(CH2)3
Ph(CH2)3
CF3CO2




C28H30NO2F3
469.539
39.6


162
R1 + R2 = iINw

nPentyl


nHexyl

Br
NR1R2R3
1197914-56-9
R4X
111-25-1
C19H32NBr
354.374
36.5


163
R1 + R2 = iINw

nPentyl


nOctyl

Br
HNR3R4
6835-13-8
o-(XCH2)2C6H4 + base
91-13-4
C21H36NBr
382.428
42.1


164
R1 + R2 = iINw

nHexyl


nHexyl

Br
HNR1R2
496-12-8
2xR4X + base
111-25-1
C20H34NBr
368.401
39.3


165
R1 + R2 = iINw

nHeptyl


nHexyl

Br
NR1R2R3
1197914-59-2
R4X
111-25-1
C21H36NBr
382.428
42.0


166
R1 + R2 = iINw

nHeptyl


nHeptyl

Br
HNR1R2
496-12-8
2xR4X + base
629-04-9
C22H38NBr
396.454
44.4


167
R1 + R2 = iINw

nHeptyl


nHeptyl

CF3CO2




C24H38NO2F3
429.566
44.4


168
R1 + R2 = iINw

nHeptyl


nOctyl

Br
NR1R2R3
1197914-59-2
R4X
111-83-1
C23H40NBr
410.481
46.8


169
R1 + R2 = iINw

nHeptyl


nOctyl

Br
HNR3R4
26627-77-0
o-(XCH2)2C6H4 + base
91-13-4
C23H40NBr
410.481
46.8


170
R1 + R2 = iINw

nOctyl


nOctyl

Br
HNR1R2
496-12-8
2xR4X + base
111-83-1
C24H42NBr
424.508
49.1


171
R1 + R2 = iINw
Methyl

nNonyl

Br
NR1R2R3
3474-87-1
R4X
693-58-3
C18H30NBr
340.347
37.0


172
R1 + R2 = iINw
Methyl

nNonyl

CF3CO2




C20H30NO2F3
373.459
37.0


173
R1 + R2 = iINw
Methyl

nDecyl

Br
NR1R2R3
3474-87-1
R4X
112-29-8
C19H32NBr
354.374
40.4


174
R1 + R2 = iINw
Methyl

nDecyl

CF3CO2




C21H32NO2F3
387.486
40.4


175
R1 + R2 = iINw
Methyl

nUndecyl

Br
NR1R2R3
3474-87-1
R4X
693-67-4
C20H34NBr
368.401
43.5


176
R1 + R2 = iINw
Methyl

nUndecyl

CF3CO2




C22H34NO2F3
401.513
43.5


177
R1 + R2 = THiQw

nPentyl


nButyl

Br
NR1R2R3
170964-25-7
R4X
109-65-9
C18H30NBr
340.347
31.3


178
R1 + R2 = THiQw

nPentyl


nPentyl

Br
HNR1R2
91-21-4
2xR4X + base
110-53-2
C19H32NBr
354.374
34.5


179
R1 + R2 = THiQw

nPentyl


nHexyl

Br
NR1R2R3
170964-25-7
R4X
111-25-1
C20H34NBr
368.401
37.5


180
R1 + R2 = THiQw

nPentyl


nOctyl

Br
HNR3R4
6835-13-8
o-(XCH2)—C6H4—(CH2CH2X) + base
38256-56-3
C22H38NBr
396.454
42.8


181
R1 + R2 = THiQw

nHexyl


nHexyl

Br
HNR1R2
91-21-4
2xR4X + base
111-25-1
C21H36NBr
382.428
40.2


182
R1 + R2 = THiQw

nHexyl


nHexyl

CF3CO2




C23H36NO2F3
415.542
40.2


182b
R1 + R2 = THiQw
Ph(CH2)3
Ph(CH2)3
Br
HNR1R2
91-21-4
2xR4X + base
637-59-2
C27H32NBr
450.454
40.5


182c
R1 + R2 = THiQw
Ph(CH2)3
Ph(CH2)3
CF3CO2




C29H32NO2F3
483.565
40.5


183
R1 + R2 = THiQw

nHeptyl


nHexyl

Br
NR1R2R3
170964-26-8
R4X
111-25-1
C22H38NBr
396.454
42.7


184
R1 + R2 = THiQw

nHeptyl


nHeptyl

Br
HNR1R2
91-21-4
2xR4X + base
629-04-9
C23H40NBr
410.481
45.1


185
R1 + R2 = THiQw

nHeptyl


nOctyl

Br
NR1R2R3
170964-26-8
R4X
111-83-1
C24H42NBr
424.508
47.4


186
R1 + R2 = THiQw

nHeptyl


nOctyl

Br
HNR3R4
26627-77-0
o-(XCH2)—C6H4—(CH2CH2X) + base
38256-56-3
C24H42NBr
424.508
47.4


187
R1 + R2 = THiQw

nOctyl


nOctyl

Br
HNR1R2
91-21-4
2xR4X + base
111-83-1
C25H44NBr
438.535
49.6


188
R1 + R2 = THiQw
Methyl

nNonyl

Br
NR1R2R3
1612-65-3
R4X
693-58-3
C19H32NBr
354.374
37.9


189
R1 + R2 = THiQw
Methyl

nNonyl

CF3CO2




C21H32NO2F3
387.486
37.9


190
R1 + R2 = THiQw
Methyl

nDecyl

Br
NR1R2R3
1612-65-3
R4X
112-29-8
C20H34NBr
368.401
41.2


191
R1 + R2 = THiQw
Methyl

nDecyl

CF3CO2




C22H34NO2F3
401.513
41.2


192
R1 + R2 = THiQw
Methyl

nUndecyl

Br
NR1R2R3
1612-65-3
R4X
693-67-4
C21H36NBr
382.428
44.3


193
R1 + R2 = THiQw
Methyl

nUndecyl

CF3CO2




C23H36NO2F3
415.540
44.3



















194

nDecyl

Methyl
Methyl
PhC(O)CH2
Cl
NR1R2R3
1120-24-7
R4X
532-27-4
C20H34NOCl
339.943
42.7


195

nDecyl

Methyl
Methyl
PhC(O)CH2
Br
NR1R2R3
1120-24-7
R4X
70-11-1
C20H34NOBr
384.394
42.7


196

nDecyl

Methyl
Methyl
PhC(O)CH2
CF3CO2




C22H34NO3F3
417.512
42.7


197

nDecyl

Methyl
Methyl
4-FC6H4C(O)CH2
Cl
NR1R2R3
1120-24-7
R4X
456-04-2
C20H33NOClF
357.939
42.9


198

nDecyl

Methyl
Methyl
4-FC6H4C(O)CH2
CF3CO2




C22H33NO3F4
435.503
42.9


199

nDecyl

Methyl
Methyl
4-CH3C6H4C(O)CH2
Br
NR1R2R3
1120-24-7
R4X
619-41-0
C21H36NOBr
398.421
44.5


200

nDecyl

Methyl
Methyl
4-CF3C6H4C(O)CH2
Br
NR1R2R3
1120-24-7
R4X
383-53-9
C21H33NOBrF3
452.398
45.9


201

nDecyl

Methyl
Methyl
4-ClC6H4C(O)CH2
Cl
NR1R2R3
1120-24-7
R4X
937-20-2
C20H33NOCl2
374.394
45.2


202

nDecyl

Methyl
Methyl
4-BrC6H4C(O)CH2
Br
NR1R2R3
1120-24-7
R4X
99-73-0
C20H33NOBr2
463.296
45.7


203

nDecyl

Methyl
Methyl
dl-PhC(O)CH(Ph)—
Cl
NR1R2R3
1120-24-7
R4X
447-31-4
C26H38NOCl
416.047
46.2


204

nDecyl

Methyl
Methyl
Ph(CH2)4
Br
NR1R2R3
1120-24-7
R4X
13633-25-5
C22H40NBr
398.470
46.0


205

nDecyl

Methyl
Methyl
Ph(CH2)3
Br
NR1R2R3
1120-24-7
R4X
673-59-2
C21H38NBr
384.443
44.4


206

nDecyl

Methyl
Methyl
dl-PhCH2CH(OH)CH2
Cl
HNR1R2R3Cl
10237-16-8
2-benzyloxirane
4436-24-2
C21H38NOCl
355.992
40.9


207

nDecyl

Methyl
Methyl
t-PhCH═CHCH2
Cl
NR1R2R3
1120-24-7
R4X
2687-12-9
C21H36NCl
337.970
44.9


208

nDecyl

Methyl
Methyl
Ph(CH2)2
Br
NR2R3R4
1126-71-2
R1X
112-29-8
C20H36NBr
370.417
42.8


209

nDecyl

Methyl
Methyl
1-(CH2)naphthylene
Cl
NR1R2R3
1120-24-7
R4X
86-52-2
C24H38NCl
376.018
44.8


210

nDecyl

Methyl
Methyl
9-(CH2)anthracene
Cl
NR1R2R3
1120-24-7
R4X
24463-19-2
C27H38NCl
412.058
48.2


211

nNonyl

Methyl
Methyl
PhC(O)CH2
Cl
NR1R2R3
17373-27-2
R4X
532-27-4
C19H32NOCl
325.922
39.6


212

nNonyl

Methyl
Methyl
PhC(O)CH2
Br
NR1R2R3
17373-27-2
R4X
70-11-1
C19H32NOBr
370.373
39.6


213

nNonyl

Methyl
Methyl
PhC(O)CH2
CF3CO2




C21H32NO3F3
403.485
39.6


214

nNonyl

Methyl
Methyl
4-FC6H4C(O)CH2
Cl
NR1R2R3
17373-27-2
R4X
456-04-2
C19H31NOClF
343.912
39.8


215

nNonyl

Methyl
Methyl
4-FC6H4C(O)CH2
CF3CO2




C21H31NO3F4
421.476
39.8


216

nNonyl

Methyl
Methyl
4-CH3C6H4C(O)CH2
Br
NR1R2R3
17373-27-2
R4X
619-41-0
C20H34NOBr
384.400
41.9


217

nOctyl

Ethyl
Ethyl
Benzyl
Cl
NR1R2R3
4088-37-3
R4X
100-44-7
C19H34NCl
311.938
37.1


218

nOctyl

Ethyl
Ethyl
Benzyl
CF3CO2




C21H34NO2F3
389.502
37.1


219

nOctyl

Ethyl
Ethyl
4-FC6H4CH2
Cl
NR1R2R3
4088-37-3
R4X
352-11-4
C19H33NClF
329.929
37.3


220

nOctyl

Ethyl
Ethyl
4-FC6H4CH2
CF3CO2




C21H33NO2F4
407.492
37.3


221

nNonyl

Ethyl
Ethyl
Benzyl
Cl
NR1R2R3
45124-35-4
R4X
100-44-7
C20H36NCl
325.965
40.1


222

nNonyl

Ethyl
Ethyl
Benzyl
CF3CO2




C22H36NO2F3
403.529
40.1


223

nNonyl

Ethyl
Ethyl
Benzyl
Br
NR1R2R3
45124-35-4
R4X
100-39-0
C20H36NBr
370.417
40.1


224

nNonyl

Ethyl
Ethyl
Benzyl
Br
NR2R3R4
772-54-3
R1X
693-58-3
C20H36NBr
370.417
40.1


225

nNonyl

Ethyl
Ethyl
PhC(O)CH2
Cl
NR1R2R3
45124-35-4
R4X
532-27-4
C21H36NOCl
353.976
41.8


226

nNonyl

Ethyl
Ethyl
4-FC6H4CH2
Cl
NR1R2R3
45124-35-4
R4X
352-11-4
C20H35NFCl
343.950
40.4


227

nNonyl

Ethyl
Ethyl
4-FC6H4CH2
CF3CO2




C22H35NO2F4
421.519
40.4


228

nDecyl

Ethyl
Ethyl
Benzyl
Cl
NR1R2R3
6308-94-7
R4X
100-44-7
C21H38NCl
339.986
43.3


229

nDecyl

Ethyl
Ethyl
Benzyl
CF3CO2




C23H38NO2F3
417.549
43.3


230

nDecyl

Ethyl
Ethyl
Benzyl
Br
NR1R2R3
6308-94-7
R4X
100-39-0
C21H38NBr
384.437
43.3


231

nDecyl

Ethyl
Ethyl
Benzyl
Br
NR2R3R4
6308-94-7
R1X
100-39-0
C21H38NBr
384.437
43.3


232

nDecyl

Ethyl
Ethyl
4-FC6H4CH2
Cl
NR1R2R3
6308-94-7
R4X
352-11-4
C21H37NClF
357.983
43.5


233

nDecyl

Ethyl
Ethyl
4-FC6H4CH2
CF3CO2




C23H37NO2F4
435.546
43.5


234

nUndecyl

Ethyl
Ethyl
Benzyl
Cl
NR1R2R3
54334-64-4
R4X
100-44-7
C22H40NCl
354.019
46.3


235

nUndecyl

Ethyl
Ethyl
Benzyl
CF3CO2




C24H40NO2F3
431.582
46.3


236

nUndecyl

Ethyl
Ethyl
4-FC6H4CH2
Cl
NR1R2R3
54334-64-4
R4X
352-11-4
C22H39NClF
372.010
46.5


237

nUndecyl

Ethyl
Ethyl
4-FC6H4CH2
CF3CO2




C24H39NO2F4
449.573
46.5


238

nHeptyl


nPropyl


nPropyl

Benzyl
Cl
NR1R2R3
Newd
R4X
100-44-7
C20H36NCl
325.965
37.9


239

nHeptyl


nPropyl


nPropyl

Benzyl
CF3CO2




C22H36NO2F3
403.529
37.9


240

nHeptyl


nPropyl


nPropyl

4-FC6H4CH2
Cl
NR1R2R3
Newd
R4X
352-11-4
C20H35NClF
343.956
38.1


241

nHeptyl


nPropyl


nPropyl

4-FC6H4CH2
CF3CO2




C22H35NO2F4
421.519
38.1


242

nOctyl


nPropyl


nPropyl

Benzyl
Cl
NR1R2R3
99209-95-7
R4X
100-44-7
C21H38NCl
339.992
41.0


243

nOctyl


nPropyl


nPropyl

Benzyl
CF3CO2




C23H38NO2F3
417.555
41.0


244

nOctyl


nPropyl


nPropyl

4-FC6H4CH2
Cl
NR1R2R3
99209-95-7
R4X
352-11-4
C21H37NClF
357.983
41.2


245

nOctyl


nPropyl


nPropyl

4-FC6H4CH2
CF3CO2




C23H37NO2F4
435.546
41.2


246

nNonyl


nPropyl


nPropyl

Benzyl
Cl
NR1R2R3
90105-55-8
R4X
100-44-7
C22H40NCl
354.019
44.1


247

nNonyl


nPropyl


nPropyl

Benzyl
CF3CO2




C24H40NO2F3
431.582
44.1


248

nNonyl


nPropyl


nPropyl

4-FC6H4CH2
Cl
NR1R2R3
90105-55-8
R4X
352-11-4
C22H39NClF
372.010
44.3


249

nNonyl


nPropyl


nPropyl

4-FC6H4CH2
CF3CO2




C24H39NO2F4
449.573
44.3


250

nDecyl


nPropyl


nPropyl

Benzyl
Cl
NR1R2R3
88090-10-2
R4X
100-44-7
C23H42NCl
368.046
47.2


251

nDecyl


nPropyl


nPropyl

Benzyl
CF3CO2




C25H42NO2F3
445.609
47.2


252

nDecyl


nPropyl


nPropyl

4-FC6H4CH2
Cl
NR1R2R3
88090-10-2
R4X
352-11-4
C23H41NClF
386.036
47.4


253

nDecyl


nPropyl


nPropyl

4-FC6H4CH2
CF3CO2




C25H41NO2F4
463.600
47.4


254

nUndecyl


nPropyl


nPropyl

Benzyl
Cl
NR1R2R3
220644-99-1
R4X
100-44-7
C24H44NCl
382.073
50.2


255

nUndecyl


nPropyl


nPropyl

Benzyl
CF3CO2




C26H44NO2F3
459.636
50.2


256

nUndecyl


nPropyl


nPropyl

4-FC6H4CH2
Cl
NR1R2R3
220644-99-1
R4X
352-11-4
C24H43NClF
400.063
50.4


257

nUndecyl


nPropyl


nPropyl

4-FC6H4CH2
CF3CO2




C26H43NO2F4
477.627
50.4


258

nHexyl


nButyl


nButyl

Benzyl
Cl
NR1R2R3
23601-43-6
R4X
100-44-7
C21H38NCl
339.992
40.2


259

nHexyl


nButyl


nButyl

Benzyl
CF3CO2




C23H38NO2F3
417.555
40.2


260

nHexyl


nButyl


nButyl

4-FC6H4CH2
Cl
NR1R2R3
23601-43-6
R4X
352-11-4
C21H37NClF
357.983
40.4


261

nHexyl


nButyl


nButyl

4-FC6H4CH2
CF3CO2




C23H37NO2F4
435.546
40.4


262

nHeptyl


nButyl


nButyl

Benzyl
Cl
NR1R2R3
3553-87-5
R4X
100-44-7
C22H40NCl
354.019
42.7


263

nHeptyl


nButyl


nButyl

Benzyl
CF3CO2




C24H40NO2F3
431.582
42.7


264

nHeptyl


nButyl


nButyl

4-FC6H4CH2
Cl
NR1R2R3
3553-87-5
R4X
351-11-4
C22H39NClF
372.010
42.9


265

nHeptyl


nButyl


nButyl

4-FC6H4CH2
CF3CO2




C24H39NO2F4
449.573
42.9


266

nOctyl


nButyl


nButyl

Benzyl
Cl
NR1R2R3
41145-51-1
R4X
100-44-7
C23H42NCl
368.046
45.6


267

nOctyl


nButyl


nButyl

Benzyl
CF3CO2




C25H42NO2F3
445.609
45.6


268

nOctyl


nButyl


nButyl

4-FC6H4CH2
Cl
NR1R2R3
41145-51-1
R4X
352-11-4
C23H41NClF
386.036
45.8


269

nOctyl


nButyl


nButyl

4-FC6H4CH2
CF3CO2




C25H41NO2F4
463.600
45.8


270

nNonyl


nButyl


nButyl

Benzyl
Cl
NR1R2R3
93658-58-3
R4X
100-44-7
C24H44NCl
382.073
48.7


271

nNonyl


nButyl


nButyl

Benzyl
CF3CO2




C26H44NO2F3
459.636
48.7


272

nNonyl


nButyl


nButyl

4-FC6H4CH2
Cl
NR1R2R3
93658-58-3
R4X
352-11-4
C24H43NClF
400.063
48.9


273

nNonyl


nButyl


nButyl

4-FC6H4CH2
CF3CO2




C26H43NO2F4
477.627
48.9


274

nDecyl


nButyl


nButyl

Benzyl
Cl
NR1R2R3
13573-55-2
R4X
100-44-7
C25H46NCl
396.100
51.8


275

nDecyl


nButyl


nButyl

Benzyl
CF3CO2




C27H46NO2F3
473.663
51.8


276

nDecyl

MeO(CH2)2
MeO(CH2)2
Benzyl
Cl
NR1R2R3
Newg
R4X
100-44-7
C23H42NO2Cl
400.045
46.7


277

nDecyl


nButyl


nButyl

4-FC6H4CH2
Cl
NR1R2R3
13573-55-2
R4X
352-11-4
C25H45NClF
414.090
52.0


278

nDecyl


nButyl


nButyl

4-FC6H4CH2
CF3CO2




C27H45NO2F4
491.653
52.0


279

nUndecyl


nButyl


nButyl

Benzyl
Cl
NR1R2R3
220645-00-1
R4X
100-44-7
C26H48NCl
410.127
54.8


280

nUndecyl


nButyl


nButyl

Benzyl
CF3CO2




C28H48NO2F3
487.690
54.8


281

nUndecyl


nButyl


nButyl

4-FC6H4CH2
Cl
NR1R2R3
220645-00-1
R4X
352-11-4
C26H47NClF
428.117
60.0


282

nUndecyl


nButyl


nButyl

4-FC6H4CH2
CF3CO2




C28H47NO2F4
505.680
60.0


















282b
Ph(CH2)3
R2 + R3 = —(CH2)4
same as R1
Br
HNR2R3
123-75-1
2xR1X + base
637-59-2
C22H30NBr
388.384
34.4


282c
Ph(CH2)3
R2 + R3 = —(CH2)4
same as R1
CF3CO2




C24H30NO2F3
421.496
34.4


282d
Ph(CH2)4
R2 + R3 = —(CH2)4
Ph(CH2)3
Br
NR1R2R3
163675-54-5
R4X
637-59-2
C23H32NBr
402.411
36.7


282e
Ph(CH2)4
R2 + R3 = —(CH2)4
Ph(CH2)3
CF3CO2




C25H32NO2F3
435.522
36.7


282f
Ph(CH2)4
R2 + R3 = —(CH2)4
same as R1
Br
HNR2R3
123-75-1
2xR1X + base
13633-25-5
C24H34NBr
416.438
39.0


282g
Ph(CH2)4
R2 + R3 = —(CH2)4
same as R1
CF3CO2




C26H34NO2F3
449.549
39.0


283

nHeptyl

R2 + R3 = —(CH2)4
Benzyl
Cl
NR1R2R3
121409-85-6
R4X
100-44-7
C18H30NCl
295.887
33.3


283b

nHeptyl

R2 + R3 = —(CH2)4
Benzyl
CF3CO2




C20H30NO2F3
373.450
33.3


283c

nHeptyl

R2 + R3 = —(CH2)4
4-FC6H4CH2
Cl
NR1R2R3
121409-85-6
R4X
352-11-4
C18H29NClF
313.877
33.5


283d

nHeptyl

R2 + R3 = —(CH2)4
4-FC6H4CH2
CF3CO2




C20H29NO2F4
391.441
33.5


284

nOctyl

R2 + R3 = —(CH2)4
Benzyl
Cl
NR1R2R3
7335-08-2
R4X
100-44-7
C19H32NCl
309.923
36.5


284b

nOctyl

R2 + R3 = —(CH2)4
Benzyl
CF3CO2




C21H32NO2F3
387.486
36.5


285

nOctyl

R2 + R3 = —(CH2)4
4-FC6H4CH2
Cl
NR1R2R3
7335-08-2
R4X
352-11-4
C19H31NClF
327.913
36.4


286

nOctyl

R2 + R3 = —(CH2)4
4-FC6H4CH2
CF3CO2




C21H31NO2F4
405.476
36.4


287

nOctyl

R2 + R3 = —(CH2)4
PhC(O)CH2
Cl
NR1R2R3
7335-08-2
R4X
532-27-4
C20H32NOCl
337.927
38.1


288

nOctyl

R2 + R3 = —(CH2)4
PhC(O)CH2
CF3CO2




C22H32NO3F3
415.496
38.1


289

nOctyl

R2 + R3 = —(CH2)4
4-FC6H4C(O)CH2
Cl
NR1R2R3
7335-08-2
R4X
456-04-2
C20H31NOClF
355.923
38.3


290

nOctyl

R2 + R3 = —(CH2)4
4-FC6H4C(O)CH2
CF3CO2




C22H31NO3F4
433.487
38.3


291

nNonyl

R2 + R3 = —(CH2)4
Benzyl
Cl
NR1R2R3
74673-25-9
R4X
100-44-7
C20H34NCl
323.949
39.5


292

nNonyl

R2 + R3 = —(CH2)4
Benzyl
CF3CO2




C22H34NO2F3
401.513
39.5


293

nNonyl

R2 + R3 = —(CH2)4
4-FC6H4CH2
Cl
NR1R2R3
74673-25-9
R4X
352-11-4
C20H33NClF
341.940
39.7


294

nNonyl

R2 + R3 = —(CH2)4
4-FC6H4CH2
CF3CO2




C22H33NO2F4
419.503
39.7


294b
Ph(CH2)6
R2 + R3 = —(CH2)4
4-FC6H4CH2
Cl
NR1R2R3
New
R4X
352-11-4
C23H31NClF
375.950
40.1


294c
Ph(CH2)6
R2 + R3 = —(CH2)4
4-FC6H4CH2
CF3CO2




C25H31NO2F4
453.513
40.1


295

nNonyl

R2 + R3 = —(CH2)5
Benzyl
Cl
NR1R2R3
30538-80-8
R4X
100-44-7
C21H36NCl
337.970
41.4


296

nNonyl

R2 + R3 = —(CH2)5
4-FC6H4CH2
Cl
NR1R2R3
30538-80-8
R4X
352-11-4
C21H35NClF
355.961
41.6


297

nNonyl

R2 + R3 = —(CH2)4
PhC(O)CH2
Cl
NR1R2R3
74673-25-9
R4X
532-27-4
C21H34NOCl
351.960
41.2


298

nNonyl

R2 + R3 = —(CH2)4
PhC(O)CH2
CF3CO2




C23H34NO3F3
429.523
41.2


299

nNonyl

R2 + R3 = —(CH2)4
4-FC6H4C(O)CH2
Cl
NR1R2R3
74673-25-9
R4X
456-04-2
C21H33NOClF
369.950
41.4


300

nNonyl

R2 + R3 = —(CH2)4
4-FC6H4C(O)CH2
CF3CO2




C23H33NO3F4
447.514
41.4


301

nUndecyl

R2 + R3 = —(CH2)4
Benzyl
Cl
NR1R2R3
74673-27-1
R4X
100-44-7
C22H38NCl
352.003
45.8


302

nUndecyl

R2 + R3 = —(CH2)4
Benzyl
CF3CO2




C24H38NO2F3
429.566
45.8


303

nUndecyl

R2 + R3 = —(CH2)4
4-FC6H4CH2
Cl
NR1R2R3
74673-27-1
R4X
352-11-4
C22H37NClF
369.994
46.0


304

nUndecyl

R2 + R3 = —(CH2)4
4-FC6H4CH2
CF3CO2




C24H37NO2F4
447.557
46.0


305

nUndecyl

R2 + R3 = —(CH2)4
PhC(O)CH2
Cl
NR1R2R3
74673-27-1
R4X
532-27-4
C23H38NOCl
380.007
47.4


306

nUndecyl

R2 + R3 = —(CH2)4
PhC(O)CH2
CF3CO2




C25H38NO3F3
457.577
47.4


307

nUndecyl

R2 + R3 = —(CH2)4
4-FC6H4C(O)CH2
Cl
NR1R2R3
74673-27-1
R4X
456-04-2
C23H37NOClF
398.004
47.6


308

nUndecyl

R2 + R3 = —(CH2)4
4-FC6H4C(O)CH2
CF3CO2




C25H37NO3F4
475.567
47.6


309

nDecyl

R2 + R3 = —(CH2)4
Benzyl
Cl
NR1R2R3
74673-26-0
R4X
100-44-7
C21H36NCl
337.976
42.7


310

nDecyl

R2 + R3 = —(CH2)4
Benzyl
Br
NR1R2R3
74673-26-0
R4X
100-39-0
C21H36NBr
382.428
42.7


311

nDecyl

R2 + R3 = —(CH2)4
Benzyl
OH




C21H37NO
319.531
42.7


312

nDecyl

R2 + R3 = —(CH2)4
Benzyl
CF3CO2




C23H36NO2F3
415.540
42.7


313

nDecyl

R2 + R3 = —(CH2)4
2-FC6H4CH2
Cl
NR1R2R3
74673-26-0
R4X
345-35-7
C21H35NClF
355.967
42.8


314

nDecyl

R2 + R3 = —(CH2)4
3-FC6H4CH2
Cl
NR1R2R3
74673-26-0
R4X
456-42-8
C21H35NClF
355.967
42.8


315

nDecyl

R2 + R3 = —(CH2)4
4-FC6H4CH2
Cl
NR1R2R3
74673-26-0
R4X
352-11-4
C21H35NClF
355.967
42.9


316

nDecyl

R2 + R3 = —(CH2)4
4-FC6H4CH2
Br
NR1R2R3
74673-26-0
R4X
459-46-1
C21H35NBrF
400.418
42.9


317

nDecyl

R2 + R3 = —(CH2)4
4-FC6H4CH2
OH




C21H36NOF
337.521
42.9


318

nDecyl

R2 + R3 = —(CH2)4
4-FC6H4CH2
CF3CO2




C23H35NO2F4
433.530
42.9


319

nDecyl

R2 + R3 = —(CH2)4
4-FC6H4CH2
HCO2




C22H36NO2F
365.532
42.9


320

nDecyl

R2 + R3 = —(CH2)4
4-FC6H4CH2
CH3CO2




C23H38NO2F
379.559
42.9


321

nDecyl

R2 + R3 = —(CH2)4
4-FC6H4CH2
CH3SO3




C22H38NO3FS
415.607
42.9


322

nDecyl

R2 + R3 = —(CH2)4
4-FC6H4CH2
CF3SO3




C22H35NO3F4S
469.578
42.9


323

nDecyl

R2 + R3 = —(CH2)4
3-ClC6H4CH2
Cl
NR1R2R3
74673-26-0
R4X
620-20-2
C21H35NCl2
372.421
44.5


324

nDecyl

R2 + R3 = —(CH2)4
2,6-F2C6H3CH2
Cl
NR1R2R3
74673-26-0
R4X
697-73-4
C21H34NClF2
373.957
43.2


325

nDecyl

R2 + R3 = —(CH2)4
3,5-F2C6H3CH2
Cl
NR1R2R3
74673-26-0
R4X
220141-71-9
C21H34NClF2
373.957
43.6


326

nDecyl

R2 + R3 = —(CH2)4
4-MeC6H4CH2
Cl
NR1R2R3
74673-26-0
R4X
104-82-5
C22H38NCl
352.003
45.7


327

nDecyl

R2 + R3 = —(CH2)4
4-EtC6H4CH2
Cl
NR1R2R3
74673-26-0
R4X
1467-05-6
C23H40NCl
366.030
47.9


328

nDecyl

R2 + R3 = —(CH2)4
4-MeOC6H4CH2
Cl
NR1R2R3
74673-26-0
R4X
824-94-2
C22H38NOCl
368.003
43.8


329

nDecyl

R2 + R3 = —(CH2)4
PhC(O)CH2
Cl
NR1R2R3
74673-26-0
R4X
532-27-4
C22H36NOCl
365.987
44.3


330

nDecyl

R2 + R3 = —(CH2)4
PhC(O)CH2
Br
NR1R2R3
74673-26-0
R4X
70-11-1
C22H36NOBr
410.438
44.3


331

nDecyl

R2 + R3 = —(CH2)4
PhC(O)CH2
CF3CO2




C24H36NO3F3
443.550
44.3


332

nDecyl

R2 + R3 = —(CH2)4
4-FC6H4C(O)CH2
Cl
NR1R2R3
74673-26-0
R4X
456-04-2
C22H35NOClF
383.977
44.5


333

nDecyl

R2 + R3 = —(CH2)4
4-FC6H4C(O)CH2
CF3CO2




C24H35NO3F4
461.540
44.5


334

nDecyl

R2 + R3 = —(CH2)4
Ph(CH2)4
Br
NR1R2R3
74673-26-0
R4X
13633-25-5
C24H42NBr
424.508
47.5


335

nDecyl

R2 + R3 = —(CH2)4
Ph(CH2)3
Br
NR1R2R3
74673-26-0
R4X
673-59-2
C23H40NBr
410.481
45.9


336

nDecyl

R2 + R3 = —(CH2)4
Ph(CH2)2
Br
NR2R3R4
6908-75-4
R1X
112-29-8
C22H38NBr
396.454
45.3


337

nDecyl

R2 + R3 = —(CH2)4
t-PhCH═CHCH2
Cl
NR1R2R3
74673-26-0
R4X
2687-12-9
C23H38NCl
364.008
46.4


338

nDecyl

R2 + R3 = —(CH2)4
Me2NC(O)CH2
Cl
NR1R2R3
74673-26-0
R4X
2675-89-0
C18H37N2OCl
332.957
36.8


339

nDecyl

R2 + R3 = —(CH2)4
Et2NC(O)CH2
Cl
NR1R2R3
74673-26-0
R4X
2315-36-8
C20H41N2OCl
361.011
41.5



















339b
4-FC6H4CH2

nPropyl


nPropyl

4-FC6H4CH2
Cl
HNR2R3
142-84-7
2xR4X + base
352-11-4
C20H26NClF2
353.877
30.9


340

nButyl


nButyl


nButyl

Ph(CH2)4
Br
NR1R2R3
102-82-9
R4X
13633-25-5
C22H40NBr
398.470
40.2


341

nButyl


nButyl


nButyl

4-PhC6H4CH2
Cl
NR1R2R3
102-82-9
R4X
1667-11-4
C25H38NCl
388.036
43.3


342
Benzyl

nButyl


nButyl

Benzyl
Cl
HNR2R3
111-92-2
2xR4X + base
100-44-7
C22H32NCl
345.956
36.6


343
Benzyl

nButyl


nButyl

Benzyl
CF3CO2




C24H32NO2F3
423.519
36.6


344
4-FC6H4CH2

nButyl


nButyl

4-FC6H4CH2
Cl
HNR2R3
111-92-2
2xR4X + base
352-11-4
C22H30NClF2
381.936
36.8


345
4-FC6H4CH2

nButyl


nButyl

4-FC6H4CH2
CF3CO2




C24H30NO2F5
459.500
36.8


346
Benzyl

nPentyl


nPentyl

Benzyl
Cl
HNR2R3
2050-92-2
2xR4X + base

C24H36NCl
374.009
41.6


347
Benzyl

nPentyl


nPentyl

Benzyl
CF3CO2




C26H36NO2F3
451.573
41.6


348
4-FC6H4CH2

nPentyl


nPentyl

4-FC6H4CH2
Cl
HNR2R3
2050-92-2
2xR4X + base
352-11-4
C24H34NClF2
409.990
41.8


349
4-FC6H4CH2

nPentyl


nPentyl

4-FC6H4CH2
CF3CO2




C26H34NO2F5
487.554
41.8


350
Benzyl

nHexyl


nHexyl

Benzyl
Cl
HNR2R3
143-16-8
2xR4X + base
100-44-7
C26H40NCl
402.063
46.6


351
Benzyl

nHexyl


nHexyl

Benzyl
CF3CO2




C28H40NO2F3
479.626
46.6


352
4-FC6H4CH2

nHexyl


nHexyl

4-FC6H4CH2
Cl
HNR2R3
143-16-8
2xR4X + base
352-11-4
C26H38NClF2
438.044
46.8


353
4-FC6H4CH2

nHexyl


nHexyl

4-FC6H4CH2
CF3CO2




C28H38NO2F5
515.607
46.8


354

nButyl


nButyl


nButyl

Benzyl
Cl
NR1R2R3
102-82-9
R4X
100-44-7
C19H34NCl
311.938
35.4


355

nButyl


nButyl


nButyl

Benzyl
CF3CO2




C21H34NO2F3
389.502
35.4


356

nButyl


nButyl


nButyl

4-FC6H4CH2
Cl
NR1R2R3
102-82-9
R4X
352-11-4
C19H33NClF
329.929
35.1


357

nButyl


nButyl


nButyl

4-FC6H4CH2
CF3CO2




C21H33NO2F4
407.492
35.1


358

nPentyl


nPentyl


nPentyl

Benzyl
Cl
NR1R2R3
621-77-2
R4X
100-44-7
C22H40NCl
354.019
42.8


359

nPentyl


nPentyl


nPentyl

Benzyl
Br
NR1R2R3
621-77-2
R4X
100-39-0
C22H40NBr
398.470
42.8


360

nPentyl


nPentyl


nPentyl

Benzyl
CF3CO2




C24H40NO2F3
431.582
42.8


361

nPentyl


nPentyl


nPentyl

4-FC6H4CH2
Cl
NR1R2R3
621-77-2
R4X
352-11-4
C22H39NClF
372.010
43.0


362

nPentyl


nPentyl


nPentyl

4-FC6H4CH2
Br
NR1R2R3
621-77-2
R4X
452-07-3
C22H39NBrF
416.461
43.0


363

nPentyl


nPentyl


nPentyl

4-FC6H4CH2
CF3CO2




C24H39NO2F4
449.573
43.0


364

nPentyl


nPentyl


nPentyl

4-CF3C6H4CH2
Cl
NR1R2R3
621-77-2
R4X
939-99-1
C23H39NClF3
422.017
45.0


365

nPentyl


nPentyl


nPentyl

PhC(O)CH2
Cl
NR1R2R3
621-77-2
R4X
532-27-4
C23H40NOCl
382.029
44.4


366

nPentyl


nPentyl


nPentyl

4-FC6H4C(O)CH2
Cl
NR1R2R3
621-77-2
R4X
456-04-2
C23H39NOClF
400.020
44.6


367

nPentyl


nPentyl


nPentyl

4-PhC6H4C(O)CH2
Br
NR1R2R3
621-77-2
R4X
135-73-9
C29H44NOBr
502.579
50.9


368

nPentyl


nPentyl


nPentyl

4-PhC6H4CH2
Cl
NR1R2R3
621-77-2
R4X
1667-11-4
C28H44NCl
430.117
49.9


369

nButyl


nButyl


nButyl

4-PhC6H4CH2
Cl
NR1R2R3
102-82-9
R4X
1667-11-4
C25H38NCl
388.036
43.2


370

nHexyl


nHexyl


nHexyl

Benzyl
Cl
NR1R2R3
102-86-3
R4X
100-44-7
C25H48NCl
396.100
49.5


371

nHexyl


nHexyl


nHexyl

4-FC6H4CH2
Cl
NR1R2R3
102-86-3
R4X
352-11-4
C25H45NClF
414.083
49.7


372

nHexyl


nHexyl


nHexyl

naphthylene-1-CH2
Cl
NR1R2R3
102-86-3
R4X
86-52-2
C29H48NCl
446.151
52.3


373

nHexyl


nHexyl


nHexyl

anthracene-9-CH2
Cl
NR1R2R3
102-86-3
R4X
24463-19-2
C33H50NCl
496.219
55.4


374

nHexyl


nHexyl


nHexyl

4-FC6H4CH2
CF3CO2




C27H45NO2F4
491.653
50.0


375

nHexyl


nHexyl

EtOC2a
Benzyl
Cl
NR1R2R3
Newf
R4X
100-44-7
C23H42NOCl
384.045
45.4


376

nHexyl


nHexyl

MeOC2OC2
Benzyl
Cl
NR1R2R3
Newe
R4X
100-44-7
C24H44NO2C1
414.072
42.4


377

nHeptyl


nHeptyl


nHeptyl

Benzyl
CF3CO2

2411-36-1


C30H52NO2F3
515.744
55.2


378

nHeptyl


nHeptyl


nHeptyl

4-FC6H4CH2
Cl
NR1R2R3
2411-36-1
R4X
352-11-4
C28H51NClF
456.171
55.4


379

nHeptyl


nHeptyl


nHeptyl

4-FC6H4CH2
CF3CO2




C30H51NO2F4
533.734
55.4


380

nOctyl


nOctyl


nOctyl

Benzyl
Cl
NR1R2R3
1116-76-3

100-44-7
C31H58NCl
480.261
60.3


381

nOctyl


nOctyl


nOctyl

Benzyl
CF3CO2




C33H58NO2F3
557.824
60.3


382

nOctyl


nOctyl

EtOC2OC2a
Benzyl
Br
NR1R2R3
Newb
R4X
100-39-0
C29H54NO2Br
528.649
53.7


383

nOctyl


nOctyl


nOctyl

4-FC6H4CH2
Cl
NR1R2R3
1116-76-3
R4X
352-11-4
C31H58NClF
499.250
60.5


384

nOctyl


nOctyl


nOctyl

4-FC6H4CH2
CF3CO2




C33H58NO2F4
576.813
60.5


385

nPentyl

Methyl
Methyl
Ph(CH2)5
Br
NR1R2R3
26153-88-8
R4X
14469-83-1
C18H32NBr
342.363
34.9


386

nPentyl

Methyl
Methyl
Ph(CH2)6
Br
NR1R2R3
26153-88-8
R4X
27976-27-8
C19H34NBr
356.385
37.6


387

nHexyl

Methyl
Methyl
Ph(CH2)5
Br
NR1R2R3
4385-04-0
R4X
14469-83-1
C19H34NBr
356.385
37.6


388

nHexyl

Methyl
Methyl
Ph(CH2)6
Br
NR1R2R3
4385-04-0
R4X
27976-27-8
C20H36NBr
370.417
40.2


389

nHexyl

Methyl
Methyl
Ph(CH2)7
Br
NR1R2R3
5277-11-2
R4X
78573-85-0
C21H38NBr
384.443
42.7


390

nHeptyl

Methyl
Methyl
Ph(CH2)6
Br
NR1R2R3
4385-04-0
R4X
27976-27-8
C21H38NBr
384.443
42.7


391

nHeptyl

Methyl
Methyl
Ph(CH2)7
Br
NR1R2R3
5277-11-2
R4X
78573-85-0
C22H40NBr
398.470
45.1


392

nHeptyl

Methyl
Methyl
Ph(CH2)6
Br
NR1R2R3
7378-99-6
R4X
54646-75-2
C23H42NBr
412.497
47.3


393

nOctyl

Methyl
Methyl
Ph(CH2)7
Br
NR1R2R3
5277-11-2
R4X
78573-85-0
C23H42NBr
412.497
47.4


394

nOctyl

Methyl
Methyl
Ph(CH2)6
Br
NR1R2R3
7378-99-6
R4X
54646-75-2
C24H44NBr
426.524
49.5


394b
HOCH2CH2
Ph(CH2)3
Ph(CH2)3
Ph(CH2)3
Br
H2NR1
141-43-5
3xR4X + 2xbase
637-59-2
C29H38NOBr
496.522
40.4


394c
HOCH2CH2
Ph(CH2)3
Ph(CH2)3
Ph(CH2)3
CF3CO2




C31H38NO3F3
529.634
40.4


394d
MeOCH2CH2
Ph(CH2)3
Ph(CH2)3
Ph(CH2)3
Br
H2NR1
109-85-3
3xR4X + 2xbase
637-59-2
C30H40NOBr
510.549
43.8


394e
MeOCH2CH2
Ph(CH2)3
Ph(CH2)3
Ph(CH2)3
CF3CO2




C32H40NO3F3
543.660
43.8






aMe = CH3—, Et = C2H5, Pr = C7H7—, Bu = C4H9—, Ph = C6H5—, Bz = C6H5CH2—, Ac = CH3C(O)—, MeOC2 = CH3OCH2CH2—, EtOC2 = EtOCH2CH2—, MeOC2OC2 = Me(OCH2CH2)2—, EtOC2OC2 = EtOCH2CH2OCH2CH2




bNew compound; prepared by method in Example 1 from di-n-octylamine [1120-48-5] and slight excess (1.1X) of 2-(2-ethoxyethoxy)ethyl bromide [54550-36-6] in the presence of excess (1.5X) base (N-ethyl-di-isopropylamine).




cChemical names and chemical structures associated with abbreviations are given below.




dNew compound; prepared pure in good yield by method in Example 1 from 1-bromoheptane [629-04-9] and excess (3X) di-n-propylamine [142-84-7] .




eNew compound; prepared by method in Example 1 from di-n-hexylamine [143-16-8] and slight excess (1.1X) of 2-(2-methoxyethoxy)ethyl bromide [54149-17-6] in the presence of excess (1.5X) base (N-ethyl-di-isopropylamine).




fNew compound; prepared by method in Example 1 from di-n-hexylamine [143-16-8] and slight excess (1.1X) of 2-ethoxyethyl bromide [592-55-2] in the presence of excess (2.0X) base (N-ethyl-di-isopropylamine). The tertiary amine product is not isolated but allowed to react in a second step with benzyl bromide.




gNew compound; prepared by method in Example 1 from bis(2-methoxyethyl)amine [111-95-5] and slight excess (1.1X) of 1-bromodecane [112-28-9] in the presence of excess (1.5X) base (N-ethyl-di-isopropylamine).




rCAS number for racemic amine. Pure enantiomers of N,N-dimethylphenylalanine N,N-dimethylamide are prepared from N,N-dimethylphenylalanine methylester (CAS# l-enantiomer, 27720-05-4; CAS# d-enantiomer, 1268357-63-6) and dimethylamine.




sLimited solubility.




tUndergoes slow transalkylation reactions at elevated temperature.





embedded image















TABLE VI





[(R1R2R3NCH2)2C6H3G]2+ 2[X] (G = H, F) and


[R1R2R3NCH2C6H4—C6H4CH2NR1R2R3]2+ 2[X]





















Nu.
R1
R2
R3
C6H3G or C6H4—C6H4
X
Amine





395

nUndecyl

Methyl
Methyl
1,2-C6H4
Cl
2xNR1R2R3


396

nUndecyl

Methyl
Methyl
1,2-C6H4
Br
2xNR1R2R3


397

nUndecyl

Methyl
Methyl
1,2-C6H4
CF3CO2



398

nUndecyl

Methyl
Methyl
1,3-C6H4
Cl
2xNR1R2R3


399

nUndecyl

Methyl
Methyl
1,3-C6H4
Br
2xNR1R2R3


400

nUndecyl

Methyl
Methyl
1,3-C6H4
CF3CO2



401

nUndecyl

Methyl
Methyl
1,4-C6H4
Cl
2xNR1R2R3


402

nUndecyl

Methyl
Methyl
1,4-C6H4
Br
2xNR1R2R3


403

nUndecyl

Methyl
Methyl
1,4-C6H4
CF3CO2



404

nDecyl

Methyl
Methyl
1,2-C6H4
Cl
2xNR1R2R3


405

nDecyl

Methyl
Methyl
1,2-C6H4
Br
2xNR1R2R3


406

nDecyl

Methyl
Methyl
1,2-C6H4
CF3CO2



407

nDecyl

Methyl
Methyl
1,3-C6H4
Cl
2xNR1R2R3


408

nDecyl

Methyl
Methyl
1,3-C6H4
Br
2xNR1R2R3


409

nDecyl

Methyl
Methyl
1,3-C6H4
CF3CO2



410

nDecyl

Methyl
Methyl
2-F-1,3-C6H3
Br
2xNR1R2R3


411

nDecyl

Methyl
Methyl
2-F-1,3-C6H3
CF3CO2



412

nDecyl

Methyl
Methyl
5-F-1,3-C6H3
Br
2xNR1R2R3


413

nDecyl

Methyl
Methyl
5-F-1,3-C6H3
CF3CO2



414

nDecyl

Methyl
Methyl
1,4-C6H4
Cl
2xNR1R2R3


415

nDecyl

Methyl
Methyl
1,4-C6H4
Br
2xNR1R2R3


416

nDecyl

Methyl
Methyl
1,4-C6H4
CF3CO2













417

nDecyl

R2 + R3 = —(CH2)4
1,2-C6H4
Cl
2xNR1R2R3


418

nDecyl

R2 + R3 = —(CH2)4
1,3-C6H4
Cl
2xNR1R2R3


419

nDecyl

R2 + R3 = —(CH2)4
1,3-C6H4
Br
2xNR1R2R3


420

nDecyl

R2 + R3 = —(CH2)4
1,3-C6H4
CF3CO2



421

nDecyl

R2 + R3 = —(CH2)4
2-F-1,3-C6H3
Br
2xNR1R2R3


422

nDecyl

R2 + R3 = —(CH2)4
2-F-1,3-C6H3
CF3CO2



423

nDecyl

R2 + R3 = —(CH2)4
5-F-1,3-C6H3
Br
2xNR1R2R3


424

nDecyl

R2 + R3 = —(CH2)4
5-F-1,3-C6H3
CF3CO2



425

nDecyl

R2 + R3 = —(CH2)4
1,4-C6H4
Cl
2xNR1R2R3













426

nNonyl

Methyl
Methyl
1,2-C6H4
Cl
2xNR1R2R3


427

nNonyl

Methyl
Methyl
1,2-C6H4
Br
2xNR1R2R3


428

nNonyl

Methyl
Methyl
1,2-C6H4
CF3CO2



429

nNonyl

Methyl
Methyl
1,3-C6H4
Cl
2xNR1R2R3


430

nNonyl

Methyl
Methyl
1,3-C6H4
Br
2xNR1R2R3


431

nNonyl

Methyl
Methyl
1,3-C6H4
CF3CO2



432

nNonyl

Methyl
Methyl
5-F-1,3-C6H3
Br
2xNR1R2R3


433

nNonyl

Methyl
Methyl
5-F-1,3-C6H3
CF3CO2













434

nNonyl

R2 + R3 = —(CH2)4
1,3-C6H4
Cl
2xNR1R2R3


435

nNonyl

R2 + R3 = —(CH2)4
1,3-C6H4
Br
2xNR1R2R3


436

nNonyl

R2 + R3 = —(CH2)4
1,3-C6H4
CF3CO2



437

nNonyl

R2 + R3 = —(CH2)4
2-F-1,3-C6H3
Br
2xNR1R2R3


438

nNonyl

R2 + R3 = —(CH2)4
2-F-1,3-C6H3
CF3CO2



439

nNonyl

R2 + R3 = —(CH2)4
5-F-1,3-C6H3
Br
2xNR1R2R3


440

nNonyl

R2 + R3 = —(CH2)4
5-F-1,3-C6H3
CF3CO2














441

nNonyl

Methyl
Methyl
1,4-C6H4
Cl
2xNR1R2R3


442

nNonyl

Methyl
Methyl
1,4-C6H4
Br
2xNR1R2R3


443

nNonyl

Methyl
Methyl
1,4-C6H4
CF3CO2



444

nOctyl

Methyl
Methyl
1,2-C6H4
Cl
2xNR1R2R3


445

nOctyl

Methyl
Methyl
1,2-C6H4
Br
2xNR1R2R3


446

nOctyl

Methyl
Methyl
1,2-C6H4
CF3CO2



447

nOctyl

Methyl
Methyl
1,3-C6H4
Cl
2xNR1R2R3


448

nOctyl

Methyl
Methyl
1,3-C6H4
Br
2xNR1R2R3


449

nOctyl

Methyl
Methyl
1,3-C6H4
CF3CO2



450

nOctyl

Methyl
Methyl
1,4-C6H4
Cl
2xNR1R2R3


451

nOctyl

Methyl
Methyl
1,4-C6H4
Br
2xNR1R2R3


452

nOctyl

Methyl
Methyl
1,4-C6H4
CF3CO2



453

nHexyl


nHexyl

Methyl
1,3-C6H4
Cl
2xNR1R2R3


454

nHexyl


nHexyl

Methyl
1,3-C6H4
Br
2xNR1R2R3


455

nPentyl


nPentyl


nPentyl

1,2-C6H4
Br
2xNR1R2R3


456

nPentyl


nPentyl


nPentyl

1,3-C6H4
Br
2xNR1R2R3


457

nPentyl


nPentyl


nPentyl

1,3-C6H4
CF3CO2



458

nPentyl


nPentyl


nPentyl

1,4-C6H4
Br
2xNR1R2R3


459

nButyl


nButyl


nButyl

1,3-C6H4
Br
2xNR1R2R3


460

nButyl


nButyl


nButyl

1,3-C6H4
CF3CO2



461

nNonyl

Methyl
Methyl
4,4′-C6H4—C6H4
Br
2xNR1R2R3


462

nNonyl

Methyl
Methyl
3,3′-C6H4—C6H4
Br
2xNR1R2R3


463

nNonyl

Methyl
Methyl
2,2′-C6H4—C6H4
Br
2xNR1R2R3













Alkyating
HPLC Method 9a













Nu.
CAS Num.
Agent
CAS Num.
Formula
Weight
Time





395
17373-28-3
o-(XCH2)2C6H4
612-12-4
C34H66N2Cl2
573.817
48.6


396
17373-28-3
o-(XCH2)2C6H4
91-13-4
C34H66N2Br2
662.720
48.6


397



C38H66N2O4F6
728.944
48.6


398
17373-28-3
m-(XCH2)2C6H4
626-16-4
C34H66N2Cl2
573.817
47.3


399
17373-28-3
m-(XCH2)2C6H4
626-15-3
C34H66N2Br2
662.720
47.3


400



C38H66N2O4F6
728.944
47.3


401
17373-28-3
p-(XCH2)2C6H4
623-25-6
C34H66N2Cl2
573.817
46.7


402
17373-28-3
p-(XCH2)2C6H4
623-24-5
C34H66N2Br2
662.720
46.7


403



C38H66N2O4F6
728.944
46.7


404
1120-24-7
o-(XCH2)2C6H4
612-12-4
C32H62N2Cl2
545.763
44.4


405
1120-24-7
o-(XCH2)2C6H4
91-13-4
C32H62N2Br2
634.666
44.4


406



C36H62N2O4F6
700.890
44.4


407
1120-24-7
m-(XCH2)2C6H4
626-16-4
C32H62N2Cl2
545.763
43.4


408
1120-24-7
m-(XCH2)2C6H4
626-15-3
C32H62N2Br2
634.666
43.5


409



C36H62N2O4F6
700.890
43.4


410
1120-24-7
2-F-1,3-(XCH2)2C6H3
25006-86-4
C32H61N2Br2F
652.656
43.5


411



C36H61N2O4F7
718.880
43.5


412
1120-24-7
5-F-1,3-(XCH2)2C6H3
19252-80-9
C32H61N2Br2F
652.656
43.6


413



C36H61N2O4F7
718.880
43.6


414
1120-24-7
p-(XCH2)2C6H4
623-25-6
C32H62N2Cl2
545.763
42.9


415
1120-24-7
p-(XCH2)2C6H4
626-15-3
C32H62N2Br2
634.666
42.9


416



C36H62N2O4F6
700.890
42.9


417
74673-26-0
p-(XCH2)2C6H4
612-12-4
C36H66N2Cl2
597.839
45.9


418
74673-26-0
p-(XCH2)2C6H4
626-16-4
C36H66N2Cl2
597.839
44.9


419
74673-26-0
p-(XCH2)2C6H4
626-15-3
C36H66N2Br2
686.742
44.9


420



C40H66N2O4F6
752.966
44.9


421
74673-26-0
2-F-1,3-(XCH2)2C6H3
25006-86-4
C36H65N2Br2F
704.732
45.0


422



C40H65N2O4F7
770.956
45.0


423
74673-26-0
5-F-1,3-(XCH2)2C6H3
19252-80-9
C36H65N2Br2F
704.732
45.1


424



C40H65N2O4F7
770.956
45.1


425
74673-26-0
p-(XCH2)2C6H4
623-25-6
C36H66N2Cl2
597.839
44.4


426
17373-27-2
o-(XCH2)2C6H4
612-12-4
C30H58N2Cl2
517.709
40.1


427
17373-27-2
o-(XCH2)2C6H4
91-13-4
C30H58N2Br2
606.612
40.1


428



C34H58N2O4F6
672.836
40.1


429
17373-27-2
m-(XCH2)2C6H4
626-16-4
C30H58N2Cl2
517.709
39.3


430
17373-27-2
m-(XCH2)2C6H4
626-15-3
C30H58N2Br2
606.612
39.2


431



C34H58N2O4F6
672.836
39.3


432
17373-27-2
5-F-1,3-(XCH2)2C6H3
19252-80-9
C32H57N2Br2F
624.602
39.5


433



C36H57N2O4F7
714.838
39.5


434
74673-25-9
p-(XCH2)2C6H4
626-16-4
C34H62N2Cl2
569.785
40.8


435
74673-25-9
p-(XCH2)2C6H4
626-15-3
C34H62N2Br2
658.688
40.8


436



C38H62N2O4F6
724.912
40.8


437
74673-25-9
2-F-1,3-(XCH2)2C6H3
25006-86-4
C34H61N2Br2F
676.678
40.9


438



C38H61N2O4F7
742.902
40.9


439
74673-25-9
5-F-1,3-(XCH2)2C6H3
19252-80-9
C34H61N2Br2F
676.678
41.0


440



C38H61N2O4F7
742.902
41.0


441
17373-27-2
p-(XCH2)2C6H4
623-25-6
C30H58N2Cl2
517.709
39.0


442
17373-27-2
p-(XCH2)2C6H4
624-24-5
C30H58N2Br2
606.612
39.0


443



C34H58N2O4F6
672.836
39.0


444
7378-99-6
o-(XCH2)2C6H4
612-12-4
C28H54N2Cl2
489.656
35.8


445
7378-99-6
o-(XCH2)2C6H4
91-13-4
C28H54N2Br2
578.558
35.8


446



C32H54N2O4F6
644.782
35.8


447
7378-99-6
m-(XCH2)2C6H4
626-16-4
C28H54N2Cl2
489.656
35.3


448
7378-99-6
m-(XCH2)2C6H4
626-15-3
C28H54N2Br2
578.558
35.3


449



C32H54N2O4F6
644.782
35.3


450
7378-99-6
p-(XCH2)2C6H4
623-25-6
C28H54N2Cl2
489.656
35.1


451
7378-99-6
p-(XCH2)2C6H4
624-24-5
C28H54N2Br2
578.558
35.1


452



C32H54N2O4F6
644.782
35.1


453
37615
m-(XCH2)2C6H4
626-16-4
C34H66N2Cl2
573.817
40.0


454
37615
m-(XCH2)2C6H4
626-15-3
C34H66N2Br2
662.720
40.0


455
621-77-2
o-(XCH2)2C6H4
91-13-4
C38H74N2Br2
718.827
42.3


456
621-77-2
o-(XCH2)2C6H4
626-15-3
C38H74N2Br2
718.827
42.6


457



C42H74N2O4F6
785.051
42.6


458
621-77-2
o-(XCH2)2C6H4
624-24-5
C38H74N2Br2
718.827
42.2


459
102-82-9
o-(XCH2)2C6H4
626-15-3
C32H62N2Br2
634.666
32.7


460



C36H62N2O4F6
700.879
32.7


461
17373-27-2
4,4′-(XCH2C6H4)2
20248-86-6
C36H62N2Br2
682.713
42.7


462
17373-27-2
3,3′-(XCH2C6H4)2
24656-53-9
C36H62N2Br2
682.713
43.0


463
17373-27-2
2,2′-(XCH2C6H4)2
38274-15-5
C36H62N2Br2
682.713
42.4
















TABLE VII





[R1R2R3R4P]+[X] and [R1R2R3S]+[X] and [R1R2R3S═O]+[X]






















Nu.
Salt Type
R1
R2
R3
R4
X
Phosphine





464
Phosphonium

nPentyl


nPentyl

Phenyl
Methyl
Cl
PR2R2R3


465
Phosphonium

nPentyl


nPentyl

Phenyl
Methyl
CF3CO2



466
Phosphonium

nHexyl


nHexyl

Phenyl
Methyl
Cl
PR1R2R3


467
Phosphonium

nHexyl


nHexyl

Phenyl
Methyl
CF3CO2



468
Phosphonium

nHeptyl


nHeptyl

Phenyl
Methyl
Cl
PR1R2R3


469
Phosphonium

nHeptyl


nHeptyl

Phenyl
Methyl
CF3CO2



470
Phosphonium

nOctyl


nOctyl

Phenyl
Methyl
Cl
PR1R2R3


471
Phosphonium

nNonyl

Methyl
Phenyl
Methyl
Cl
PR2R3R4


472
Phosphonium

nNonyl

Methyl
Phenyl
Methyl
CF3CO2



473
Phosphonium

nNonyl

Methyl
4-FC6H4
Methyl
Cl
PR2R3R4


474
Phosphonium

nNonyl

Methyl
4-FC6H4
Methyl
CF3CO2



475
Phosphonium

nDecyl

Methyl
Phenyl
Methyl
Cl
PR2R3R4


476
Phosphonium

nDecyl

Methyl
Phenyl
Methyl
CF3CO2



477
Phosphonium

nDecyl

Methyl
4-FC6H4
Methyl
Cl
PR2R3R4


478
Phosphonium

nDecyl

Methyl
4-FC6H4
Methyl
CF3CO2



479
Phosphonium

nUndecyl

Methyl
Phenyl
Methyl
Cl
PR2R3R4


480
Phosphonium

nUndecyl

Methyl
Phenyl
Methyl
CF3CO2



481
Phosphonium

nUndecyl

Methyl
4-FC6H4
Methyl
Cl
PR2R3R4


482
Phosphonium

nUndecyl

Methyl
4-FC6H4
Methyl
CF3CO2



483
Sulfonium
Ph(CH2)10
Methyl
Methyl

Br
SR2R3


484
Sulfonium

nDecyl

4-FC6H4CH2
Methyl

Br
SR1R3


485
Sulfonium

nDecyl

4-FC6H4
Methyl

Br
SR1R2


486
Sulfonium

nDecyl

4-FC6H4
Methyl

CF3CO2



487
Sulfonium
Q a
Methyl
Methyl

Br
SR2R3


488
Sulfoxonium

nDecyl

4-FC6H4CH2
Methyl

Br
O═SR1R3


489
Sulfoxonium
Q a
Methyl
Methyl

Br
O═SR2R3













Alkylating
HPLC Method 9a















Nu.
CAS Num.
Agent
CAS Num.
Formula
Weight
Time







464
71501-08-1
R4X
74-87-3
C17H30PCl
300.852
32.7



465



C19H30O2F3P
378.415
32.7



466
18297-98-8
R4X
74-87-3
C19H34PCl
328.905
37.9



467



C21H34O2F3P
406.469
37.6



468
109706-36-7
R4X
74-87-3
C21H38PCl
356.959
42.9



469



C23H38O2F3P
434.522
42.9



470
14086-46-5
R4X
74-87-3
C23H42PCl
385.013
47.7



471
672-66-2
R1X
2473-01-0
C17H30PCl
300.852
36.0



472



C19H30O2F3P
378.415
36.0



473
7217-34-7
R1X
2473-01-0
C17H29FPCl
318.842
36.2



474



C19H29O2F4P
396.405
36.2



475
672-66-2
R1X
1002-69-3
C18H32PCl
314.879
39.1



476



C20H32O2F3P
392.442
39.1



477
7217-34-7
R1X
1002-69-3
C18H31FPCl
332.869
39.3



478



C20H31O2F4P
410.432
39.3



479
672-66-2
R1X
2473-03-2
C19H34PCl
328.905
42.2



480



C21H34O2F3P
406.469
42.2



481
7217-34-7
R1X
2473-03-2
C19H33FPCl
346.896
42.4



482



C21H33O2F4P
424.459
42.4



483
75-18-3
R1X
7757-83-7
C18H31SBr
359.416
40.3



484
22438-39-2
R2X
459-46-1
C18H30FSBr
377.406
40.6



485
61671-40-7
R3X
74-83-9
C17H28FSBr
363.379
38.5



486



C19H28O2F4S
396.492
38.5



487
75-18-3
R1X
80563-37-7
C20H27SBr
379.406
34.9



488
3079-28-5
R2X
459-46-1
C18H30OFSBr
393.406
39.5



489
67-68-5
R1X
80563-37-7
C20H27OSBr
395.406
33.8








a Q = 4,4′-CH3(CH2)4C6H4—C6H4CH2














TABLE VIII





[N—R1Z]+ [X] and [N,N′—R1Z~Z′R1]2+ 2[X]





















Nu.
Z or Z~Z′
R1
CAS# known product
X
N-Base
CAS Num.





490
4-Picolinium

nUndecyl

New
Br
4-picoline
108-89-4


491
4-Picolinium

nUndecyl

New
CF3CO2




492
4-Picolinium

nDecyl

[70850-62-3]
Br
4-picoline
108-89-4


493
4-Picolinium

nDecyl

New
CF3CO2




494
4-Picolinium

nNonyl

New
Br
4-picoline
108-89-4


495
4-Picolinium

nNonyl

New
CF3CO2




496
Quinolinium

nUndecyl


Br
4-picoline
91-22-5


497
Quinolinium

nUndecyl


CF3CO2




498
Quinolinium

nDecyl

[15001-43-1]
Br
quinoline
91-22-5


499
Quinolinium

nDecyl

New
CF3CO2




500
Quinolinium

nNonyl

New
Br
quinoline
91-22-5


501
Quinolinium

nNonyl

New
CF3CO2




502
Quinolinium

nOctyl


Br
quinoline
91-22-5


503
Quinolinium

nOctyl


CF3CO2




504
Isoquinolinium

nUndecyl


Br
isoquinoline
119-65-3


505
Isoquinolinium

nUndecyl


CF3CO2




506
Isoquinolinium

nDecyl

[51808-86-7]
Br
isoquinoline
119-65-3


507
Isoquinolinium

nDecyl

New
CF3CO2




508
Isoquinolinium

nNonyl

New
Br
isoquinoline
119-65-3


509
Isoquinolinium

nNonyl

New
CF3CO2




510
Isoquinolinium

nOctyl


Br
isoquinoline
119-65-3


511
Isoquinolinium

nOctyl


CF3CO2




512
1,2-Me2imidazolium

nUndecyl


Br
DMImc
1739-84-0


513
1,2-Me2imidazolium

nUndecyl


CF3CO2




514
1,2-Me2imidazolium

nDecyl


Br
DMImc
1739-84-0


515
1,2-Me2imidazolium

nDecyl


CF3CO2




516
1,2-Me2imidazolium

nNonyl


Br
DMImc
1739-84-0


517
1,2-Me2imidazolium

nNonyl


CF3CO2




518
1,2-Me2-benzimidazolium

nUndecyl


Br
DMBImc
2876-08-6


519
1,2-Me2-benzimidazolium

nUndecyl


CF3CO2




520
1,2-Me2-benzimidazolium

nDecyl


Br
DMBImc
2876-08-6


521
1,2-Me2-benzimidazolium

nDecyl


CF3CO2




522
1,2-Me2-benzimidazolium

nNonyl


Br
DMBImc
2876-08-6


523
1,2-Me2-benzimidazolium

nNonyl


CF3CO2




524
1,2-Me2-benzimidazolium

nOctyl


Br
DMBImc
2876-08-6


525
1,2-Me2-benzimidazolium

nOctyl


CF3CO2




526
1-R1-2-Me-imidazolium

nOctyl


Br
MImc
693-98-1


527
1-R1-2-Me-imidazolium

nOctyl


CF3CO2




528
1-R1-2-Me-imidazolium

nHeptyl


Br
MImc
693-98-1


529
1-R1-2-Me-imidazolium

nHeptyl


CF3CO2




530
1-R1-2-Me-imidazolium

nHexyl


Br
MImc
693-98-1


531
1-R1-2-Me-imidazolium

nHexyl


CF3CO2




532
1-R1-2-Ph-imidazolium

nOctyl


Br
PImc
670-96-2


533
1-R1-2-Ph-imidazolium

nHeptyl


Br
PImc
670-96-2


534
1-R1-2-Ph-imidazolium

nHexyl


Br
PImc
670-96-2


535
1-R1-2-Ph-imidazolium

nPentyl


Br
PImc
670-96-2


536
1-R1-2-Me-benzimidazolium

nOctyl


Br
MBImc
615-15-6


537
1-R1-2-Me-benzimidazolium

nHeptyl


Br
MBImc
615-15-6


537b
1-R1-2-Me-benzimidazolium
Ph(CH2)3

Br
MBImc
615-15-6


537c
1-R1-2-Me-benzimidazolium
Ph(CH2)3

CF3CO2




538
1-R1-2-Me-benzimidazolium

nHexyl


Br
MBImc
615-15-6


539
1-R1-2-Me-benzimidazolium

nPentyl


Br
MBImc
615-15-6


540
1-R1-2-Me-imidazolinium

nOctyl


Br
MImNc
534-26-9


541
1-R1-2-Me-imidazolinium

nOctyl


CF3CO2




542
1-R1-2-Me-imidazolinium

nHeptyl


Br
MImNc
534-26-9


543
1-R1-2-Me-imidazolinium

nHeptyl


CF3CO2




544
1-R1-2-Me-imidazolinium

nHexyl


Br
MImNc
534-26-9


545
1-R1-2-Me-imidazolinium

nHexyl


CF3CO2




546
1-R1-2-Ph-imidazolinium

nOctyl


Br
PImNc
936-49-2


547
1-R1-2-Ph-imidazolinium

nHeptyl


Br
PImNc
936-49-2


548
1-R1-2-Ph-imidazolinium

nHexyl


Br
PImNc
936-49-2


549
1-R1-2-Ph-imidazolinium

nPentyl


Br
PImNc
936-49-2


550
5,5′-Me2-3,3′-bipyridinium
nUndecyl

Br−
5,5′-Me2-3,3′-
856796-70-8







bipyc


551
3,3′-bipyridinium

nUndecyl


Br
3,3′-bipyc
581-46-4


552
4-Me2N-pyridiniumd

nNonyl


Br
DMAPc
1122-58-3


553
4-Me2N-pyridiniumd

nUndecyl


Br
DMAPc
1122-58-3


554
4-(1-Pyrrolidino)pyridiniumd

nNonyl


Br
PyPc
2456-81-7


555
4-(1-Pyrrolidino)pyridiniumd

nUndecyl


Br
PyPc
2456-81-7


556
4-(4-nHeptylphenyl)pyridinium
Methyl
New
Br
HePPc
153855-56-2













Alkylating
HPLC Method 9a














Nu.
Agent
CAS Num.
Formula
Weight
Time







490
RnX
693-67-4
C17H30NBr
328.336
40.3



491


C19H30NO2F3
375.449
40.3



492
R1X
112-29-8
C16H28NBr
314.309
37.0



493


C18H28NO2F3
347.421
37.0



494
R1X
693-58-3
C15H26NBr
300.282
33.5



495


C17H26NO2F3
333.394
33.5



496
R1X
693-67-4
C20H30NBr
364.371
43.0



497


C22H30NO2F3
397.483
43.0



498
R1X
112-29-8
C19H28NBr
350.342
39.8



499


C21H28NO2F3
383.454
39.8



500
R1X
693-58-3
C18H26NBr
336.315
36.5



501


C20H26NO2F3
369.427
36.5



502
R1X
111-83-1
C17H24NBr
322.290
33.1



503


C19H24NO2F3
355.402
33.1



504
R1X
693-67-4
C20H30NBr
364.371
43.0



505


C22H30NO2F3
397.483
43.0



506
R1X
112-29-8
C19H28NBr
350.342
39.9



507


C21H28NO2F3
383.454
39.9



508
R1X
693-58-3
C18H26NBr
336.315
36.7



509


C20H26NO2F3
369.427
36.7



510
R1X
111-83-1
C17H24NBr
322.290
33.4



511


C19H24NO2F3
355.402
33.4



512
R1X
693-67-4
C16H31N2Br
331.340
40.9



513


C18H31N2O2F3
364.452
40.9



514
R1X
112-29-8
C15H29N2Br
317.313
37.6



515


C17H29N2O2F3
350.425
37.6



516
R1X
693-58-3
C14H27N2Br
303.286
34.2



517


C16H27N2O2F3
336.398
34.2



518
R1X
693-67-4
C20H33N2Br
381.402
44.7



519


C22H33N2O2F3
414.514
44.7



520
R1X
112-29-8
C19H31N2Br
367.375
41.6



521


C21H31N2O2F3
400.487
41.6



522
R1X
693-58-3
C18H29N2Br
353.348
38.5



523


C20H29N2O2F3
386.460
38.5



524
R1X
111-83-1
C17H27N2Br
339.321
35.3



525


C19H27N2O2F3
372.433
35.3



526
2xR1X + base
111-83-1
C20H39N2Br
387.447
47.1



527


C22H39N2O2F3
420.559
47.1



528
2xR1X + base
629-04-9
C18H35N2Br
359.393
42.0



529


C20H35N2O2F3
392.505
42.0



530
2xR3X + base
111-25-1
C16H31N2Br
331.340
36.5



531


C18H31N2O2F3
364.452
36.5



532
2xR1X + base
111-83-1
C25H41N2Br
449.518
51.9



533
2xR1X + base
629-04-9
C23H37N2Br
421.464
47.3



534
2xR1X + base
111-25-1
C21H33N2Br
393.411
42.9



535
2xR1X + base
110-53-2
C19H29N2Br
365.357
37.5



536
2xR1X + base
111-83-1
C24H41N2Br
437.509
50.7



537
2xR1X + base
629-04-9
C22H37N2Br
409.456
45.9



537b
2xR1X + base
637-59-2
C26H29N2Br
449.426
41.0



537c


C28H29N2O2F3
482.537
41.0



538
2xR1X + base
111-25-1
C20H33N2Br
381.402
40.6



539
2xR1X + base
110-53-2
C18H29N2Br
353.348
36.1



540
2xR1X + base
111-83-1
C20H41N2Br
389.457
47.8



541


C22H41N2O2F3
422.568
47.8



542
2xR1X + base
629-04-9
C18H37N2Br
361.404
42.7



543
2xR1X + base

C20H37N2O2F3
394.515
42.7



544
2xR1X + base
111-25-1
C16H33N2Br
333.351
37.2



545


C18H33N2O2F3
366.462
37.2



546
2xR1X + base
111-83-1
C25H43N2Br
451.526
52.8



547
2xR1X + base
629-04-9
C23H39N2Br
423.473
48.1



548
2xR1X + base
111-25-1
C21H35N2Br
395.420
43.2



549
2xR1X + base
110-53-2
C19H31N2Br
367.367
38.1



550
2xR1X
693-67-4
C34H58N2Br2
654.659
46.4



551
2xR1X
693-67-4
C32H54N2Br2
626.593
43.8



552
R1X
693-58-3
C16H29N2Br
329.325
37.2



553
R1X
693-67-4
C18H33N2Br
357.379
43.5



554
R1X
693-58-3
C18H31N2Br
355.363
39.9



555
R1X
693-67-4
C20H35N2Br
383.417
46.2



556
R1X
74-83-9
C19H26NBr
348.328
37.3








cMIm = 2-methylimidazole, DMIm = 1,2-dimethylimidazole, PIm = 2-phenylimidazole, MImN = 2-methylimidazoline, PImN = 2-phenylimidazoline, MBIm = 1-methylbenzimidazole, DMBIm = 1,2-Dimethylbenzimidazole, DMAP = 4-(dimethylamino)pyridine, PyP = 4-(1-pyrrolidino)pyridine, HePP = 4-(4-nheptylphenyl)pyridine, bipy = bipyridine,





dalkylation at pyridine nitrogen.














TABLE IX







Derivatives of Benzo-18-Crown-6•M+Cl


M+ = Na+, K+, NH4+, CH3NH3+


A




embedded image







B




embedded image


































HPLC Method





CAS



CAS

CAS

9a



















Nu.
R1
R2
Num.
Cation
Comment
Reactant
Num.
Reactant
Num.
Formulab
Weightb
Time





770
4′-H—
5′-H—
14098-
K+
(A)Benzo
Catechol
120-
Pentaethylene-
57602-
C16H24O6
312.356
25.8





24-9



80-9
glycol dibromide
02-5





771
4′-Br—
5′-H—
75460-
K+
(A)
Benzo-18-
14098-
NBS
128-08-
C16H23O6Br
391.252
32.7





28-5


Crown-6
24-9

5





772
4′Br—
5′-Br—
108695-
K+
(A)
Benzo-18-
14098-
NBS
128-08-
C16H22O6Br2
470.148
37.4





32-2


Crown-6
24-9

5





773
R1 + R2 =

17454-
K+
2,3-
2,3-
92-44-
Pentaethylene-
57602-
C20H26O6
362.414
35.4



4′,5′-C4H4

52-3

Nathpho
Naphthalenediol
4
glycol dibromide
02-5





774
4′-C6H5
5′-H—
New
K+
(A)
4′-Br-Benzo-18-
75460-
C6H5B(OH)2
98-80-6
C22H28O6
388.451
38.6








C-6
28-5







775
4′-(4-
5′-H—
85420-
K+
(A)
4′-Br-Benzo-18-
75460-
p-
5720-
C23H30O6
402.477
41.7



CH3C6H4)—

09-5


C-6
28-5
MeC6H4B(OH)2
05-8





776
4′-(4-
5′-H—
New

(B)
4′-Me-3,4-
New
2 x
54149-
C23H32O6
404.493
40.5



CH3C6H4)—




(OH)2-biphenyl

MeOC2H4O—
17-6













C2H4Br






777
4′-(4-
5′-H—
New
K+
(A)
4′-Br-Benzo-18-
75460-
p-EtC6H4B(OH)2
63139-
C24H32O6
416.504
44.8



C2H5C6H4)—




C-6
28-5

21-9





778
4′-(4-
5′-H—
New
K+
(A)
4′-Br-Benzo-18-
75460-
p-
134150-
C25H34O6
430.530
47.9




nC3H7C6H4)—





C-6
28-5

nPrC6H4B(OH)2

01-9





779
4′-(4-
5′-H—
New
K+
(A)
4′-Br-Benzo-18-
75460-
p-
145240-
C26H36O6
444.557
51.0




nC4H9C6H4)—





C-6
28-5

nBuC6H4B(OH)2

28-4





780
4′-(4-
5′-H—
New
K+
(A)
4′-Br-Benzo-18-
75460-
p-nC5H11
121219-
C27H38O6
458.583
54.0




nC5H11C6H4)—





C-6
28-5
C6H4B(OH)2
12-3






bcation-free crown ether






Claims
  • 1. A process for separating organic compounds from a mixture by reverse-phase displacement chromatography, comprising: providing a hydrophobic stationary phase;applying to the hydrophobic stationary phase a mixture comprising organic compounds to be separated;displacing the organic compounds from the hydrophobic stationary phase by applying thereto an aqueous composition comprising a non-surface active hydrophobic cationic displacer molecule and about 10 wt % or less of an organic solvent; andcollecting a plurality of fractions eluted from the hydrophobic stationary phase containing the separated organic compounds;wherein the non-surface active hydrophobic cationic displacer molecule comprises a hydrophobic cation and a counterion, CI, having the general formula A or B:
  • 2. The process of claim 1 wherein the aqueous composition comprising a non-surface active hydrophobic displacer molecule is free of added salt other than a pH buffer.
  • 3. The process of claim 1 wherein CM has a general formula I or II:
  • 4. The process of claim 1 wherein CM has a general formula I or II:
  • 5. The process of claim 1 wherein CM has a general formula VIII, IX, X or XI, R1 is C5-C11 alkyl and R2 is C1-C8 alkyl.
  • 6. The process of claim 1 wherein CM has a general formula I or II:
  • 7. The process of claim 1 wherein CM has a general formula I or II:
  • 8. The process of claim 1 wherein CM has a general formula I or II:
  • 9. The process of claim 1 wherein CM has a general formula [(R1R2R3NCH2)2C6H3G]2+, wherein R1 is C4-C11 alkyl, R2 and R3 independently are C1-C6 alkyl or R2 and R3 taken together are —(CH2)4—, and G is H or F.
  • 10. The process of claim 1 wherein CM has a general formula [R1R2R3NCH2C6H4—C6H4CH2NR1R2R3]2+, wherein R1 is C4-C11 alkyl, R2 and R3 independently are C1-C6 alkyl or R2 and R3 taken together are —(CH2)4—.
  • 11. The process of claim 1 wherein CM has a general formula III or IV:
  • 12. The process of claim 1 wherein CM has a general formula XIV or XV:
  • 13. The process of claim 1 wherein CM has a general formula XIIIa, XIIIb, XIIIc, XIIId or XIIIe:
  • 14. The process of claim 1 wherein CM has a general formula VII:
  • 15. The process of claim 1 wherein CM has a general formula XII:
  • 16. The process of claim 1 wherein CM has a general formula XXIV or XXV:
  • 17. The process of claim 1 wherein CM has a general formula selected from 4-R1C6H4SO3H, 5-R1-2-HO—C6H3SO3H, 4-R1—C6H4—C6H3X-4′-SO3H, and 4-R1—C6H4—C6H3X-3′-SO3H, wherein R1 is CH3(CH2)n, wherein n=4-10 and X is H or OH.
  • 18. The process of claim 1 wherein CM has a general formula XVIII or XXIII:
  • 19. The process of claim 1 wherein CM has a general formula selected from 5-R1-2-HO—C6H3CO2H and R1C(O)NHCH(C6H5)CO2H, wherein R1 is CH3(CH12)n—, wherein n=4-10.
  • 20. The process of claim 1 wherein CM has a general formula 4-R1C6H4PO3H2 wherein R1 is CH3(CH2)n—, wherein n=4-10.
  • 21. The process according to claim 1 wherein CI is a non-interfering anion or mixture of non-interfering anions selected from: Cl−, Br−, I−, OH−, F−, OCH3−, d,l-HOCH2CH(OH)CO2−, HOCH2CO2−, HCO2−, CH3CO2−, CHF2CO2−, CHCl2CO2−, CHBr2CO2−, C2H5CO2−, C2F5CO2−, nC3H7CO2−, nC3F7CO2−, CF3CO2−, CCl3CO2−, CBr3CO2−, NO3−, ClO4−, BF4−, PF6−, HSO4−, HCO3−, H2PO4−, CH3OCO2−, CH3OSO3−, CH3SO3−, C2H5SO3−, NCS−, CF3SO3−, H2PO3−, CH3PO3H−, HPO32−, CH3PO32−, CO32−, SO42−, HPO42−, PO43−.
  • 22. The process according to claim 16 wherein CI is a non-interfering inorganic cation or mixture of such non-interfering cations selected from the groups: alkali metal ions (Li+, Na+, K+, Rb+, Cs+), alkaline earth metal ions (Mg2+, Ca2+, Sr2+, Ba2+), divalent transition metal ions (Mn2+, Zn2+) and NH4+; wherein CI is a non-interfering organic cation or mixture of such non-interfering cations selected from the groups: protonated primary amines (1+), protonated secondary amines (1+), protonated tertiary amines (1+), protonated diamines (2+), quaternary ammonium ions (1+), sulfonium ions (1+), sulfoxonium ions (1+), phosphonium ions (1+), bis-quaternary ammonium ions (2+) that may contain C1-C6 alkyl groups and/or C2-C4 hydroxyalky groups.
PCT Information
Filing Document Filing Date Country Kind 371c Date
PCT/US2012/058546 10/3/2012 WO 00 4/2/2014
Provisional Applications (2)
Number Date Country
61542424 Oct 2011 US
61542370 Oct 2011 US